WO1996039137A1

WO1996039137A1 - Inhibitors of farnesyl-protein transferase

Info

Publication number: WO1996039137A1
Application number: PCT/US1996/008740
Authority: WO
Inventors: Neville J. Anthony; Kelly M. Solinsky; Robert P. Gomez; Theresa M. Williams; Jeffrey M. Bergman; S. Jane Desolms; Christopher J. Dinsmore; Suzanne C. Mactough
Original assignee: Merck & Co., Inc.
Priority date: 1995-06-06
Filing date: 1996-06-03
Publication date: 1996-12-12
Also published as: EP0833633A4; CA2223561A1; EP0833633A1; AU708564B2; AU6150596A; US5756528A

Abstract

The present invention comprises low molecular weight peptidyl compounds that inhibit the farnesyl-protein transferase. Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.

Description

TITLE OF THE INVENTION

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

RELATED APPLICATION

The present patent application is a continuation-in-part application of copending application Serial No. 08/468,160, filed June 6, 1995.

BACKGROUND OF THE INVENTION

The Ras protein is part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate thar Aas functions like a G -regulatory protein. In the inactive state, Ras is bound to GDP. Upon frowth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, Ann. Rev. Biochem. 62:851-891 (1993)). Mutated ras genes are found in many human cancers, includinf colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.

Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational

modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus contains a sequence motif termed a "CAAX" or "Cys-Aaa¹-Aaa²-Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al, Nature 310:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the enzymes famesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C₁₅ or C₂₀ isoprenoid, respectively. (S. Clarke., Ann. Rev. Biochem. 61:355-386 (1992); W.R. Schafer and J. Rine, Ann. Rev. Genetics 30:209- 237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational farnesylation. Other farnesylated

proteins.include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear larnins, and the gamma subunit of transducin. James, et al., J. Biol Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above

Inhibition of famesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and to modify other aspects of their transformed phenotype. It has also been

demonstrated that certain inhibitors of famesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly (N.E. Kohl et al. , Science, 260:1934-1937 (1993) and G.L. James et al. , Science, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of famesyl-protein transferase blocks the growth of ras- dependent tumors in nude mice (N.E. Kohl et al. , Proc. Natl Acad. Sci U.S.A., 91:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in ras transgenic mice (N.E. Kohl et al. , Nature Medicine, 1:792-797 (1995). It has also been reported that a farnesyl- protein transferase inhibitor inhibits the growth of a broad range of human tumor cell lines, including those that do not have mutant forms of ras (L. Sepp-Lorenzino et al. , Cancer Research, 55:5302-5309 (1995)).

Indirect inhibition of famesyl-protein transferase in vivo has been demonstrated with lovastatin (Merck & Co., Rahway, NJ) and compactin (Hancock et al. , ibid; Casey et al. , ibid; Schafer et al. , Science 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including farnesyl pyrophosphate. Famesyl-protein transferase utilizes farnesyl

pyrophosphate to covalently modify the Cys thiol group of the Ras

CAAX box with a farnesyl group (Reiss et al. , Cell, 62:81-88 (1990); Schaber et al, J. Biol. Chem., 265:14701-14704 (1990); Schafer et al. , Science, 249:1133-1139 (1990); Manne et al. , Proc. Natl Acad. Sci USA, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of famesyl-protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene

biosynthesis.

Inhibitors of famesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of farnesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrates (e.g., Ras) for the enzyme. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber et al. , ibid; Reiss et. al., ibid; Reiss et al. , PNAS, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the famesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141,851, University of Texas; N.E. Kohl et al. , Science, 260:1934-1937 (1993); Graham, et al., J. Med. Chem., 37, 725 (1994)). In general, deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound. However, the thiol group

potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.

It has recently been disclosed that certain tricyclic compounds which optionally incorporate a piperidine moiety are inhibitors of FPTase (WO 95/10514, WO 95/10515 and WO 95/10516). Imidazole-containing inhibitors of farnesyl protein transferase have also been disclosed (WO 95/09001, WO 96/00736 and EP 0 675 112 A1). Substituted di-, tri- tetra- and pentapeptide inhibitors of famesyl-protein transferase have also recently been disclosed (WO 95/12612 and WO 95/11917).

It is, therefore, an object of this invention to develop small molecules that do not have a thiol moiety, and that will inhibit famesyl- protein transferase and thus, the post-translational farnesylation of proteins. It is a further object of this invention to develop

chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention. SUMMARY OF THE INVENTION

The present invention comprises low molecular weight peptidyl compounds that inhibit the famesyl-protein transferase.

Furthermore, these compounds differ from the mono- or dipeptidyl analogs previously described as inhibitors of famesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid

autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are

chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.

The compounds of this invention are illustrated by the formula:

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention inhibit the famesyl-protein transferase. In a first embodiment of this invention, the famesyl-protein transferase inhibitors are illustrated by the formula I:

wherein:

R^1a is independently selected from:

a) hydrogen,

b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂- C₂₀ alkynyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)N R¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-,

c) C₁ -C₆ alkyl unsubstituted or substituted by aryl,

heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN,

(R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)-NR¹⁰-; R^1b is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, R¹⁰O-, R^{1 1}S(O)_m-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃ or -N(R¹⁰)₂,

c) C₁-C₆ alkyl unsubstituted or substituted by substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, R¹⁰O-, R^{1 1}S(O)_m-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃ or -N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a naturally occurring amino acid, b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substituted or unsubstituted C₁-C₂₀ alkyl, substituted or unsubstituted C₂-C₂₀ alkenyl, substituted or unsubstituted C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(R¹⁰)₂, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-,

CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl, and d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl; or

R² and R³ are combined to form - (CH₂)_s - ; or

R² or R³ are combined with R⁷ to form a ring such that

R⁴ and R⁵ are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₂₀ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) unsubstituted or substituted aryl, unsubstituted or

substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-

C₂₀ alkenyl, halogen, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-,

R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₂₀ alkenyl,

R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) unsubstituted or substituted aryl, unsubstituted or

substituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₂₀ alkenyl, halogen, R¹⁴O-, R^{1 1}S(O)_m-,

R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R⁶ is selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₁-C₂₀ perfluoroalkyl, allyloxy, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m -, R¹⁰C(O)NR¹⁰-, CN, NO₂,

R¹⁰ ₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substituted by substituted or unsubstituted aryl, substituted or unsubstituted heterocycle,

C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂- C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NH-, CN, H₂N-C(NH)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹⁰OC(O)NH-; R⁷ is independently selected from

a) hydrogen,

b) unsubstituted or substituted aryl,

c) unsubstituted or substituted heterocycle,

d) unsubstituted or substituted C₃-C₁₀ cycloalkyl, and e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocycle and C3-

C₁₀ cycloalkyl;

R⁸ is selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₁-C₂₀ perfluoroalkyl, allyloxy, F, Cl, Br, R¹⁰O-, R¹¹ S(O)_m-, R¹⁰C(O)NR¹⁰-, -S(O)₂NR¹⁰ ₂, CN, NO₂, R¹⁰ ₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substituted by substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C_{1 0} cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂- C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-,

R¹⁰C(O)NH-, CN, H₂N-C(NH)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R¹⁰OC(O)NH-;

R⁹ is selected from:

a) hydrogen,

b) C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂-C₂₀ perfluoroalkyl, F,

Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C-(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃,

-N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and c) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R¹¹ C(O)NR¹⁰-; R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl and aryl;

R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl and aryl, or (R¹²)₂ forms - (CH₂)_s - ;

R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with CO₂R¹⁰, C₁-C₆ alkyl substituted with aryl, C₁-

C₆ alkyl substituted with substituted aryl, C₁-C₆ alkyl substituted with heterocycle, C₁-C₆ alkyl substituted with substituted heterocycle, aryl and substituted aryl; A¹, A² and A³ are independently selected from: a bond, -CH=CH-,

-C≡C-, -C(O)-, -C(O)NR⁷-, -NR⁷C(O)-, O, -N(R⁷)-, -S(O)₂N(R⁷)-, -N(R⁷)S(O)₂-, or S(O)_m;

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

V is selected from:

a) hydrogen,

b) heterocycle,

c) aryl,

d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C₂-C₂₀ alkenyl,

provided that V is not hydrogen if A₁ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m; W is a heterocycle;

Z is independently R^1a2 or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

r is 0 to 5, provided that r is 0 when V is hydrogen;

s is 4 or 5; and

t is 3, 4 or 5; or the pharmaceutically acceptable salts thereof.

In a preferred embodiment of this invention, the Ras famesyl transferase inhibitors are illustrated by the Formula I:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂ or C₂-C₆ alkenyl, and c) C₁-C₆ alkyl unsubstituted or substituted by substituted or unsubstituted aryl, substituted or unsubstituted heterocycle,

C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a naturally occurring amino acid,

b) an oxidized form of a side chain of a naturally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone,

c) substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl, substituted or unsubstituted

C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl, and d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocycle and C₃-

C₁₀ cycloalkyl;

wherein said substituted group is substituted with 1 or 2 substitutents selected from: F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-

C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, N₃,(C₁-C₆ alkyl)OC(O)NH- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₆ alkenyl, R¹⁰o-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substituted or unsubstituted aryl, substituted or

unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, halogen, R¹⁰O-, RHS(O)_m-,

R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, ( R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substituted or unsubstituted aryl, substituted or

unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, halogen, R¹⁴O-, R^{1 1}S(O)_m-,

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R⁶ is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy,

R¹⁰C(O)NR¹⁰-, CN, NO₂, ( R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstituted or substituted aryl,

c) unsubstituted or substituted heterocycle,

d) unsubstituted or substituted C₃-C₁₀ cycloalkyl, and e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, indolyl, quinolinyl, isoquinolinyl, and thienyl; R⁸ is selected from:

a) hydrogen,

b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰ -, CN, NO₂, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or

R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl and aryl;

R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substituted with CO₂R¹⁰, C₁-C₆ alkyl substituted with aryl, C₁- C₆ alkyl substituted with substituted aryl, C₁-C₆ alkyl substituted with heterocycle, C₁-C₆ alkyl substituted with substituted

heterocycle, aryl and substituted aryl;

A¹, A² and A³ are independently selected from: a bond, -CH=CH-,

-C≡C-, -C(O)-, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-, -NR⁷S(O)₂-, O, -N(R⁷)-, or S(O)_m;

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

V is selected from:

a) hydrogen,

b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl,

c) aryl, d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m;

W is a heterocycle selected from pyrrolidinyl, imidazolyl, imidazolinyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, oxazolyl, isoxazolyl, indolyl, quinolinyl, or isoquinolinyl;

Z is independently R^1a ₂ or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

r is 0 to 5, provided that r is 0 when V is hydrogen; and t is 3, 4 or 5; or the pharmaceutically acceptable salts thereof.

In a further preferred embodiment of this invention, the Ras famesyl transferase inhibitors are illustrated by the Formula I:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from: a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O- or C₂-C₆ alkenyl, c) C₁-C₆ alkyl unsubstituted or substituted by aryl,

heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or

-N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a naturally occurring amino acid,

i) methionine sulfoxide, or

ii) methionine sulfone, and

C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂,

R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen,

unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, fluoro, chloro, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl ;

R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N-

C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substituted or unsubstituted aryl, substituted or

unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, fluoro, chloro, R¹⁴O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl;

R⁶ is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstituted or substituted aryl,

c) unsubstituted or substituted heterocycle,

d) unsubstituted or substituted cycloalkyl, and

e) C₁-C₆ alkyl substituted with hydrogen or an unsubstituted or substituted group selected from aryl, heterocycle and cycloalkyl;

wherein heterocycle is selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, indolyl, quinolinyl, isoquinolinyl, and thienyl;

R⁸ is selected from:

a) hydrogen,

b) C₁ -C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂,

(R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-_;

R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰0-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-

C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆

R¹ ₁ is independently selected from C₁-C₆ alkyl and aryl;

heterocycle, aryl and substituted aryl;

A¹ and A² are independently selected from: a bond, -CH=CH-,

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

A³ is selected from: a bond, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-,

-NR⁷S(O)₂- or -N(R⁷)-;

V is selected from:

a) hydrogen,

c) aryl,

d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C₂-C₂₀ alkenyl, and

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or

isoquinolinyl;

Z is independently R^1a ₂ or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is O or 1;

r is 0 to 5, provided that r is 0 when V is hydrogen; and t is 3, 4 or 5; or the pharmaceutically acceptable salts thereof. In another preferred embodiment of this invention, the Ras famesyl transferase inhibitors are illustrated by the Formula la:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from:

a) hydrogen, b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O- or C₂-C₆ alkenyl, c) C₁-C₆ alkyl unsubstituted or substituted by aryl,

heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a naturally occurring amino acid,

i) methionine sulfoxide, or

ii) methionine sulfone, and

R^{1 1}OC (O)NR¹⁰- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substituted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰ -, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substituted or unsubstituted aryl, substituted or

unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, fluoro, chloro, R¹⁰O-, R¹¹ S(O)_m-,

d) C₁-C₆ alkyl substituted with an unsubstituted or

substituted group selected from substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl; R^13a and R^13b are independently selected from:

a) hydrogen,

d) C₁-C₆ alkyl substituted with an unsubstituted or

R⁶ is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R^{1 0} O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstituted or substituted aryl,

c) unsubstituted or substituted heterocycle,

d) unsubstituted or substituted cycloalkyl, and

R⁸ is selected from:

a) hydrogen,

b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, CN, NO₂,

c) C₁-C₆ alkyl substituted by C₁-C₆ perfluoroalkyl, R 1 ⁿO-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-;

R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)N R¹⁰-C, CN, NO₂, (R¹⁰)₂N-

c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-;

R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl and aryl;

R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

heterocycle, aryl and substituted aryl;

A¹ and A² are independently selected from: a bond, -CH=CH-,

-CΞC-, -C(O)-, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-, -NR⁷S(O)₂-, O, -N(R⁷)-, or S(O)_m;

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

A³ is selected from: a bond, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-,

-NR⁷S(O)₂- or -N(R⁷)-;

V is selected from:

a) hydrogen,

c) aryl,

provided that V is not hydrogen if A¹ is S(O)_m and V is not hydrogen if A¹ is a bond, n is 0 and A² is S(O)_m; Z is independently R^1a2 or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is O or 1;

The preferred compounds of this invention are as follows:

N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)- 1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)- methyl pentanamine

N-Methoxycarbonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)- 1H-imidazol-5-yl)acetyl}amino-3(S)- methyl pentanamine

N-Acetyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methylpentanamine N-Proρionyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Methylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine N-Ethylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(l-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Methylaminocarbonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4- cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Propyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)- methylpentanamine N-3-Chlorobenzyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-(2-Imidazolylmethyl )-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)- 1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(naphth-1-ylmethyl)propionamide 2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-methyl-N-benzyl propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(2-methylbenzyl) propionamide 2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(3-methylbenzyl) propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-(naphth-1-ylmethyl)propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-methyl-N-benzyl propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-(2-methylbenzyl)propionamide 2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- amino-N-(3-methylbenzyl)propionamide 2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- acetylamino-N-(3-methylbenzyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- acetylamino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3-(2- methylpropionyl)amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- (phenylacetyl)amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- (phenylacetyl)amino-N-methyl-N-benzyl)propionamide [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]-N-butylacetamide

[1-(Naphth-2-ylmet-yl)-1H-imidazol-5-yl)]-N-methyl-N-(3,3- diphenylpropyl)acetamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-methyl-N-benzyl propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-(3-methylbenzyl) propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-methyl-N-benzyl-propionamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-(3-methylbenzyl)propionamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3- (phenylacetyl)amino-N-methyl-N-benzyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3- (acetyl)amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(2- methylpropionyl)amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(2- methylpropionyl)amino-N-(naphth-1-ylmethyl)propionamide N-[2(S)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yllacetylamino)-3(S)- methylpentyl]-N-(1-naphthylmethyl)glycine isopropylamide

N-[2(S)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylpentyl]-N-(1-naphthylmethyl)glycine piperidinylamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-methyl-N-(naphth-1-ylmethyl)propionamide N-{1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S){N'- methanesulfonyl-N'-(naphth-1-ylmethyl)aminomethyl}-pyrrolidine

N-{1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'- naphth-1-ylmethyl-aminomethyl}-pyrrolidine N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)-[1(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[l(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-[1(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-4(R)-hydroxy-2(S)- [1(R)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-4(R)-hydroxy-2(S)- [1(S)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(S)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine -[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(S)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine N-[1-(4-Cyanobenzyl)-1-imidazol-5-ylmethyl]-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-hydroxy-2(S)-{N - acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanophenethyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-acetyl}-4(R)-methoxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanopheneth-1-yl)-1H-imidazol-5-yl-acetyl-4(R)-methoxy- 2(S)-{N'-acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-- imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl-aminomethyl}pyrrolidine

N-{ 1-(4-Cyanophenethyl)-1H-- imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)- { N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

N-{ 1-(4-Cyanobenzyl)-5-imidazolacetyl}-4(R)-benzyloxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-5-imidazol-5-ylmethyl}-4(R)-(2- henylbenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(4- chlorobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-5-imidazolemethyl}-4(R)-(4-cyanobenzyloxy)- 2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-5-imidazol-5-ylmethyl}-4(R)-(3- pyridylmethoxy)-2(S)-{N'-acetyl-N'-3-chlorobenzyl}

aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(phenoxy)-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(2- methylacetyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(acetyloxy)-2(S)- { N'-acetyl-N'-3-chlorobenzyl } aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(2- methylacetyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(acetyloxy)-2(S)- { N'-3-chlorobenzyl-N'-acetyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(S)-(phenoxy)-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-5-imidazolethyl}-4(S)-(phenoxy)-2(S)-{N'-acetyl- N'-3-chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(S)-fluoro-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5ylethyl-4(R)-(2-phenylbenzyloxy)- 2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl }-4(R)-(4- chlorobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(4- cyanobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(3-pyridylmethoxy)- 2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethyl-ρyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-2(S)-{N'-acetyl-N'-3- cyanobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S)-{N'-acetyl-N'-3- methoxybenzyl}aminomethylpyrrolidine.

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- trifluoromethylbenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N^,-2- methoxybenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-2- trifluoromethylbenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N"-acetyl-N'-(2,2- diphenylethyl)}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'- diphenylmethyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N^,-acetyl-N^,-2- chlorobenzyl}aminomethylpyrrolidine

N-{2(R)-Methyl-2-(1-(4-Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{2(S)-Methyl-2-(1-(4-Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N^,-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-4- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N^,-2,3- dichlorobenzyl}aminomethylpyrrolidine

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylJacetyl-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-naphth-1-ylmethyl}aminomethylpyrrolidine

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl-4(R)-benzyloxy-proline naphth-1-ylmethylamide N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylproline naphth-1- ylmethylamide N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)-methoxy-2(S)-{N'- acetyl-N'-5,6,7,8-tetrahydronaphth-1-ylmethyl}aminomethylpyrrolidine

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-5,56,7,8-tetxahydronaphth-1-ylmethyl}aminomethylpyrrolidine

1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-Allyloxycarbonyl-2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)-methyl- N-(naphth-2-ylsulfonyl)-pentanamine

N-Acetyl-N-2-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

N-Acetyl-N-3-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

N-Acetyl-N-4-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine N-Acetyl-N-2,3-dichlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)-methyl-pentanamine

N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{2(R,S)-methyl-2-(1-(4- cyanobenzyl)-1H-imidazol -5-yl)acetyl}amino-3(S)-methyl-pentanamine N-t-Butoxycarbonylaminoacetyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4- cyanobenzyl)-1H-imidazol-5-ylacetyl}amino-3(S)-methylpentanamine

N-Aminoacetyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H- imidazol-5-ylacetyl}amino-3(S)-methylpentanamine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethoxycarbonyl}-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-ylacetyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)ethyl}-2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-{N^,-acetyl-N^,-3- chlorophenyl}aminomethylpyrrolidine hydrochloride

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine

N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)glycine N'-(3-chlorophenyl)amide 1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)-glycine N'-(3-chlorophenylmethyl) amide

N-[1-(3-[1H-Imidazol-4-ylJpropionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine N'-methyl-N'-(3-chlorophenyl) amide 1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)-glycine N'-methyl-N'-(3- chlorophenylmethyl) amide (S)-2-[(1-(4-cyanobenzyl)-5-imidazolylmethyl)amino]-1-[N-(2,3- dimethylphenyl)acetamido]hexane

(S)-2-[N -(1-(4-cyanobenzyl)-5-imidazolylmethyl)-N-(methyl)amino]-1- [N-(2,3-dimethylphenyl)acetamido]hexane

N-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-N'-(3- chlorophenyl)ethylenediamine

1-(4-Cyanobenzyl)-5-[N-(3-phenylpropyl)aminomethyl] imidazole and

(S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)aminoJ-N- (benzyloxycarbonyl)-N -(3-chlorobenzyl)-4-(methanesulfonyl)butanamine or the pharmaceutically acceptable salts thereof.

Specific examples of the compounds of the invention are:

N-Allyloxycarbonyl-N-1-naphthylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-1-Acetyl-N-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methylpentanamine

N-Propionyl-N-1-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Methylsulfonyl-N-1-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Ethylsulfonyl-N-1-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methylpentanamine

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- (phenylacetyl)amino-N-methyl-N-benzyl)propionamide

N-[2(S)-{ [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylpentyl]-N-(1-naphthylmethyl)glycine piperidinylamide

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S)-{N'-acetyl-N'- (naphth-1-ylmethyl)aminomethyl}-pyrrolidine

N-(2,3-Dimethylphenyl)-N-methoxycarbonyl-2(S)-[4-cyanobenzyl-4- (imidazolylmethyl)amino]-3(S)-methylpentamine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

or the pharmaceutically acceptable salts or optical isomers thereof.

In the present invention, the amino acids which are disclosed are identified both by conventional 3 letter and single letter abbreviations as indicated below:

The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. It is also understood that when a bond is drawn from a substituent into a ring, such as the bonds drawn into the imidazolyl ring in formula la hereinabove, that attachement of that substituent is at any carbon or heteroatom of the ring as long as a stable compound is formed.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.

As used herein, "cycloalkyl" is intended to include non- aromatic cyclic hydrocarbon groups having the specified number of carbon atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

"Alkenyl" groups include those groups having the specified number of carbon atoms and having one or several double bonds.

Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, isoprenyl, famesyl, geranyl, geranylgeranyl and the like.

As used herein, "aryl" is intended to include any stable monocyclic, bicyclic or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl and the like.

The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11- membered bicyclic or stable 11-15 membered tricyclic heterocycle ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl,

benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl,

benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, oxazolyl, isoxazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, pyridonyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolinyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl,

thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl.

As used herein, the terms "substituted aryl", "substituted heterocycle" and "substituted cycloalkyl" are intended to include the cyclic group which is substituted with 1 or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF₃, NH₂, N(C₁- C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁- C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆

alkyl)OC(O)-, N₃,( C₁-C₆ alkyl)OC(O)NH- and C₁-C₂₀ alkyl.

The following structure:

represents a cyclic amine moiety having 5 or 6 members in the ring, such a cyclic amine which may be optionally fused to a phenyl or cyclohexyl ring. Examples of such a cyclic amine moiety include, but are not limited to, the following specific structures:

It is also understood that substitution on the cyclic amine moiety by R^13a and R^13b may be on different carbon atoms or on the same carbon atom.

When R² and R³ are combined to form - (CH₂)_s -_, cyclic moieties are formed. Examples of such cyclic moieties include, but are not limited to:

The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.

It is intended that the definition of any substituent or variable (e.g., R¹⁰, Z, n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, -N(R¹⁰)₂ represents -NHH, -NHCH₃, -NHC₂H₅, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth below.

Preferably, R^1a and R^1b are independently selected from: hydrogen, -N(R¹⁰)₂, R¹⁰C(O)NR¹⁰- or unsubstituted or substituted C₁- C₆ alkyl wherein the substituent on the substituted C₁-C₆ alkyl is selected from unsubstituted or substituted phenyl, -N(R¹⁰)₂, R¹⁰O- and R¹⁰C(O)NR¹⁰-. More preferably, R^1a and R^1b are independently selected from: hydrogen or unsubstituted or substituted C₁-C₆ alkyl. Further preferably, R^1b is not -N(R¹⁰)₂ or C₁-C₆ alkyl substituted with -N(R¹⁰)₂.

Preferably, R² and R³ are independently selected from: a side chain of a naturally occurring amino acid, methionine sulfoxide, methionine sulfone, C₁-C₆ alkyl and C₁-C₆ alkyl substituted by a group selected from aryl, heterocycle and C₃-C₁₀ cycloalkyl; or R² or R³ are combined with R⁷ to form a ring such that

Most preferably, R² or R³ are combined with R⁷ to form a ring such that

Preferably, R⁴ and R⁵ are independently selected from: H, unsubstituted or substituted C₁-C₆ alkyl, R¹⁰O- and halogen.

Preferably, R^13a and R^13b are independently selected from: H, unsubstituted or substituted C₁-C₆ alkyl, R¹⁴O- and halogen.

Preferably, R⁶ is not hydrogen or C₁-C₆ alkyl when A³ is .- N(R⁷)-.

Preferably, R⁷ is hydrogen, unsubstituted aryl, substituted aryl, or C₁-C₆ alkyl substituted with an unsubstituted aryl or a substituted aryl. Most preferably, R⁷ is substituted aryl or C₁-C₆ alkyl substituted with a substituted aryl .

Preferably, R⁸ is selected from: hydrogen, perfluoroalkyl, F,

Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, CN, NO₂, R¹⁰ ₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰- and C₁-C₆ alkyl.

Preferably, R⁹ is hydrogen. Preferably, R¹⁰ is selected from H, C₁-C₆ alkyl and benzyl. Preferably, A¹ and A² are independently selected from: a bond, -C(O)NR⁷-, -NR⁷C(O)-, O, -N(R⁷)-, -S(O)₂N(R⁷)- and-

N(R⁷)S(O)₂-.

Preferably, A⁴ is selected from a bond and O.

Preferably, V is selected from hydrogen, heterocycle and aryl. More preferably, V is phenyl.

Preferably, W is selected from imidazolinyl, imidazolyl, oxazolyl, pyrazolyl, pyrrolidinyl, thiazolyl and pyridyl. More preferably, W is selected from imidazolyl and pyridyl.

Preferably, Z is O or H₂. Most preferably, Z is H₂.

Preferably, n and p are independently 0, 1, or 2.

Preferably r is 1, 2 or 3.

Preferably t is 3 or 4.

Preferably q is 1.

The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods.

Generally, the salts are prepared by reacting the free base with

stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.

The compounds of the invention can be synthesized from readily available amino acids by conventional peptide synthesis

techniques, and the additional methods, well known in the art, described below. Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al, "The Peptides", Vol. I,

Academic Press 1965, or Bodanszky et al, "Peptide Synthesis",

Interscience Publishers, 1966, or McOmie (ed.) "Protective Groups in

Organic Chemistry", Plenum Press, 1973, or Barany et al, "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, or Stewart et al., "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. Also useful in exemplifying syntheses of specific unnatural amino acid residues are European Pat. Appl. No. 0 350 163 A2 (particularly page 51-52) and J. E. Baldwin et al. Tetrahedron, 50:5049-5066 (1994). The teachings of these works are hereby

incorporated by reference.

Abbreviations used in the description of the chemistry and in the Examples that follow are:

Ac2θ Acetic anhydride;

Boc t-Butoxycarbonyl;

DBU 1,8-diazabicyclo[5.4.0]undec-7-ene;

DMAP 4-Dimethylaminopyridine;

DME 1,2-Dimethoxyethane;

DMF Dimethylformamide;

EDC 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide

hydrochloride;

HOBT 1-Hydroxybenzotriazole hydrate;

Et₃N Triethylamine;

EtOAc Ethyl acetate;

FAB Fast atom bombardment;

HOOBT 3-Hydroxy-1,2,2-benzotriazin-4(3H)-one;

HPLC High-performance liquid chromatography;

MCPBA m-Chloroperoxybenzoic acid;

MsCl Methanesulfonyl chloride;

NaHMDS Sodium bis(trimethylsilyl)amide;

Py Pyridine;

TFA Trifluoroacetic acid;

THF Tetrahydrofuran.

Compounds of this invention are prepared by employing the reactions shown in the following Reaction Schemes A-J, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Some key bond-forming and peptide modifying reactions are: Reaction A Amide bond formation and protecting group cleavage using standard solution or solid phase methodologies. Reaction B Preparation of a reduced peptide subunit by reductive

alkylation of an amine by an aldehyde using sodium cyanoborohydride or other reducing agents.

Reaction C Alkylation of a reduced peptide subunit with an alkyl or aralkyl halide or, alternatively, reductive alkylation of a reduced peptide subunit with an aldehyde using sodium cyanoborohydride or other reducing agents.

Reaction D Peptide bond formation and protecting group cleavage using standard solution or solid phase methodologies.

Reaction E Preparation of a reduced subunit by borane reduction of the amide moiety. These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes and in Reaction Schemes 1- 5 hereinbelow.

REACTION SCHEME A

Reaction A. Coupling of residues to form an amide bond

REACTION SCHEME B

Reaction B. Preparation of reduced peptide subunits by reductive alkylation

REACTION SCHEME C

Reaction C. Alkylation/reductive alkylation of reduced peptide subunits

REACTION SCHEME D

Reaction D. Coupling of residues to form an amide bond

REACTION SCHEME E

Reaction E. Preparation of reduced dipeptides from peptides

where R^A and R^B are R², R³ or R⁵ as previously defined; RC and R^D are R⁷ or R¹²; XL is a leaving group, e.g., Br-, I- or MsO-; and Ry is defined such that R⁷ is generated by the reductive alkylation process.

In addition to the reactions described in Reaction Schemes A - E, other reactions used to generate the compounds of this invention are shown in the Reaction Schemes 1-20. All of the substituents shown in the Reaction Schemes, represent the same substituents as defined hereinabove. The substituent "Ar" in the Reaction Schemes represents a carbocyclic or heterocyclic, substituted or unsubstituted aromatic ring.

These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to

synthesize fragments which are subsequently joined by the alkylation reactions described in the Reaction Schemes. The sequential order whereby substituents are incorporated into the compounds is often not critical and thus the order of reactions described in the Reaction Schemes are illustrative only and are not limiting.

Synopsis of Reaction Schemes 1-20:

The requisite intermediates are in some cases commercially available, or can be readily prepared according to known literature procedures, including those described in Reaction Schemes A-E hereinabove. Thus, the intermediate II, generally prepared from the appropriate amino acid by the above noted methods with the suitable substituents fully incorporated, (Scheme 3), can be reductively alkylated with a variety of aldehydes, such as III. The aldehydes can be prepared by standard procedures, such as that described by O. P. Goel, U. Krolls, M. Stier and S. Kesten in Organic Syntheses, 1988, 67, 69-75. The reductive alkylation can be accomplished at pH 5-7 with a variety of reducing agents, such as sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as dichloroethane, methanol or dimethylformamide. The product IV can be deprotected to give the compounds V with trifluoroacetic acid in methylene chloride. The intermediate V is isolated in the salt form, for example, as a

trifluoroacetate, hydrochloride or acetate salt, among others. The product diamine V can further be selectively protected to obtain VI, which can subsequently be reductively alkylated with a second aldehyde to obtain VII. Removal of the protecting group, and conversion to cyclized products such as the dihydroimidazole VIII can be accomplished by literature procedures.

Alternatively, the protected intermediate II can be reductively alkylated with other aldehydes (which may be suitably protected if necessary), many of which are readily commercially available, such as 4-bromo-2-thiophenecarboxaldehyde, 5- methoxyindole-3-carboxaldehyde, 6-methyl-2-pyridinecarboxaldehyde, 3-pyridinecarboxaldehyde, 4-imidazolyl-acetaldehyde and the like, to give products such as IX (Reaction Scheme 2). The trityl protecting group can be removed from IX to give X, or alternatively, IX can first be treated with an alkyl halide then subsequently deprotected to give the alkylated imidazole XI.

As shown in Reaction Scheme 3, related carboxylic acids, such as the imidazole acetic acid XII, can be converted to the acetate XIII by standard procedures and incorporation of a protecting group, and XIII can be first reacted with an alkyl halide, then treated with refluxing methanol to provide the regiospecifically alkylated imidazole acetic acid ester XIV. Hydrolysis and reaction with the fully functionalized peptidyl portion of the molecule II in the presence of condensing reagents such as l-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) leads to acylated products such as XVI.

It is also understood that the reactions illustrated in Reaction Schemes 1-3 can be utilized to prepare an intermediate that can

subsequently be treated as described in Reaction Schemes A-E. Thus, as shown in Reaction Schemes 4 and 5, suitably protected amino acids XVII and XVIII, can be reacted with the acetic acid XV to provide

intermediates XIX and XX, which can then undergo further

functionalization by standard techniques.

Reaction Schemes 6 and 7 illustrate synthetic routes to the instant compounds in which the sequential order that the substituents are incorporated is shuffled. Thus in Reaction Scheme 6 the suitably protected aldehyde XXI can be reductively aminated to provide

compound XXII. The amine group of XXII can be blocked and the BOC protecting group removed. Coupling with the substituted acetic acid provides XXIV, which can then be deblocked with Pd(PPh₃)₄ and further functionalized. Alternatively, compound XXII can first be functionalized on the amine to provide, for example, amide XXV. Deprotection and reaction with intermediate XV as before provides the instant compound XXVI.

In Reaction Scheme 7, the primary amine XXVIII is prepared from the alcohol XXVII and blocked with an allyloxycarbonyl group. Deprotection and reaction with intermediate XV as before provides the blocked amine XXIX which, after removal of the

allyloxycarbonyl protecting moiety by standard procedures, may be mono- or di-substituted using techniques described above.

Reaction Scheme 8 illustrates incorporation of a cyclic amine moiety, such as a reduced prolyl moiety, into the compounds of the instant invention. Reduction of the azide XXX provides the amine

XXXI, which may be mono- or di-substituted using techniques described above. As an example, incorporation of a naphthylmethyl group and an acetyl group is illustrated. As shown in Reaction Scheme 9, direct attachment of a aromatic ring to a substituted amine such as XXXII is accomplished by coupling with a triarylbismuth reagent, such as tris(3- chlorophenyl)bismuth.

Reaction Scheme 10 illustrates the use of protecting groups to prepare compounds of the instant invention wherein the cyclic amine contains an alkoxy moiety. The hydroxy moiety of key intermediate XXXIV may be further converted to a fluoro or phenoxy moiety, as shown in Reaction Scheme 11. Intermediates XXXV and XXXVI may then be further elaborated to provide the instant compounds.

Reaction Scheme 12 illustrates syntheses of instant

compounds wherein the variable -(CR⁴2)_qA₃(CR⁵ ₂)_nR⁶ is a suitably substituted α-hydroxybenzyl moiety. Thus the protected intermediate aldehyde XXXVII is treated with a suitably substituted phenyl Grignard reagent to provide the enantiomeric mixture XXXVIII. Treatment of the mixture with 2-picolinyl chloride allows chromatographic resolution of compounds IXL and XL. Removal of the picolinoyl group followed by deprotection provides the optically pure intermediate XLI which can be futher processed as described hereinabove to yield the instant compounds.

Syntheses of imidazole-containing intermediates useful in synthesis of instant compounds wherein the variable p is 0 or 1 and Z is H₂ are shown in Reaction Scheme 13 and 14. Thus the mesylate XLII can be utilized to alkylate a suitably substituted amine or cyclic amine, while aldehyde XLIII can be used to similarly reductively alkylate such an amine.

Reaction Scheme 15 illustrates te syntheses of imidazole- containing intermediates wherein the attachment point of the

-(CR^1b ₂)_p-C(Z)- moiety to W (imidazolyl) is through a ring nitrogen. Reaction Scheme 16 illustrates the synthesis of an intermediate wherein a R^1b substitutent is a methyl.

Reaction Schemes 17-20 illustrate syntheses of suitably substituted aldehydes useful in the syntheses of the instant compounds wherein the variable W is present as a pyridyl moiety. Similar synthetic strategies for preparing alkanols that incorporate other heterocyclic moieties for variable W are also well known in the art.

)

X

XV

The instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras activity (i.e., neurofibromin (NF-1), neu, ser, abl, lck, fyn) or by other mechanisms.

The compounds of the instant invention inhibit famesyl- protein transferase and the farnesylation of the oncogene protein Ras. The instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575- 4580 (1995)). Such anti-angiogenesis properties of the instant

compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.

The compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment. For example, a component of NF-1 is a benign proliferative disorder.

The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256:1331-1333 (1992).

The compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1:541-545(1995).

The instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffner et al.

American Journal of Pathology, 142: 1051-1060 (1993) and B. Cowley, Jr. et al.FASEB Journal, 2: A3160 (1988)).

The instant compounds may also be useful for the treatment of fungal infections. The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous,

intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.

For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or

suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral

administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added. For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.

The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the

administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.

The compounds of the instant invention may also be co- administered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated. For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Similarly, the instant

compounds may be useful in combination with agents that are effective in the treatment and prevention of NF- 1 , restenosis, polycystic kidney disease, infections of hepatitis delta and related viruses and fungal infections.

If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically

acceptable agent(s) when a combination formulation is inappropriate.

When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.

In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 20 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 10 mg/kg of body weight per day.

The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of famesyl-protein transferase (FPTase) in a composition. Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.

It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain famesyl-protein transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of famesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor (i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.

EXAMPLES

Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof.

EXAMPLE 1

N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine Step A: Preparation of 1H-Imidazole-4- acetic acid methyl ester hydrochloride.

A solution of 1H-imidazole-4-acetic acid hydrochloride (4.00g, 24.6 mmol) in methanol (100 ml) was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature (RT) for 18hr. The solvent was evaporated in vacuo to afford the title compound as a white solid.

¹H NMR(CDCl₃, 400 MHz) δ 8.85(1H, s),7.45(1H, s), 3.89(2H, s) and 3.75(3H, s) ppm.

Step B: Preparation of 1-(Triphenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester.

To a solution of the product from Step A (24.85g, 0.141mol) in dimethyl formamide (DMF) (115ml) was added triethylamine (57.2 ml, 0.412mol) and triphenylmethyl bromide(55.3g, 0.171mol) and the suspension was stirred for 24hr. After this time, the reaction mixture was diluted with ethyl acetate (EtOAc) (1 1) and water (350 ml). The organic phase was washed with sat. aq. NaHCO₃ (350 ml), dried (Na₂SO₄) and evaporated in vacuo. The residue was purified by flash chromatography (SiO₂, 0-100% ethyl acetate in hexanes; gradient elution) to provide the title compound as a white solid.

¹H NMR (CDCl₃, 400 MHz) δ 7.35(1H, s), 7.31(9H, m), 7.22(6H, m), 6.76(1 H, s), 3.68(3H, s) and 3.60(2H, s) ppm.

Step C: Preparation of [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetic acid methyl ester.

To a solution of the product from Step B (8.00g, 20.9mmol) in acetonitrile (70 ml) was added bromo-p-tolunitrile (4.10g, 20.92 mmol) and heated at 55°C for 3 hr. After this time, the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was heated at 55°C for 18hr. The reaction mixture was cooled to room temperature and evaporated in vacuo. To the residue was added EtOAc (70 ml) and the resulting white precipitate collected by filtration. The precipitated imidazolium salts were combined, suspended in methanol (100 ml) and heated to reflux for 30min. After this time, the solvent was removed in vacuo, the resulting residue was suspended in EtOAc (75ml) and the solid isolated by filtration and washed (EtOAc). The solid was treated with sat aq

NaHCO₃ (300ml) and CH₂CI₂ (300ml) and stirred at room temperature for 2 hr. The organic layer was separated, dried (MgSO₄) and

evaporated in vacuo to afford the title compound as a white solid :

1HNMR(CDCl₃, 400 MHz) δ 7.65(1H, d, J=8Hz), 7.53(1H, s), 7.15(1H, d, J=8Hz), 7.04(1H, s), 5.24(2H, s), 3.62(3H, s) and 3.45(2H, s) ppm.

Step D: Preparation of [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetic acid.

A solution of [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetic acid methyl ester (4.44g, 17.4mmol ) in THF (100ml) and 1 M lithium hydoxide (17.4 ml, 17.4 mmol) was stirred at RT for 18 hr. 1 M HCl

(17.4 ml) was added and the THF was removed by evaporation in vacuo.

The aqueous solution was lyophilised to afford the title compound containing lithium chloride as a white solid.

1H NMR(CD₃OD, 400 MHz) δ 8.22(1H, s), 7.74(1H, d, J=8.4Hz),

7.36(1H, d, J=8.4Hz), 7.15(1H, s), 5.43(2H, s) and 3.49(2H, s) ppm.

Step E: Preparation of N-Naphth-1-ylmethyl-2(S)-(t-butoxy- carbonyl)amino-3(S)-methylpentanamine

To a slurry of 1-naphthylmethylamine (5.84g, 37.2 mmol), crushed 3A molecular sieves (10g), and N-t-butoxycarbonyl-isoleucinal (8.0g, 37.2 mmol) in 1,2-dichloroethane (50 ml) was added sodium triacetoxyborohydride (15.8g, 74.3 mmol) at 0°C. The reaction was allowed to warm slowly to RT and stirred for 48 hrs. The reaction was cooled to 0°C and quenched with sat. aq. NaHCO₃ and stirred for 30min. The organic layer was separated, washed with saturated brine, dried (MgSO₄) and evaporated in vacuo. The residue was purified by flash chromatography (SiO₂, 25% ethyl acetate in hexanes) to provide the title compound as an oil. ¹HNMR(CDCl₃, 400 MHz) δ 8.16(1H, d, J=7.9Hz), 7.87(1H, d,

J=7.9Hz), 7.78(1H, d, J=7.7Hz), 7.60-7.40 (4H, m), 4.62(1H, m), 4.25(1H, d, J=13.2Hz), 4.19(1H, d, J=13.2Hz), 3.68(1H, m), 2.90- 2.70(2H, m), 1.70-1.35(3H, m) and 1.45(9H, s) 1.12(1H, m) and 1.00- 0.80 (6H, m) ppm.

Step F: Preparation of N-Allyoxycarbonyl-N-naphth-1-ylmethyl-

2(S)-(t-butoxycarbonyl)amino-3(S)-methylpentanamine To a solution of the amine from step E (4.62g, 13.0 mmol), and triethylamine (4.40ml, 31.6 mmol) at 0°C , allylchloroformate

(1.85ml, 17.4 mmol) was added dropwise. The reaction was allowed to warm slowly to RT and stirring was continued for 18hrs. The solvent was evaporated in vacuo and the residue was chromatographed (SiO₂, 10% EtOAc in hexanes) to afford the title compound as an oil.

1HNMR(CDCl₃, 400 MHz) δ 8.10(0.4H, d, J=7.9Hz), 8.00(0.6H, d, J=7.9Hz), 7.88(1H, m), 7.80(1H, m), 7.60-7.30 (4H, m), 6.10-5.85(1H, m), 5.50-5.10(3H, m), 4.90-4.40(4H,m), 3.90(1H,m), 3.71(0.6H, t, J= 12.6Hz), 3.36(0.4H,t, J= 12.6Hz), 2.90-2.70(1H,m), 1.47(9H,s), 1.50- 1.20(2H,m), 1.05(1H,m)and 0.95-0.70 (6H, m) ppm.

FAB HRMS exact mass calc'd for C₂₆H₃₇N₂O₄ 441.275333 (MH⁺), found 441.275084.

Step G: Preparation of N-Allyoxycarbonyl-N-naphth -1-ylmethyl- 2(S)-amino-3(S)-methylpentanamine hydrochloride

A solution of the product from step F (4.75g, 10.8 mmol) in

EtOAc (200 ml) at 0°C was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature (RT) for 30min. The solvent was evaporated in vacuo to afford the title compound as a white solid.

1H NMR(CD₃OD, 400 MHz) δ 8.06(1H, m), 7.93(1H, m), 7.88(1H,d, J=8.2Hz), 7.60-7.45(3H,m), 7.38(1H,m), 6.01(1H,m), 5.40-5.19(2H,m), 5.10(2H,m), 4.80-4.60(2H,m), 3.62(1H,m), 3.50-3.20(1H,m),

3.11(1H,m), 1.57(1H,m), 1.23(1H,m), 1.03(1H,m) and 0.90-0.75(6H,m) ppm. FAB HRMS exact mass calc'd for C₂₁H₂₉N₂O₂ 341.222903 (MH⁺), found 341.223321

Step H: Preparation of N-Allyoxycarbonyl-N-naphth-1-ylmethyl- 2(S)-[1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetylamino-

3(S)-methylpentanamine hydrochloride

To a solution of the acid from step D (1.47g, 3.32mmol), the amine hydrochloride salt from step G (1.252g, 3.32mmol), HOOBT

(650mg, 3.98mmol), and triethylamine (1.60ml, llmmol) in DMF was added EDC (764mg, 3.99 mmol). The reaction was stirred at room temperature for 48hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃ , brine , dried (Na₂SO₄). and evaporated in vacuo.

The residue was chromatographed (SiO₂, 3.5% MeOH in CH₂CI₂) to afford the title compound as an oil.

1H NMR(CD₃OD, 400 MHz) δ 8.00-7.70 (6H, m), 7.52(2H, m),

7.44(1H,t, J=7.6Hz), 7.38-7.25(3H,m), 6.96(1H,s), 6.10-5.90(1H,m),

5.43(2H,m), 5.40-4.80(5H,m), 4.60(2H,m), 4.18(1H,m), 3.60-

3.10(4H,m), 1.40(2H,m), 1.06(1H,m), 0.85(3H, t, J=7.5Hz), and 0.77(3H, d, J=7.5Hz) ppm.

Anal, calc'd for C₃₄H₃₇N₅O₃ 0.65H₂O: C, 70.97; H, 6.71; N, 12.17.

Found: C, 70.59; H, 6.59; N, 12.56.

FAB HRMS exact mass calc'd for C₃₄H₃₈N₅O₃ 564.297465(MH⁺), found 564.296221 EXAMPLE 2

N-Naphth-1-ylmethyl -2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)- methyl pentanamine

The product of Example 1 (1.67g, 2.96 mmol), and 5,5- dimethyl-1,3- cyclohexandione (3.31g, 23.6 mmol) were combined, the flask was purged with argon and tetrakis(triphenylphosphine) palladium (0) (585mg, 0.506 mmol) was added and the flask purged with argon again. The flask was wrapped with foil , THF (36ml) was added and the reaction was stirred in the dark, at room temperature for 90min. The solvent was evaporated in vacuo and the residue was chromatographed (SiO₂, 2% NH₄OH in 98% CH₃CN -5% NH₄OH in 95% CH₃CN and then 5% MeOH,5% NH₄OH in 90% CH₃CN; gradient elution) to afford the title compound as a pale yellow solid.

1H NMR(CD₃OD, 400 MHz) δ 8.10(1H, m),7.98(1H,m), 7.84(1H,d, J=7.5Hz), 7.68(1H,s), 7.63(2H, d, J=8.3Hz), 7.53(2H,m), 7.48-7.40(2H, m), 7.16(2H,d, J=8.3Hz), 6.91(1H, s), 5.30(2H, s), 4.35(1H, d, J=13.3Hz), 4.22(1H, d, J=13.3Hz), 3.96(1H, m), 3.40(1H, dd, J=15.7 and 7.0Hz), 3.36-3.28(1H,m), 2.96(1H, dd, J=11.9 and 3.6Hz), 2.75(1H, dd, J=11.9 and 9.5Hz), 1.60-1.35(2H,m), 1.20-1.05(1H,m), 0.95-0.84(6H,m) ppm. Anal, calc'd for C₃₀H₃₃N₅O₁ 0.25H₂O: C, 74.43; H, 6.97; N, 14.47. Found: C, 74.39; H, 6.92; N, 14.34.

FAB HRMS exact mass calc'd for C₃₀H₃₄N₅O₁ 480.276336 (MH⁺), found 480.276866

EXAMPLE 3

N-Methoxycarbonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl)amino-3(S)- methyl pentanamine.

To a solution of the product of Example 2 (40mg, 0.083 mmol) in CH₂CI₂ (1ml) and triethylamine (24μl, 0.17mmol) at 0°C was added methyl chloroformate(39μl of a 2.1M solution in CH₂CI₂, 0.082 mmol). The reaction was stirred at room temperature for 3hr, the solvent evaporated in vacuo and the residue purified by preparative HPLC (C-18; 95:5 to 5:95 water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.97(1H, m), 8.02-7.76(5H, m), 7.80- 7.20(7H,m), 5.58(2H,s), 5.12( 1H,m), 4.20(1H,m), 3.80-3.45(6H,m), 3.16(1H,m), 1.42(2H,m), 1.08 (1 H, m), 0.90-0.80(3H,m), and 0.77(3H, d, J=7.0Hz) ppm.

FAB Mass spectmm, m/z = 538 (M+1).

Anal, calc'd for C₃₂H₃₅N₅O₃ 0.25H₂O, 1.85TFA; C, 56.94; H, 5.00; N, 9.30. Found: C, 56.96; H, 5.02; N, 9.26. EXAMPLE 4

N- Acetyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)-methylpentanamine.

The title compound was prepared using the protocol described in Example 3 using acetyl chloride in place of

methylchloroformate.

¹H NMR(CD₃OD, 400 MHz) δ 8.98(1H, m),8.20-7.76(6H, m), 7.70- 7.20(7H, m), 5.70-5.40(2H, m), 5.09(1H, m), 4.80-4.60(0.5H, m),

4.28(0.5H, m), 4.14(0.5H, m), 3,75(1H, m), 3.65-3.60(1.5H,m), 3.40-

3.10(2H,m), 2.22(1.5H, s), 2.02(1.5H, s), 1.45(2H,m), 1.11(1H, m),

0.87(3H, t, J=7.0Hz), 0.81(1.5H, d, J=7.0Hz), 0.75(1.5H, d, J=7.0Hz) ppm.

FAB Mass spectrum, m/z = 522 (M+ 1 ).

Anal, calc'd for C₃₂H₃₅N₅O₂ 0.05H₂O, 2.35TFA; C, 55.76; H, 4.78; N,

8.86. Found: C, 55.77; H, 4.78; N, 8.94.

EXAMPLE 5

N-Propionyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine.

The title compound was prepared using the protocol described in Example 3 using propionyl chloride in place of

methylchloroformate.

¹H NMR(CD₃OD, 400 MHz) δ 8.90(1H, m), 8.20-7.76(6H, m), 7.70- 7.16(7H, m), 5.70-5.40(2H, m), 5.09(1H, m), 4.80-4.60(0.5H, m),

4.27(0.5H, m), 4.14(0.5H, m), 3,82-3.64(1H, m), 3.65-3.60(1.5H,m), 3.42-3.05(1H,m), 2.64-2.20(2H,m), 1.45(2H,m), 1.15(1.5H, t, J=7.2Hz), 1.20-1.10(1H,m), 1.03(1.5H, t, J=7.2Hz), 0.96-0.70((6H,m) ppm.

FAB Mass spectram, m/z = 536 (M+1).

Anal, calc'd for C₃₂H₃₅N₅O₂ 0.05H₂O, 1.80TFA; C, 59.26; H, 5.29 N, 9.44. Found: C, 59.26; H, 5.29; N, 9.39. EXAMPLE 6

N-Methylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl)amino-3(S)- methylpentanamine.

The title compound was prepared using the protocol described in Example 3 using methane sulfonyl chloride in place of methylchloroformate.

¹H NMR(CD₃OD, 400 MHz) δ 8.97(1H, m),8.30(1H,m), 7.95-7.90(2H, m), 7.81(2H, d, J=8.2Hz), 7.60-7.35(8H, m), 5.52(2H, s), 5.02(1H,d, J=14.4Hz), 4.74(1H,d, J=14.4Hz), 3.56-3.30(4H, m), 3.18(1H,dd,

J=14.6Hz and 3Hz), 2.98(3H,s), 1.26(1H, m), 1.16(1H,m), 0.92(1H,m),

0.69(3H, t, J=7.1Hz) and 0.61(3H,d, J=7.1Hz) ppm.

FAB Mass spectrum, m/z = 558 (M+1).

Anal, calc'd for C₃₁H₃₅N₅O₃S , 1.90TFA; C, 53.98; H, 4.80 N, 9.04. Found: C, 53.96; H, 4.81; N, 9.07.

EXAMPLE 7

N-Ethylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine.

The title compound was prepared using the protocol described in Example 3 using ethane sulfonyl chloride in place of methylchloroformate.

¹H NMR(CD₃OD, 400 MHz) δ 8.97(1H, m),8.27(1H,m), 7.92(2H, m), 7.81(2H, d, J=8.2Hz), 7.60-7.35(8H, m), 5.55(2H, s), 5.02(1H,d,

J=14.4Hz), 4.76(1H,d, J=14.4Hz), 3.60-3.35(4H, m), 3.18(1H,dd,

J=14.6Hz and 3Hz), 3.10(2H,m), 1.63(3H,t, J=6.5Hz), 1.30-1.10(2H, m),

0.94(1H,m), 0.71(3H, t, J=7.1Hz) and 0.61(3H,d, J=7.1Hz) ppm.

FAB Mass spectrum, m/z = 572 (M+1).

Anal, calc'd for C₃₂H₃₇N₅O₃S , 0.15 H₂O, 1.40TFA; C, 56.94; H,

5.31N, 9.54. Found: C, 56.97; H, 5.32; N, 9.54. EXAMPLE 8

N-Methylaminocarbonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4- cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine.

To a solution of the amine from Example 2 (40mg, 0.083 mmol) in CH₂CI₂ (1ml) at 0°C was added methyl isocyanate (20μl of a 4.24M solution in CH₂CI₂). The reaction was stirred at room temperature for 2hr, the solvent evaporated in vacuo and the residue purified by preparative HPLC ( C-18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the trifluoroacetate salt of the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.97(1H, m),8.00-7.76(6H, m), 7.60- 7.40(6H,m), 7.28(1H,d, J=7.4Hz), 5.58(2H, s), 5.05(1H,m), 4.90- 4.70(2H,m), 4.30-4.05(1H,m), 3.75-3.45(3H,m), 3.12(1H, dd, J=15.6 and 4.2 Hz), 2.73(3H,s), 1.50-1.35(2H,m), 1.12-1.09(1H,m), 0.90-0.8 l(3H,m) and 0.78(3H,d, J=6.7Hz) ppm.

FAB Mass spectmm, m/z = 537 (M+1).

Anal, calc'd for C₃₂H₃₆N₆O₂ 0.15H₂O, 1.60TFA; C, 58.57 H, 5.29 N, 11.64. Found: C, 58.56; H, 5.28; N, 11.66.

EXAMPLE 9

N-Propyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl]amino-3(S)- methylpentanamine

To a slurry of the amine prepared in Example 2 (100.6mg, 0.21 mmol), cmshed 3 A molecular sieves (290mg), and

propionaldehyde (15.5ml, 0.22 mmol) in 1,2 dichloroethane (2 ml) was added sodium triacetoxyborohydride (53.6mg, 0.253 mmol) at 0°C. The reaction was allowed to warm slowly to RT and stirred for 48 hrs. The reaction was cooled to 0°C diluted with EtOAc and quenched with sat. aq. NaHCO₃ and stirred for 30min. The organic layer was separated, washed with saturated brine, dried( MgSO₄) and purified by preparative HPLC ( C-18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the trifluroacetate salt of the title compound as a white solid. A portion of the product was partitioned between EtOAc and sat aq. Na₂CO₃, the organic layer separated and dried (Na₂SO₄) and the solvent evaporated in vacuo to afford the corresponding free base as an oil.

1H NMR Free Base (CD₃OD, 400 MHz) δ 8.30(1H, d, J=7.5Hz),

7.83(1H, d, J=7.5Hz), 7.77(1H, d, J=7.5Hz), 7.70-7.60(3H,m), 7.50- 7.30(4H,m), 7.15(2H, d, J=8.7Hz), 6.85(1H, s), 5.30(2H,s), 4.02- 3.90(3H,m), 3.23(2H,m), 2.56(1H, dd, J=12.4 and 5.8Hz), 2.44(2H, t, J=7.4Hz), 2.36(1H, dd, J=12.4 and 8.9Hz), 1.56(2H,m), 1.45(1H,m),

1.07(1H,m), 0.90-0.76(1H,m), 0.83(3H,t, J=7.6Hz), 0.73(3H,d, J=7.6Hz) and 0.64(3H,t, J=7.6Hz) ppm.

FAB Mass spectmm, m/z = 522 (M+1).

Anal, calc'd for C₃₂H₃₉N₅O 0.15H₂O, 2.70TFA; C, 58.57 H, 5.29 N, 11.64. Found: C, 58.56; H, 5.28; N, 11.66.

EXAMPLE 10

N-3-Chlorobenzyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl)amino-3(S)- methylpentanamine

To a slurry of the amine prepared in Example 2 (45.0mg, 0.094 mmol), crushed 3A molecular sieves (190mg), and 3- chlorobenzaldehyde (13μl, 0.11 mmol) in methanol (2 ml) was added sodium cyanoborohydride (125μl of a 1M solution in THF, 0.13 mmol) at room temperature The reaction was stirred at RT for 18 hrs, and 3- chlorobenzaldehyde (26μl, 0.22 mmol) and sodium cyanoborohydride (200μl of a 1M solution in THF, 0.20 mmol) was added. The reaction was stirred an additional 18hr and then diluted withEtOAc, quenched with sat. aq. NaHCO₃ and stirred for 30min. The organic layer was separated, washed with saturated brine, dried( Na₂SO₄) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC ( C- 18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the trifluroacetate salt of the title compound as a white solid. A portion of the product was partitioned between EtOAc and sat aq. Na₂CO₃, the organic layer separated, dried (Na₂SO₄) and the solvent evaporated in vacuo to afford the corresponding free base as an oil.

1H NMR Free Base (CD₃OD, 400 MHz) d 8.02(1H, d, J=8.3Hz), 7.81(1H, d, J=8.3Hz), 7.77(1H, d, J=8.3Hz), 7.74-7.66(3H,m), 7.46- 7.15(10H,m), 6.86(1H, s), 5.37(2H,m), 4.07(1H,m), 3.96 (1H, d,

J=13.5Hz), 3.84 (1H, d, J=13.5Hz), 3.66 (1H, d, J=13.0Hz), 3.52 (1H, d, J=13.0Hz), 3.15(2H,m), 2.56(1H,dd, J=12.6 and 5.7 Hz), 2.37(1H,dd, J=12.6 and 5.7 Hz), 1.39(1H,m), 0.94(1H,m), 0.80(1H, m), 0.72(3H,d, J=7.0Hz) and 0.61(3H,t, J=7.0Hz) ppm.

FAB HRMS exact mass calc'd for C₃₇H₃₉N₅O 604.284314 (MH⁺), found 604.284876

Anal, calc'd for C₃₇H₃₈N₅OCI 0.95H₂O, 3.70TFA; C, 51.12 H, 4.21 N, 6.71. Found: C, 51.12; H, 4.18; N, 6.88.

EXAMPLE 11

N-(2-Imidazolylmethyl )-N-naphth-1-ylmethyl-2(S)-((1-(4-cyanobenzyl)-

1H-imidazol-5-yl)acetyl)amino-3(S)- methylpentanamine

The title compound was prepared using the protocol described in Example 10 using 2-imidazole carboxaldehyde in place of 3- chlorobenzaldehyde.

FAB HRMS exact mass calc'd for C₃₄H₃₈N₇O 560.313784 (MH⁺), found 560.312362

Anal, calc'd for C₃₇H₃₈N₅OCI 0.35H₂O, 3.25TFA; C, 51.94 H, 4.41 N,

10.47. Found: C, 51.94; H, 4.41; N, 10.80.

EXAMPLE 12 2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl) amino- N-(naphth-1-ylmethyl)propionamide

Step A: Preparation of [1-(Naphth-2-ylmethyl)-1H-imidazol-5- yl)] acetic acid methyl ester A solution of 1-(Triphenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester, the product of Example 1 step B, (4.36g, 11.4 mmol) and 2-(bromomethyl)naphthalene in CH₃CN (70 ml) was heated at 55°C for 4hr. After this time, the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was concentrated to 30 ml and heated at 55°C for 18hr. After this time, the reaction was cooled to room temperature and the resulting white precipitate collected by filtration. The filtrate was concentrated to 10ml volume and heated at 55°C for lhr. After this time, the reaction was again cooled to room temperature and diluted with ethyl acetate (25 ml). The resulting precipitate was collected by filtration and combined with the previous 2 precipitates in methanol (100 ml) and heated at reflux for 30min. The solvent was removed in vacuo and the resulting residue was partioned between methylene chloride(200 ml) and sodium bicarbonate (100 ml). The organic layer was evaporated in vacuo and the residue was purified by flash chromatography (SiO₂, 0-6% methanol in methylene chloride, gradient elution) to provide the title compound as an off white solid :

1HNMR(CDCl₃, 400 MHz) δ 7.82(2H, m), 7.75(1H, m), 7.70(1H, s), 7.49(3H, m), 7.20(1H, d, J=8.4Hz), 7.06(1H, s), 5.32(2H, s), 3.57(3H, s) and 3.49(2H, s) ppm.

Step B: Preparation of 2-[1-(Naphth-2-ylmethyl)-1H-imidazol-5- yl]acetic acid hydrochloride

2-[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl]acetic acid methyl ester (0.92g, 3.28mmol ) was dissolved in 2.5M hydrochloric acid ( 50ml ) and heated at 55°C for 3h. After this time, the solution was evaporated in vacuo to give the title compound as a white solid.

1HNMR(CD₃OD, 400 MHz) δ 8.92(1H, s), 7.94(1H, d, J=8.6Hz), 7.88(2H, m), 7.83(1H, s), 7.54(3H, m), 7.43(1H, d, J=14Hz), 5.60(2H, s) amd 3.82(2H, s) ppm.

Step C: Preparation of (R,S)-2,3-Diaminopropionic acid methyl ester A suspension of 2,3-diaminopropionic acid hydrobromide (15.3g, 82.7 mmol) in methanol (600 ml) was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room temperature for 18hr. The solvent was evaporated in vacuo to afford the title compound as a pale yellow solid.

¹H NMR(d₆ DMSO 400 MHz) δ 8.75(6H,s), 4.43(1H, t, J=6.1Hz), 3.80(3H, s) and 3.34(2H, s) ppm.

Step D: Preparation of 3-(t-Butoxycarbonyl)amino-2-(RS)- aminopropionic acid methyl ester

Di-t-butyldicarbonate (16.31g, 74.7 mmol) in methylene chloride (130ml) was added dropwise to (RS)-2,3-diamino propionic acid methyl ester (17.42g, 82.7 mmol) and triethylamine (46m1,330mmol) in methylene chloride (2.61) at -78°C. The reaction was then stirred at 0°C for 90min and quenched by addition of 10% aq. KHSO₄ (150ml) . The aqueous layer was separated, and the pH adjusted to 10 with sat aq

NaHCO₃ and 2.5M NaOH. The aqueous solution was extracted with methylene chloride and the combined extracts were dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was purified by flash chromatography (SiO₂, 2.5%-8% methanol in EtOAc; gradient elution) to afford the title compound as an oil.

¹H NMR(CDCl₃, 400 MHz) δ 4.98(1H,s), 3.75(3H, s) and 3.58(1H, t), J=6.0Hz), 3.49(1H, m) and 3.26(1H,m) ppm. Step E: Preparation of 3-t-Butoxycarbonylamino-2-(RS)-[(Naphth-2- ylmethyl)-1H-imidazol-5-yl]acetylamino-propionic acid methyl ester.

To a solution of 2-[1-(Naphth-2-ylmethyl)-1H-imidazol-5- yl]acetic acid hydrochloride (3.83g, 12.7mmol),

3-t-butoxycarbonylamino-2(R,S)- aminopropionic acid methyl ester (3.33g, 15.3mmol), HOOBT (2.30g, 14.1mmol), and triethylamine (5.80ml, 42.0mmol) in DMF (150ml) at 0°C, was added EDC (2.67g, 13.9 mmol). The reaction was stirred at room temperature for 18hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃ , brine , dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 5% MeOH in CH₂CI₂) to afford the title compound as a white solid.

¹H NMR(CDCl₃, 400 MHz) δ 7.81(1H, d, J=8.5Hz)),7.80-7.75(2H, m),

7.60(1H, s), 7.52(1H,s), 7.49(2H,m), 7.24(1H,d, J=8.5Hz), 7.06(1H,s),

6.86(1H, br d, J=3Hz), 5.32(2H,s), 4.74(1H,m), 4.45(1H,m), 3.73(3H,s),

3.52-3.40(4H,m), and 1.41(9H,s) ppm.

FAB HRMS exact mass calc'd for C₂₅H₃₁N₄O₅ 467.229445 (MH⁺), found 467.229649.

Step F: Preparation of 3-t-Butoxycarbonylamino-2-(RS)-[(Naphth-2- ylmethyl)-1H-imidazol-5-yl]acetylaminopropionic acid.

A solution of the methyl ester prepared in step E (4.80g,

10.3mmol ) in methanol (100ml) and 1 M lithium hydroxide (10.4 ml, 10.4 mmol) was stirred at 0°C for 18 hr. The pH was adjusted to pH 5 by the addition of 1M HCl and the title compound was collected by filtration and dried in vacuo.

¹NMR(CD₃OD, 400 MHz) δ 8.15(1H, s), 7.72-7.82(3H,m), 7.70(1H,m),

7.50(2H, m), 7.34(1H,dd, J=8.2 and 1.8Hz), 7.16(1H,s), 5.49(2H,s), 4.34(1H,m), 3.59(2H,m), 3.48(1H,dd, J=14.0 and 4.5Hz), 3.34(1H,m) and

1.40(9H,s) ppm.

FAB Mass spectmm, m/z = 453 (M+1).

Step G: Preparation of 2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol- 5-yl] acetyl}amino-3-(t-butoxycarbonyl)amino - N-(naphth-

1-ylmethyl) propionamide

To a solution of the acid prepared in step F (125mg,

0.276mmol), 1-naphthylmethylamine (39μl, 0.28mmol), HOBT (38.1mg, 0.28mmol), and triethylamine (40.0μl, 0.29mmol) in DMF (3.0ml) at 0°C, was added EDC (53.0mg, 0.28 mmol). The reaction was stirred at room temperature for 4hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃ , brine and dried (Na₂SO₄). The solvent was evaporated in vacuo to afford the title compound. ¹NMR(CDCl₃, 400 MHz) δ 7.92(1H,d, J=7.8Hz), 7.82(1H,d, J=8.2Hz), 7.80-7.65(4H,m),7.60-7.30(9H,m), 7.22(1H,t, J=5.4Hz), 7.05(1H,d, J=8.6Hz), 6.93(1H,s), 5.29(1H,t, J=5.7Hz), 5.06(1H,d, J=16.5Hz), 4.97(1H,d, J=16.5Hz), 4.83(1H,dd, J=14.8 and 5,8Hz), 4.76(1H,dd, J=14.8 and 5.3Hz), 4.38(1H,m), 3.50-3.25(4H,m) and 1.34(9H,s) ppm. FAB HRMS exact mass calc'd for C₃₅H₃₈N₅O₄ 592.292380(MH⁺), found 592.293910.

EXAMPLE 13

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-methyl-N-benzyl propionamide

The title compound was prepared using the protocol described in Example 12, step G using N-methyl benzylamine in place of 1-naphthylmethylamine.

¹NMR(CDCl₃ 400 MHz) δ 7.84-7.74(3H,m), 7.62(0.7H,s), 7.58(0.3H,s), 7.52-7.42(3H,m), 7.38-7.26(2H,m), 7.24-7.10(2H,m), 7.07(0.7H,s), 7.01(0.3H,s), 6.67(0.7H,d, J=3.5Hz), 6.59(0.3H, d, J=3.5Hz),

5.32(1.4H,s), 5.28(0.6H,s), 5.0-4.85(2H,m) 4.75-4.45(2H,m), 3.52- 3.00(4H,m), 2.96(2.1H,s), 2.90(0.9H,s),1.42(6.3H, s) and 1.39(2.7H,s) ppm.

F.AB Mass spectrum, m/z = 556(M+1).

EXAMPLE 14

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(2-methylbenzyl) propionamide

The title compound was prepared using the protocol described in Example 12 step G using 2-methyl benzylamine in place of 1-naphthylmethylamine.

¹NMR(CD₃OD 400 MHz) δ 7.88-7.78(3H,m) 7.76(1H,s), 7.58(1H,s), 7.52-7.45(2H,m), 7.30-7.20(2H,m), 7.17-7.10(3H,m), 6.95(1H,s),

5.39(2H,m), 4.40(1H,m), 4.40(1H,d, J=15.0Hz), 4.32(1H,d, J=15.0Hz), 3.52(2H,s), 3.40-3.20(2H,m), 2.30(3H,s) and 1.40(9H,s) ppm. EXAMPLE 15

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(3-methylbenzyl) propionamide

The title compound was prepared using the protocol described in Example 12 step G using 3-methylbenzylamine in place of 1 -naphthylmethylamine.

¹NMR(CDCl₃, 400 MHz) δ 7.85-7.72(3H,m) 7.56(1H,s), 7.52-

7.46(2H,m), 7.44(1H,s), 7.28(1H,m), 7.25-7.12(3H,m), 7.12-6.98 (3H,m), 6.90(1H,m), 5.26(1H,d, J=16Hz), 5.18(1H,d, J=16Hz), 4.30(1H,m), 3.50- 3.30(4H,m), 2.37(3H,s) and 1.42(9H,s) ppm.

FAB Mass spectrum, m/z = 556(M+1).

EXAMPLE 16

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-(naphth-1-ylmethyl)propionamide hydrochloride.

A solution of the product of Example 12 (174mg, 0.294mmol) in CH₂CI₂ (10ml) and trifluoroacetic acid (5ml) was stirred at room temperature for 3hrs. The solvent was evaporated in vacuo, methanol (5ml) was added to the residue and the resulting solution saturated with gaseous HCl. The solvent was evaporated and the title compound was dried in vacuo.

FAB Mass spectrum, m/z = 492(M+1).

EXAMPLE 17

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-methyl-N-benzyl propionamide hydrochloride

The title compound was prepared using the protocol described in Example 16 using the product from Example 13

¹NMR(CD₃OD 400 MHz) δ 8.83(0.5H,s), 8.73(0.5H,s), 7.96-

7.80(3H,m), 7.70(1H,s), 7.60(7.44(3H,m), 7.38-7.12(6H,m), 5.59(1H,m), 5.38(1H,m), 5.23(0,5H,t, J=5.0Hz), 5.06(0.5H,t, J=5.0Hz), 4.74- 4.63(1H,m), 4.50-4.38(1H,m), 3.76(1H,s), 3.60-3.50(0.5H,m), 3.30- 3.20(1.5H,m), 3.10-3.00(1H,m), 2.92(1.5H,s), and 2.88(1.5H,s) ppm. FAB HRMS exact mass calc'd for C₂₇H₃₀N₅O₂ 456.239951 (MH⁺), found 456.239252

EXAMPLE 18

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-(2-methylbenzyl)propionamide hydrochloride

The title compound was prepared using the protocol described in the Example 16 using the product of Example 14.

F.AB Mass spectrum, m/z = 456(M+1).

EXAMPLE 19

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- amino- N-(3-methylbenzyl)propionamide hydrochloride

The title compound was prepared using the protocol described in the Example 16 using the product of Example 15.

FAB Mass spectmm, m/z = 456(M+1).

EXAMPLE 20

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- acetylamino- N-(3-methylbenzyl)propionamide

To a solution of the amine from Example 19 (6.48mg, 0.0116mmol), and triethylamine (8.53μl, 0.0612 mmol) in CHCl₃ (0.165ml) at 0°C, was added acetyl chloride (116μl of a 0.1M solution in CHCl₃, 0.0116 mmol). The reaction was vortexed at room temperature, and allowed to stand at room temperature for 18 hrs. The solvent evaporated in vacuo and the residue was purified by preparative HPLC ( C-18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution), to afford the title compound after lyophilisation.

FAB Mass spectmm, m/z = (M+1). EXAMPLE 21

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- acetylamino- N-(naphth-1-ylmethyl)propionamide

The title compound was prepared using the protocol described in the Example 20 using the amine from Example 16 and acetyl chloride.

¹NMR(CDCl₃ 400 MHz) δ 8.37(1H,s), 8.15(1H,m), 7.94(1H,d, J=8Hz), 7.90-7.70(5H,m), 7.60-7.45(4H, m), 7.40-7.35(2H,m), 7.35-7.25(2H,m), 7.20(1H, s), 7.12(1H,d, J=8.0Hz), 6.50(1H,m), 5.26(1H,d, J=15Hz), 5.14(1H,d, J=15Hz), 4.92(1H,m), 4.79(1H,dd, J=15.0 and 5.0Hz), 4.37(1H,m), 3.70-3.40(4H,m), and 1.85(3H,s) ppm.

F.AB Mass spectrum, m/z = 534(M+1). EXAMPLE 22

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(2- methylpropionyl)amino- N-(naphth-1-ylmethyl)propionamide

The title compound was prepared using the protocol described in Example 20 using the amine from Example 16 and 2- methylpropionyl chloride instead of acetyl chloride.

¹NMR(CD₃OD 400 MHz) δ 8.89(1H,s), 8.60(1H,m), 8.03(1H,d, J=8.4Hz), 8.00-7.70(6H,m), 7.60-7.46(5H,m), 7.41(1H,dd, J=7.5 and 7.0Hz), 7.36(1H,dd, J=8.9 and 1.5Hz), 5.53(2H,m), 5.0-4.70(2H,m), 4.40(1H, t, J=6.0Hz), 3.71(2H,s), 3.43(2H,m), 2.31(1H, sept, J=6.8Hz), 1.01(3H,d,J=6.8Hz), and 0.99(3H,d, J=6.8Hz) ppm.

FAB HRMS exact mass calc'd for C₃₄H₃₆N₅O₃ 4562.281815 (MH⁺), found 562.281831 EXAMPLE 23

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-IMidazol-5-yl)] acetyl}amino-3- (phenylacetyl)amino- N-(naphth-1-ylmethyl)propionamide The title compound was prepared using the protocol described in Example 20 using the amine from Example 16 and phenylacetyl chloride instead of acetyl chloride.

1NMR(CDCl₃ 400 MHz) δ 8.32(1H,s), 8.15(1H,d, J=5.7Hz),

7.92(1H,m), 7.86-7.70(5H,m), 7.60-7.44(5H,m), 7.38(2H,m), 7.30- 7.20(4H,m), 7.13(2H.d, J=6.8Hz), 7.08(2H,m), 6.58(1H,m), 5.17(1H,d, J=15,4Hz), 5.07(1H,d, J=15.4Hz), 4.84(1H,dd, J=15.0 and 5.5Hz), 4.75(1H,dd, J=15.0 and 5.5Hz), 4.40(1H,m), 3.60(1H,m), 3.47(1H,m) and 3.45-3.20(4H,m) ppm.

FAB Mass spectmm, m/z = 610(M+1).

EXAMPLE 24

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3- (phenylacetyl)amino- N-methyl-N-benzyl) propionamide

The title compound was prepared using the protocol described in Example 20 using the amine from Example 17 and

phenylacetyl chloride instead of acetyl chloride.

¹H NMR(CDCl₃, 400MHz) δ 8.85(0.5H,s), 8.74(0.5H,s), 8.00- 7.80(1H,m), 7.74(1H,s), 7.60-7.45(1H,m), 7.40-7.10(10H,m),

5.60(2H,m), 5.40(2H,m), 5.25(0,5H,t, J=5Hz), 5.10(0.5H,t, J=5.0Hz),

4.70(1H,dd, J=15 and 5.5Hz), 4.45(1H,dd, J=15.0 and 7.5Hz),

3.78(2H,m), 3.30(1H,m), 3.08(1H,m), 2.94(1.5H,s) and 2.88(1.5H,s) ppm.

FAB HRMS exact mass calc'd for C₃₅H₃₆N₅O₃ 3574.281815(MH⁺), found 574.281831.

EXAMPLE 25 [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)1-N-butylacetamide

To a solution of 2-[1-(Naphth-2-ylmethyl)-1H-imidazol-5- yl]acetic acid hydrochloride (89mg, 0.294mmol), n-butylamine (30μl, 0.30mmol), HOOBT (57mg, 0.35mmol), and triethylamine (140ml, 42.0mmol) in DMF (4ml) at 0°C, was added EDC (2.67g, 13.9 mmol). The reaction was stirred at room temperature for 18hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine, dried

(Na₂SO₄) and the solvent evaporated in vacuo to afford the title compound as a clear oil.

¹H NMR(CDCl₃, 400 MHz) δ 7.86-7.74(3H, m),7.65(1H, m), 7.55-

7.45(3H, m), 7.22(1H,dd, J=8.6 and 2.0Hz), 7.04(1H,s), 5.30(1H,m),

5.25(2H,s), 3.46(2H,s), 2.95(1H,q, J=8Hz), 1.30-1.10(4H,m) and

0.83(3H,t, J=7.5Hz) ppm.

FAB HRMS exact mass calc'd for C₂₀H₂₄N₃O 322.191938 (MH⁺), found 322.191669.

EXAMPLE 26

[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]- N-methyl-N-(3,3- diphenylpropyl)acetamide

Step A: Preparation of N-Benzyl-N-3,3-diphenylpropyl amine

To a solution of 3,3-diphenylpropylamine (l.Olg, 4.79 mmol), acetic acid (28ml, 049mmol), and benzaldehyde (490μl, 4.80 mmol) in CH₃CN (2 ml) was added sodium cyanoborohydride (4.80ml of a 1M solution in THF, 4.8mmol) at 0°C. The reaction was allowed to warm to room temperature and stirred for 18hrs. The solvent was evaporated in vacuo, quenched with sat. aq. NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine, dried (Na₂SO₄) and the solvent evaporated in vacuo. The residue was dissolved in MeOH (100ml) and sodium borohydride (182mg, 5.55mmol) added and the reaction was stirred for 30min. The solvent was evaporated and the residue treated with sat. aq. NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with saturated brine, dried(

Na₂SO₄) and the solvent evaporated in vacuo to afford the title compound as an oil.

¹H NMR(CDCl₃, 400 MHz) δ 7.40-7.00 (15H, m), 4.04(1H,t, J=7.5Hz), 3.62(2H,s), 2.62(2H,t, J=7.0Hz) 2.26(2H,q, J=7.5Hz) ppm.

Step B: Preparation of N-Benzyl-N-methyl-3,3-diphenylpropylamine To a solution of N-benzyl-3,3-diphenylpropylamine (1.29g, 4.30mmol) and 30% aq. formaldehyde (1.50ml, 20 mmol) in

CH₃CN:H₂o (2:1, v/v, 40 ml) was added sodium cyanoborohydride (563mg , 8.96mmol) at 0°C. The reaction was allowed to warm to room temperature and stirred for 90min. The organic solvent was evaporated, and the residue diluted with water and extracted with CH₂CI₂. The organic extracts were washed with brine, dried (Na₂SO₄) and the solvent evaporated in vacuo to afford the title compound as an oil.

¹H NMR(CDCl₃, 400 MHz) δ 7.40-7.00 (15H, m), 4.05(1H,t, J=7.5Hz), 3.44(2H,s), 2.38-2.22(4H,m) and 2.16(3H,s) ppm.

Step C: Preparation of N-Methyl-3,3-diphenylpropylamine

A solution of N-benzyl-N-methyl-3,3-diphenylpropylamine (1.03g, 3.27mmol) in methanol (35ml) and aq. HCl (0.27ml, of a 12.1M aq. solution, 3.3mmol) was purged with argon and palladium hydroxide (405mg) added. The flask was evacuated and shaken under an

atmosphere of hydrogen (50psi) for 18hrs. The hydrogen was replaced by argon and the catalyst removed by filtration. The filtrate was treated with aq. NaOH (100ml of a 1M solution) and extracted into Et₂O. The organic extracts were dried (Na₂SO₄) and evaporated in vacuo to afford the title compound as an oil.

¹H NMR(CDCl₃, 400 MHz) δ 7.32-7.14 (10H, m), 4.05(1H,t, J=7.5Hz), 2.54(2H, t, J=7.1Hz), 2.38(3H,s) and 2.24(2H,m) ppm.

FAB Mass spectmm, m/z = 226 (M+1).

Step D: Preparation of [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]-

N-methyl-N-3,3- diphenylpropyl acetamide

To a solution of 2-[1-(Naphth-2-ylmethyl)-1H-imidazol-5- yl]acetic acid hydrochloride (160.8mg, 0.531mmol),N-methyl-3,3- diphenylpropylamine (104mg, 0.462mmol) HOOBT (81mg, 0.50mmol), and triethylamine (215ml, 1.54mmol) in DMF (5ml) at 0°C, was added EDC (94.3mg, 0.50mmol). The reaction was stirred at room temperature for 18hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine, dried (Na₂SO₄) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC ( C-18; 95:5 to 5:95 water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution), to afford the title compound after lyophilisation.

¹H NMR(CDCl₃, 400 MHz) d 8.45(1H, d, J=11.4Hz), 7.90-7.82(2H, m), 7.82-7.74(1H,m), 7.64-7.50(3H,m), 7.32-7.16(9.5H,m), 7.09(2H,d, J=7.8Hz), 6.98(0.5H,s),5.45(1H,s), 5.40(1H,s), 3.90(0.5H,d, J=7.5Hz), 3.75(0.5H,d, J=7.5Hz), 3.40(1H,s), 3.37(1H,m), 3.22(1H,dd, J=5.6 and4.6Hz), 3.12(1H,s), 2.93(1.5H,s), 2.77(1.5H,s), 2.30(1H,m), and 2.20(1H,m) ppm.

FAB HRMS exact mass calc'd for C₃₂H₃₂N₃O 474.253538 (MH⁺), found 474.255055.

EXAMPLE 27 2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino -3-(t- butoxycarbonyl)amino - N-methyl-N-benzyl propionamide

Step A: Preparation of 3-t-Butoxycarbonylamino-2-(RS)-[1-(4- cyanobenzyl)-1H-imidazol-5-yl]acetylamino-propionic acid methyl ester

To a solution of [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetic acid (607mg, 1.64mmol), 3-t-Butoxycarbonylamino-2(RS)- aminopropionic acid methyl ester (352mg, 1.61mmol), HOOBT (319mg, 1.96mmol), and triethylamine (0.54ml, 3.87mmol) in DMF (13ml) at 0°C, was added EDC (2.67g, 13.9 mmol). The reaction was stirred at room temperature for 18hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine, dried (Na₂SO₄). and the solvent evaporated in vacuo to afford the title compound as a white solid.

¹H NMR(CDCl₃, 400 MHz) d 7.65(2H, d, J=8.5Hz), 7.55((1H, s), 7.21(1H, d, J=8.5Hz), 7.07(1H,s), 5.28(2H,m), 4.78(1H, m), 4.49(1H,m), 3.78(3H,s), 3.60-3.44(3H,m), 3.44(1H,d,J=16.0Hz), 3.36(1H,d,J=16.0Hz) and 1.43(9H,s) ppm.

Step B: Preparation of 3-t-Butoxycarbonylamino-2-(RS)-[1-(4- cyanobenzyl)-1H-imidazol-5-yl]acetylamino-propionic acid A solution of the methyl ester from Step A (604mg,

1.37mmol ) in methanol (14ml) and 1 M lithium hydroxide (1.40 ml, 1.40 mmol) was stirred at 0°C for 18 hr. The reaction was quenched by the addition of 1M HCl (1.40ml) and the solvent was evaporated in vacuo to afford the title compound and lithium chloride which was used as is.

¹H NMR(CD₃OD, 400 MHz) δ 8.03(1 H, s), 7.74(2H,d, J=8.4Hz), 7.35(2H,d, J=8.4Hz), 7.11(1H,s), 5.41(2H,s), 4.34(1H,m), 3.60- 3.45(3H,m), 3.36(1H,m) and 1.41(9H,s) ppm

FAB HRMS exact mass calc'd for C₂₁H₂₅N₅O₅ 428.193394 (MH⁺), found 428.193423.

Step C: Preparation of 2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5- yl] acetyl} amino -3-(t-butoxycarbonyl)amino-N-methyl-N- benzyl propionamide

To a solution of the acid from Step B(163.5mg, 0.348mmol), N-methylbenzylamine (45μl, 0.29mmol), HOOBT

(58.4mg, 0.358mmol), and triethylamine (100.0μl, 0.29mmol) in DMF (3.6ml) at 0°C, was added EDC (55.4mg, 0.289 mmol). The reaction was stirred at room temperature for 4hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine, dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 5% -7.5% MeOH in CH₂CI₂; gradient elution) to afford the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.10-7.70(3H, m), 7.40-7.20(7H, m), 6.97(0.66H,s), 6.91(0.33H,s), 5.42-5.28(2H,m), 5.08(0.33H, m),

4.86(0.66H,m), 4.76-4.42(2H, m), 3.55-3.20(4H,m), 3.08(2H,s),

2.84(1H,s), 1.42(6H,s) and 1.40(3H, s) ppm.

FAB HRMS exact mass calc'd for C₂₉H₃₄N₆O₄ 531.271979(MH⁺), found 531.270872.

EXAMPLE 28

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino-3-(t- butoxycarbonyl)amino-N-(3-methylbenzyl) propionamide The title compound was prepared using the protocol described in the Example 27 step C using 3-methylbenzylamine in place of N-methylbenzylamine.

¹H NMR(CD₃OD, 400 MHz) δ 7.75(1H, s), 7.68(2H,d, J=8.4Hz), 7.26(2H,d, J=8.4Hz), 7.19(1H,t, J=7.7Hz), 7.12(1H, s), 7.07(2H,t, J=6.0Hz), 6.95(1H,s), 5.33(2H,m), 4.87(1H,m), 4.38(3H, m), 4.31(1H,d, J=15.2Hz), 3.47(2H,s), 2.32(3H,s) and 1.42(9H,s) ppm.

FAB HRMS exact mass calc'd for C₂₉H₃₄N₆O₄ 531.271979(MH⁺), found 531.271895.

EXAMPLE 29

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino-3-(t- butoxycarbonyl)amino-N-(naphth-1-ylmethyl) propionamide

The title compound was prepared using the protocol described in Example 27 step C using 1-naphthylmethylamine in place of

N-methylbenzylamine.

¹H NMR(CD₃OD, 400 MHz) δ 8.04(1H, d, J=8.5Hz), 7.89(1H, d,

J=7.0Hz), 7.81(1H,d, J=8.0Hz), 7.72(1H,s), 7.68(2H, d, J=7.4Hz), 7.58- 7.38(4H, m), 7.23(2H, d, J=7.4Hz), 7.07(2H,t, J=6.0Hz), 6.95(1H,s),

5.28(2H,m), 4.87(2H,m), 4.40(1H, m), 3.47(2H,s), 3.40-3.20(2H,m) and

1.42(9H,s) ppm.

FAB HRMS exact mass calc'd for C₂₉H₃₅N₆O₄ 567.271979(MH⁺), found 567.269604.

EXAMPLE 30

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl}amino-3-amino -

N-methyl-N-benzyl- propionamide

A solution of the product from Example 27 (86.3mg, 0.163 mmol) in EtOAc (5ml) at 0°C was saturated with gaseous HCl and stirred for 15 min. The solvent was evaporated and the title compound was dried in vacuo. ¹H NMR (d6 DMSO, 400 MHz) δ 9.20-9.00(2H,m), 8.20(3H,s),

7.88(1H,d,J=7.5Hz), 7.65-7.10(6H,m), 5.60-5.40(2H,m), 5.15-5.00(1H,s), 4.70-4.40(2H, m), 3.80-3.00(4H,m), 2.94(2H,s) and 2.78(1H,s) ppm.

FAB HRMS exact mass calc'd for C₂4H₂7N6O4 431.219549 (MH⁺), found 431.218412.

EXAMPLE 31

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl}amino-3-amino- N-(3-methylbenzyl) propionamide

The title compound was prepared using the protocol described in Example 30 using the product from Example 28.

¹H NMR(d₆ DMSO, 400 MHz) δ 9.12(1H,m), 8.86(1H, d,J=7.6Hz),

8.73(1H,t, J=5.7Hz), 8.20(3H,m), 7.87(2H,d, J=8.7Hz), 7.60(1H,s), 7.47(2H,d, J=8.7Hz),7.19(1H,t, J=7.2Hz), 7.10-7.00(3H,m), 5.53(2H,m),

4.56(1H,m), 4.27(2H,m), 3.73(2H,s), 3.23(1H,m), 2.90(1H,m) and

2.26(3H,s) ppm.

FAB HRMS exact mass calc'd for C₂₄H₂₇N₆O₂ 431.219549 (MH⁺), found 431.219835.

EXAMPLE 32

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino -3-amino - N-(naphth-1-ylmethyl) propionamide

The title compound was prepared using the protocol described in Example 30 using the product from Example 29.

¹H NMR (d₆ DMSO, 400 MHz) δ 9.12(1H,m), 8.92(1H, d,J=7.6Hz), 8.81(1H,t, J=5.7Hz), 8.22(3H,m), 8.04(1H,m), 7.92(1H,m), 7.88-7.80(3H, m), 7.58(1H,s), 7.52(2H,m), 7.48-7.38(4H,m), 5.51(2H,m), 4.74(2H,m), 4.57(1H,m), 3.73(2H,s), 3.20(1H,m) and 3.01(1H,m)ppm.

FAB HRMS exact mass calc'd for C₂₇H₂₇N₆O₂ 467.219549MH⁺), found 467.219920. EXAMPLE 33

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl}amino-3-

(phenylacetyl)amino - N-methyl-N-benzyl) propionamide

To a solution of the product from Example 30 (42.5mg,

84.4mmol), and triethylamine (58μl, 420 mmol) in CHC l₃ (0.85ml) at 0°C, was added phenylacetyl chloride (11.2μl 84.4 mmol). The reaction was vortexed and allowed to stand at room temperature for 18hrs. The reaction was diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine and dried (Na₂SO₄). The solvent evaporated in vacuo and the residue was purified by preparative HPLC ( C-18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution), to afford the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.95(0.67H,d, J=1.7Hz,), 8.92(0.33H, d, J=1.7Hz), 7.76(0.67H, d, J=8.7Hz), 7.75(1.33H, d, J=8.7Hz), 7.51(0.67H, s), 7.44(2H,d, J=8.7Hz), 7.38-7.20(10.33H,m), 5.55-5.37(2H,m),

5,12(0.33H, dd, J=4.0 and 3.0Hz),4.98(0.67H, dd, J=4.0 and 3.0Hz), 4.94-4.66(1H,m), 4.76(0.67H, dd, J=10.4Hz), 4.28(0.33H, d, J=10.4Hz), 3.64-3.36(5H,m), 2.98(2H,s), and 2.83(1H,s) ppm.

FAB HRMS exact mass calc'd for C₃₂H₃₃N₆O₃ 549.261414(MH⁺), found 549.262581.

EXAMPLE 34 2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl}amino-3-

(acetyl)amino - N-(naphth-1-yl methyl)propionamide

To a solution of the product from Example 32 (37.3mg, 69.1mmol), and triethylamine (52μl, 345 mmol) in CHCl₃ (0.85ml) and DMF (0.5ml) at 0°C, was added acetyl chloride (5.0μl 69.1 mmol). The reaction was vortexed and allowed to stand at room temperature for

18hrs. The reaction was diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine and dried (Na₂SO₄). The solvent evaporated in vacuo and the residue was purified by preparative HPLC ( C-18; 95:5 to 5:95 Water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution), to afford the title compound as a white solid.

¹H NMR (CD₃OD, 400 MHz) δ 8.95(1H,d, J=1.0Hz,), 8.06 (1H, d, J=6.6Hz), 7.89(1H, d, J=7.0Hz), 7.89(1H, d, J=7.0Hz), 7.82(1H, d, J=8.4Hz), 7.54(2H,d, J=8.4Hz), 7.60-7.48(5H,m), 7.43(2H,t, J=7.9Hz), 5.58(2H,m), 4.98-4.70(2H,m), 4.43(1H,dd, J=6.4 and 5.1Hz), 3.72(1H,d, J=16.0Hz), 3.65(1H, d, J=16.0Hz), 3.54(1H, dd, J=13.6 and 4.5Hz), 3.42(1H, dd, J=13.6 and 6.4Hz) and 1.86(3H,s)ppm.

FAB HRMS exact mass calc'd for C₂₉H₂₉N₆O₃ 509.230114(MH⁺), found 509.229190.

EXAMPLE 35

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl}amino-3-(2- methylpropionyl)amino - N-(naphth-1-ylmethyl) propionamide

The title compound was prepared using the protocol described in Example 34 using isobutyryl chloride in place of acetyl chloride.

¹H NMR(CD₃OD, 400 MHz) δ 8.96(1H,d, J=1.0Hz,), 8.06 (1H, d, J=8.6Hz), 7.99(1H, d, J=8.6Hz), 7.82(1H, d, J=7.9Hz), 7.74(2H, d,

J=8.6Hz), 7.58-7.48(5H,m), 7.43(2H,t, J=7.9Hz), 5.52(1H,d, J=15.2Hz),

5.47(1H,d, J=15.2Hz), 4.98-4.70(2H,m), 4.44(1H,dd, J=5.8 and 5.0Hz),

3.70(1H,d, J=13.9Hz), 3.66(1H, d, J=13.9Hz), 3.50(1H, dd, J=13.6 and

3.0Hz), 3.42(1 H, dd, J=13.6 and 6.4Hz), 2.34(1H,sept, J=6.8Hz),

1.04(3H,d, J=6.8Hz) and 1.02(3H,d, J=6.8Hz)ppm.

FAB HRMS exact mass calc'd for C₃₁H₃₃N₆O₃ 537.261414 (MH⁺), found 537.262247.

EXAMPLE 36

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino -3-(2- methylpropionyl)amino - N-(naphth-1-ylmethyl) propionamide

The title compound was prepared using the protocol described in Example 34 using phenylacetyl chloride in place of acetyl chloride. ¹H NMR(CD₃OD, 400 MHz) δ 8.72(1H,s), 7.94 (1H, d, J=7.4Hz), 7.79(1H, d, J=7.6Hz), 7.72(1H, d, J=8.4Hz), 7.62(2H, d, J=8.3Hz), 7.48- 7.22(7H,m), 7.22-7.08(5H,m), 5.34(1H,d, J=15.7Hz), 5.28(1H,d,

J=15.7Hz), 4.90-4.60(2H,m), 4.38(1H,dd, J=5.0 and 4.2Hz), 3.46(2H,s), 3.40(2H, m) and 3.34(2H,s)ppm.

FAB HRMS exact mass calc'd for C₃₅H₃₃N₆O₃ 585.261414 (MH⁺), found 585.260592.

EXAMPLE 37

N-[2(S)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylpentyl1-N-(1-naphthylmethyl)glycine isopropylamide

Step A: Preparation of N-(2(S)-(t-Butoxycarbonylamino)-3(S)- methylpentyl)glycine methyl ester.

Glycine methyl ester hydrochloride (4.41 g, 0.035 mol) was dissolved in 1,2-dichloroethane (50 mL) and DMF (5 mL) and treated with 3 A molecular sieves (10 g) and N-t-butoxycarbonyl-isoleucinal (6.3 g, 0.029 mol) with stirring at 0°C. Sodium triacetoxyborohydride (9.27 g, 0.044 mol) was added, and the pH of the mixture was adjusted to 6 with triethylamine (3 ml, 0.022 mol). After stirring for 18 h the mixture was filtered, concentrated and partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with aqueous saturated NaHCO₃ solution, brine, and dried (Na₂SO₄). Filtration and evaporation in vacuo afforded a residue which was purified by flash chromatography (SiO₂,

EtOAc:hexane, 1:3) to give the title compound as an oil.

¹H NMR (CDCl₃ 400MHz) δ 4.69 (1H, m), 3.72 (3H, s), 3.48-3.62 (1H, m), 3.42 (2H, m), 2.65 (2H, d, J=6Hz), 1.4-1.6 (2H, m), 1.48 (9H, s), 1.04-1.2 (1H, m), 0.85-0.95 (6H, m)ppm.

Step B: Preparation of N-[2(S)-(t-Butoxycarbonylamino)-3(S)- methylpentyl]-N-(1-naphthylmethyl)glycine methyl ester N-[2(S)-(t-Butoxycarbonylamino)-3(S)-methylpentyl] glycine methyl ester (2.00 g, 6.97 mmol) was dissolved in 1,2- dichloroethane (56 ml) and 3A molecular sieves were added followed by 1-naphthaldehyde (1.89 ml, 13.9 mmol) and sodium

triacetoxyborohydride (6.65 g, 31.4 mmol). The mixture was stirred at ambient temperature for 16 h, filtered and evaporated in vacuo. The residue was partitioned between EtOAc (100 ml) and sat. aq. NaHCO₃ (25 ml). The aqueous layer was extracted with EtOAc (3x50 ml). The organic extracts were combined, dried (Na₂SO₄), filtered, and

evaporated in vacuo to afford a residue which was purified by

chromatography (SiO₂ , 15-33% ethyl acetate in hexanes) to afford the title compound as an oil.

¹H NMR (CD₃OD, 400MHz) δ 8.44-8.38 (1H, d, J=6Hz), 7.88-7.77 (2H, m,), 7.55-7.35 (4H, m), 6.34-6.27 (1H, m), 4.25 (2H, m), 3.66 (3H, s), 3.40-3.23 (1H, m), 2.95-2.85 (1H, dd, J=6 and 15Hz), 2.68-2.57 (1H, dd, J=6 and 15Hz), 1.57-1.46 (1H, m), 1.43 (9H, s), 1.34-1.18 (2H, m), 1.06- 0.85 (1H, m) and 0.85-0.71 (6H, m)ppm.

Step C: Preparation of N-[2(S)-(Amino)-3(S)-methylpentyl]-N-(1- naphthylmethyl)glycine methyl ester hydrochloride

A solution of N-[2(S)-(t-Butoxycarbonylamino)-3(S)- methylpentyl]-N-(1-naphthylmethyl) glycine methyl ester (5.90g, 13.8 mmol) in EtOAc (100 ml) was saturated with gaseous hydrogen chloride.

The resulting solution was allowed to stand at room temperature for lhr.

The solvent was evaporated in vacuo to afford the title compound as a white solid.

¹H NMR(CD₃OD 400 MHz) δ 8.26(1H, d, J=8.6Hz),7.92(1H, d,

J=7.2Hz), 7.87(1H, d, J=8.6Hz), 7.63-7.42(4H,m), 4.34(1H,d, J=12.3Hz),

4.26(1H,d, J=12.3Hz), 3.68(3H,s), 3.13(1H, d, J=10.3Hz), 2.67-

2.55(2H,m), 1.46(1H,m), 1.28(2H,m), 1.10-0.90(2H,m),

0.84(3H,d,J=6.8Hz) and 0.77(3H,t, J=6.8Hz)ppm.

Step D: Preparation of N-[2(S)-{ [1-(4-Cyanobenzyl)-1H-imidazol- 5- yl] acetylamino)-3(S)-methylpentyl]-N-(1- naphthylmethyl) glycine methyl ester To a solution of 2-[1-(4-cyanobenzyl)-1H-imidazol-5- yl]acetic acid (220mg,0.533mmol) and the amine hydrochloride salt from step C (212mg,0.533mmol), HOBT (72mg, 0.533mmol), and N- methylmorpholine (117μl, l.llmmol) in DMF (2ml) was added EDC (764mg, 3.99 mmol). The reaction was stirred at room temperature for 72hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃ , brine, dried (Na₂SO₄). and evaporated in vacuo. The residue was chromatographed (SiO₂, 3-4% MeOH in CH₂CI₂, gradient elution) to afford the title compound as a white solid.

1H NMR(CD₃OD, 400 MHz) δ 8.30(1H,d, J=8.4Hz),

7.84(1H,d, J=8.0Hz), 7.80(1H,t, J=4.5Hz), 7.68-7.38(3H,m), 7.48- 7.32(4H,m), 7.10(2H,d, J=8.0Hz), 6.87(1H,s), 5.24(1H,d, J=16.7Hz), 5.18(1H,d,J=16.7Hz), 4.83(2H,s), 4.27(1H,d, J=12.8Hz), 4.10(1H,d, J=12.8Hz), 3.97(1H,m), 3.65(3H,s), 3.40-3.20(2H,m), 2.92(1H,dd, J=13.3 and 4.3Hz), 2.60(1H,dd, J=13.3 and 10.0Hz), 1.48(1H,m), 1.25(1H,m), 0.98(1H,m), 0.78(3H,d, J=6.8Hz) and 0.77(3H,t, J=7.5Hz) ppm.

Anal, calc'd for C₃₃H₃₇N₅O₃ 1.05H₂O, 2.85 TFA C, 51.90; H, 4.72; N, 7.82. Found: C, 51.90; H, 4.70; N, 8.18.

FAB Mass spectmm, m/z = 552 (M+1).

Step E: Preparation of N-[2(S)-{ [1-(4-Cyanobenzyl)-1H-imidazol- 5-yl]acetylamino)-3(S)-methylpentyl]-N-(1-naphthylmethyl) glycine

A solution of the methyl ester from step D (2.32g, 4.21 mmol) in MeOH(20ml) and 1 M lithium hydroxide (4.70 ml, 4.70 mmol) was stirred at RT for 6hr. The aqueous solution diluted with water (15ml) and extracted with EtOAc (100ml), dried (Mg₂SO₄), and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 20% MeOH in CH₂CI₂) to afford the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.33(1H, d,J=8.3Hz),

7.87(2H,d, J=7.7Hz), 7.78(1H,s), 7.63(2H,d, J=6.6Hz), 7.57(1H,d, J=6.4Hz), 7.50-7.38(4H,m), 7.17(1H,d, J=8.3Hz), 6.96(1H,s), 5.32(1H,d, J=16.6Hz), 5.25(1H,d,J=16.6Hz), 4.64(1H,d, J=13.2Hz), 4.40(1H,d, J=13.2Hz), 3.99(1H,m), 3.60-3.28(4H,m), 3.22(1H,dd, J=13.3 and 3.1Hz), 2.93(1H,dd, J=13.3 and 10.3Hz), 1.52(1H,m), 1.29(1H,m), 1.06(1H,m), 0.86-0.76(6H,m) ppm.

Anal, calc'd for C₃₂H₃₅N₅O₃ 1.00H₂O, C, 69.17; H, 6.71 N, 12.60. Found: C, 68.95; H, 6.37; N, 12.54.

FAB Mass spectmm, m/z = 538 (M+1).

Step F: Preparation of N-[2(S)-([1-(4-Cyanobenzyl)-1H- imidazol-5-yl]acetylamino)-3(S)-methylpentyl]-N-(1- naphthylmethyl)glycine isopropylamide

To a solution of the acid from step E (50mg, 0.093mmol) and isopropyl amine (212mg,0.533mmol), HOBT resinl (93mg,

1.08mmol/g ; 0.100mmol), in CH₂CI₂ (1.1ml) was added DCC (23.0mg, 1.12 mmol). The reaction was stirred at room temperature for 20min, the resin bound active ester was isolated by filtration and washed with

CH₂CI₂ (100ml) and isopropanol: CH₂CI₂ (1:1), (50ml) and dried in vacuo. This resin was added to a solution of isopropylamine (7.0ml, 0.08mmol) in CH₂CI₂ (0.6ml) and stirred at room temperature for 20min. The resin was removed by filtartion, the filtrate evaporated, and the residue purified by chromatography (SiO₂, 3% MeOH in CH₂CI₂) to afford the title compound as a white solid.

¹H NMR(CDCl₃, 400 MHz) δ 8.33(1H, m),7.79(1H,m), 7.84(1H,d, J=8.2Hz), 7.61(2H,d, J=8.4Hz), 7.50-7.40(4H,m), 7.37(1H,d, 5.9Hz), 7.05(2H, d, J=8.5Hz), 6.81(1H, d, J=7.4Hz), 6.57(1H,s), 5.19(1H,d, J=9.3Hz), 5.11(2H,m), 4.27(1H,d, J=12.7Hz), 4.05-3.85(2H,m),

3.71(lh,d, j=12.9Hz), 3.32(1H,d, J=13.4Hz), 3.06(1H, d, J=13.4Hz), 2.95(1H,d, j=12.4Hz), 2.81(1H,d J=12.4Hz), 2.53(1H, dd, J=13.5 and 3.4Hz), 2.44(1H,dd, J=13.5 and 9.6Hz), 1.70-1.60(1H,m), 1.37(1H,m), 1.15(1H,m), 1.05(3H,d, J=6.5Hz) 1.01(3H,d, J=6.5Hz), 0.78(3H,t,

J=6.2Hz, 0.71(3H,d, J=6.7Hz) ppm.

FAB HRMS exact mass calc'd for C₃₅H₄₃N₆O₂ 579.344750(MH⁺), found 579.343531.

1. Prepared as described by A Berrada, F. Cavelier, R. Jacquier and J. Verducci in Bulletin de la Societe Chimique de France . 4, 513-314, 1989. EXAMPLE 38

N-[2(S)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylpentyll-N-(1-naphthylmethyl)glycine ρiρeridinylamide

The title compound was prepared using the protocol described in Example 37 step F using piperidine in place of

isopropylamine.

¹H NMR(CDCl₃, 400 MHz) δ 8.11(1H, d, J=8.0Hz), 7.82(1H,d, J=7.9Hz), 7.80-7.74(2H,m), 7.55(2H,d, J=8.2Hz), 7.48-7.30(5H,m), 7.05(2H,d, J=8.0Hz), 6.97(1H,s), 5.27(1H,d, J=16.0Hz), 5.22(1H,d, J=16.0Hz), 4.28(1H,d, J=13.5Hz), 4.00(1H,m), 3.90(1H,d, J=13.5Hz), 3.58(1H,m),3.30(2H,s), 3.16(1H,d, J=15.7Hz), 3.20(1H,d, J=15.7Hz), 3.15(1H,m), 3.05(1H,m), 2.76-2.60(2H,m), 1.82(1H,m), 1.70- 1.20(8H,m), 1.07(1H,m), 0.88(3H,t, J=7.3Hz) and 0.76(3H,d,J=6.8Hz) ppm.

EXAMPLE 39

2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino -3-(t- butoxycarbonyl)amino - N- methyl-N-(naphth-l-ylmethyl) propionamide

The title compound was prepared using the protocol described in the Example 27 step C using N-methylnaphth-1- ylmethylamine in place of N-methylbenzylamine.

¹H NMR(CD₃OD, 400 MHz) δ 8.96( 0.75H,s), 8.82(0.25H,s),

8.47(0.75H,d, J=8Hz), 8.42(0.25H,d, J=8Hz), 8.07-7.70(5H,m), 7.60-

7.20(13H,m), 5.51(1.5H,s), 5.30(0.5H,s), 5.20-5.00(2H,m), 5.00-

4.60(1H,m), 3.73(1H,m), 3.60-3.20( 3H,m), 3.09(2.25H,s), 2.99(.75H,s),

1.40(6.75H,s) and 1.37(2.25H,s) ppm.

FAB Mass spectmm, m/z = 581 (M+1)

EXAMPLE 40

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S){N'- methanesulfonyl-N'-(naphth-1-ylmethyl)aminomethyl)-pyrrolidine Step A: Preparation of 2(S)-Hydroxymethyl-N-trifluoroacetyl pyrrolidine

To a solution of L-prolinol (7.02g, 69.4mmol) and

triethylamine (10.6ml, 76.1mmol) in CH₂CI₂ (700ml) at -5°C was added trifluoroacetic anhydride (9.80ml, 69.4mmol) over a period of 4hr. The solvent was evaporated in vacuo and the residue purified by

chromatography(SiO₂, 15-20% EtOAc in hexanes, gradient elution). The title compound was obtained as a pale yellow oil.

¹H NMR(CDCl₃, 400 MHz) δ 4.27( 1H,m), 3.84-3.56(4H,m), 3.19(1H, dd, J=7.8 and 3.6Hz) and 2.20-1.74(4H,m) ppm.

FAB Mass spectmm, m/z = 198 (M+1)

Step B: Preparation of 2(S)-Methanesulfonyloxymethyl-N- trifluoroacetyl pyrrolidine

To a solution of the product of step A (1.002g, 5.08mmol) and triethylamine (0.78ml, 5.60mmol) in CH₂CI₂ (50ml) at -25°C was added methane sulfonyl chloride (0.40ml, 5.17mmol) over a period of 5 min and stirring was continued for 1hr. The solvent was evaporated in vacuo and the residue purified by chromatography(SiO₂, 33% EtOAc in hexanes, elution). The title compound was obtained as a colorless oil.

¹H NMR(CDCl₃, 400 MHz) δ 4.54(1H,dd, J=4.9 and 10.2Hz),

4.38(1H,m), 4.31(1H,dd, J=3.8 and 10.2Hz), 3.71(2H,m), 3.01(3H,s), 2.20- 1.90(4H,m) ppm.

FAB HRMS exact mass calc'd for C₈H₁₃NO₄SF₃ 276.051740(MH⁺), found 276.051233.

Step C: Preparation of 2(S)-Azidomethylpyrrolidine

In a flask protected by a safety screen, a solution of the product of stepB (12.27g, 0.042mmol) and lithium azide (2.47g,

0.051mmol) in DMF (30ml) was stirred at 45°C for 18hr. The solvent was evaporated in vacuo and the residue triturated with EtOAc (100ml) and filtered. The filtrate was evaporated in vacuo and the residue dissolved in MeOH (255ml) which was saturated with gaseous ammonia at 0°C and then stirred at room temperature for 72hr. The solvent was removed by distillation in vacuo to afford the title compound as an oil. ¹H NMR(CDCl₃, 400 MHz) δ 3.40-3.20(3H,m), 3.05-2.85(2H,m), 2.20- 1.60(3H,m), 1.50-1.35(1H,m)ppm.

Step D: Preparation of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}- 2(S)-azidomethyl} -pyrrolidine

To a solution of the acid from Example 1 step D (3.00g, 10.57mmol), the amine from step B (2.13g, 11.63mmol), HOOBT (1.90 g, 11.63mmol), and triethylamine (1.62ml, 11.63 mmol) in DMF (20ml) was added EDC (2.23g, 11.63 mmol). The reaction was stirred at room temperature for 24hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃ , brine , dried (MgSO₄). and evaporated in vacuo. The residue was purified by chromatography (SiO₂, 32-4% MeOH in CH₂CI₂, gradient elution) to afford the title compound as an oil.

¹H NMR(CDCl₃, 400 MHz) δ 7.64(2H,d, J=7.0Hz), 7.52(1H,s),

7.17(2H,d, J=7.0Hz), 6.97(1H,s), 5.35(2H,m), 4.14(1H,m), 3.69(1H,dd, J=12.1 and5.5Hz), 3.60-3.20(5H,m), and 2.20-1.80(4H,m) ppm. Step E: Preparation of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}- 2(S)-aminomethyl}-pyrrolidine

A solution of the azide from step D (480mg, 1.37mmol) in methanol (20ml) was purged with argon and 10% palladium on carbon (20mg) added. The flask was evacuated and stirred under an atmosphere of hydrogen (2 atm) for 3hrs. The hydrogen was replaced by argon and the catalyst removed by filtration and the solvent evaporated in vacuo to afford the title compound as an oil. A portion of this material was converted to the trifluoroacetate salt.

¹H NMR(CD₃OD, 400 MHz) Trifluoroacetate salt δ 8.88(1H,s),

7.74(2H,d, J=8.3Hz), 7.49(1H,s), 7.45(2H,d, J=8.3Hz), 5.50(2H,s), 4.18(1H,m), 3.90-3.80(2H,m), 3.60-3.40(2H,m), 3.15-2.95(2H,m) and 2.20- 1.70(4H,m) ppm. Step F: Preparation of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}- 2(S){N'-(naphth-1-ylmethyl)aminomethyl}- pyrrolidine

To a slurry of 1-naphthaldehyde (197μl, 1.63 mmol), cmshed 3 A molecular sieves (1.0g), and the amine from step E (421mg, 1.30 mmol) in 1,2-dichloroethane (10 ml) was added sodium

triacetoxyborohydride (345 mg, 1.63 mmol) at 0°C. The reaction was allowed to warm slowly to RT and stirred for 24 hrs. The reaction was cooled to 0°C and quenched with sat. aq. NaHCO₃ and stirred for 30min. The organic layer was separated, washed with saturated brine, dried (MgSO₄) and evaporated in vacuo. The residue was purified by

chromatography on a chromatatron (SiO₂, 5% MeOH in CH₂CI₂) to provide the title compound as an oil.

¹HNMR(CDCl₃, 400 MHz) δ 8.40-6.70(13H,m), 5.40-5.20(2H,m), 4.30- 4.10(2H,m), 3.60-3.40(5H,m),2.95-2.60(2H,m), 2.40-1.80(4H,m) ppm.

Step G: Preparation of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}- 2(S)-{N'-memanesulfonyl-N'-(naphth-1- ylmethyl)aminomethyl}-pyrrolidine

To a solution of the product of step F (74mg, 0.16 mmol) in

CH₂CI₂ (2 ml) and triethylamine (22μl, 0.16mmol) at 0°C was added methanesulfonyl chloride(12.3μl, 0.16mmol). The reaction was stirred at room temperature for lhr,quenched with sat aq. NaHCO₃ and extracted with CH₂CI₂ (2x 10ml). The organic extracts were dried (MgSO₄) and the solvent evaporated in vacuo.The residue was purified by preparative

HPLC (C-18; 95:5 to 5:95 water:CH₃CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the title compound as a white solid.

¹H NMR(CD₃OD, 400 MHz) δ 8.92(1H, m), 8.36(1H, m), 8.00- 7.30(l1H,m), 5.46(1.2H,s), 5.39(0.8H,s), 5.03(0.6H,d, J=14.5Hz), 4.90-

4.60(1H,m), 4.71(0.4H,d, J=14.5Hz), 3.80-3.50(2H,m), 3.50-2.70(5H,m),

3.10(1.2H,s), 2.94(1.8H,s) and 1.80-1.20(4H,m)ppm.

FAB Mass spectmm, m/z = 542 (M+1).

Anal, calc'd for C₃₀H₃₁N₅O₃ 0.25H₂O, 1.95TFA; C, 52.98; H, 4.49; N, 9.11. Found: C, 53.00; H, 4.37; N, 9.36. EXAMPLE 41

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S)-{N'-acetyl-N'- naphth-1-ylmethyl-aminomethyl}-pyrrolidine

The title compound was prepared using the protocol described in Example 40 step G using acetyl chloride instead of methane sulfonyl chloride.

¹H NMR(CD₃OD, 400 MHz) δ 9.0-8.8(1H,m), 8.20-7.0(12H,m), 5.60- 4.70(4H,m), 4.60-4.10(1H,m), 4.00-3.00(4H,m) and 2.30- 1.80(7H,m)ppm.

F.AB Mass spectrum, m/z = 506 (M+1).

Anal, calc'd for C₃₁H₃₁N₅O₂ 0.05H₂O, 1.80TFA; C, 58.39; H, 4.66; N, 9.84. Found: C, 58.40; H, 4.67; N, 9.91.

EXAMPLE 42

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine hydrochloride

Step A: N-{t-Butoxycarbonyl}-2(S)-[1-(R,S)-1-(3-chlorophenyl)-1- hydroxy]-methylpyrrolidine

To magnesium turnings (753mg, 30.99mmol) in diethylether (1 ml) was added a solution of 3-bromochlorobenzene 3.60ml ,

30.88mmol) in diethylether (25 ml) at a rate so as to maintain a gentle reflux.The reaction was heated at reflux for a further 30min, allowed to cool to room temperature and diluted with diethyl ether to a total volume of 37ml.

A solution of N-t-butoxycarbonylprolinal (2.50g, 11.61mmol) in diethylether was cooled to 0°C and 3-chloromagnesium bromide solution (17.0 ml, 14.1 mmol) was added. The reaction was stirred at 0°C for 10 min and then allowed to warm to room temperature and stirring continued for 30mins. The solution was cooled to 0°C and quenched by the addition of a saturated ammonium chloride solution (50ml). The mixture was extracted with diethyl ether and the combined extracts were washed with brine, dried (MgSO₄) and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 10-20% ethylacetate in hexanes, gradient elution) to afford the title compounds as an oil.

¹H NMR(CD₃OD, 400 MHz) δ 7.50-7.00(4H, m), 5.95(0.66H, s), 5.55(0.33H, s), 4.85(0.33H, s), 4.50(0.66H, m), 4.30(0.33H, s),

4.06(0.66H, m), 3.70-3.20( 2H, m), 2.00-1.60(13H, m)ppm. Step B: N-{t-Butoxycarbonyl}-2(S)-[(1(S)-1-(3-chlorophenyl)-1(2- picolinoyloxy)]-methylpyrrolidine and N-{t- Butoxycarbonyl}-2(S)-[(1(R)-1-(3-chl orophenyl)-1(2- picolinoyloxy)]-methylpyrrolidine

To a solution of the alcohols from step A(105mg, 0.337 mmol), triethylamine (0.235ml, 1.69 mmol), and DMAP (5mg, 0.04 mmol), in methylene chloride( 3.0ml), was added picolinoyl chloride hydrochloride (90mg, 0.51 mmol)and the mixture was stirred 16hr. The reaction was diluted with methylene chloride and washed with saturated NaHCO₃ solution. The organic extracts were dried, (Na₂SO₄) and the solvent evaporated in vacuo. The diastereomeric products were separated by chromatography (SiO₂, 25% ethylacetate in hexanes).

First diastereomer eluted:N-{t-Butoxycarbonyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-(2-picolinoyloxy)]-methylpyrrolidine.

¹H NMR (CD₃OD, 400 MHz) δ 8.75(1H, m), 8.26(1H, d, J=0.9Hz), 8.05(1H, dt, J=6.0, and 1.8Hz), 7.68(1H, m), 7.60-7.20(4H, m), 6.60(1H, m), 4.29(1H, s), 3.44(1H, m), 3.25(1H, m), 2.30-2.00(2H, m)ppm.

Second diastereomer eluted:

N-{t-Butoxycarbonyl}-2(S)-[1(S)-1-(3-chlorophenyl)-1-picolinoyloxy}- methylpyrrolidine.

¹H NMR (CD₃OD, 400 MHz) δ 8.72(1H, m), 8.25(1 H, m), 8.05(1H, m), 7.64(1H, m), 7.50(1H, m), 7.50-7.20(3H, m), 6.20-6.05(1H, m), 4.39(1H, s), 3.38(1 H, q, J=8.2Hz), 3.12(1H, m) and 2.20-1.30(1 3H, m)ppm. Step C: N-{t-Butoxycarbonyl}-2(S)-[1(R)-1-(3-chlorophenyl)-1- hydroxy]methylpyrrolidine

To a solution of N-{t-Butoxycarbonyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-(2-picolinoyloxy)]-methylpyrrolidine (32.7mg, 0.078 mmol), in THF (2.0 ml) was added lithium hydroxide (0.63ml of a 1.0M aqueous solution, 0.63mmol) at room temperature and the reaction was stirred for 16hrs. The mixture was diluted with ethylacetate and washed with water and brine, dried (Na₂SO₄), and the solvents evaporated in vacuo. The residue was purified by chromatography (SiO₂, 5% EtOAc in CH₂CI₂) to afford the product as a white solid.

¹H NMR(CDCl₃, 400 MHz) δ 7.50-7.10(4H, m), 5.57(0.8H, s),

5.15(0.2H, s), 4.85(1H, s), 4.30(0.8H, s), 4.00(0.2H, s), 3.60(0.2H, s), 3.35(0.8H, s), 2.85(0.8H, s), 2.30(0.2H, s), 2.10-1.60(4H, s), 1.56(1.8H, s), and 1.52(7.2H, s) ppm.

Step D: N-{t-Butoxycarbonyl}-2(S)-[1(S)-1-(3-chlorophenyl)-1- hydroxy]-methylpyrrolidine

The title compound was prepared using the procedure in step C and N-{t-Butoxycarbonyl}-2(S)-[l(S)-1-(3-chlorophenyl)-1-(2- picolinoyloxy)]-methylpyrrolidine.

¹H NMR(CDCl₃, 400 MHz) δ 7.50-7.10(4H, m), 6.00(1H, s), 4.50(1H, s), 4.06(1H, m), 3.48(1H, m), 3.36(1H, m) and 1.85-1.40(13H, m) ppm.

Step E: 2(S)-[1(R)-1-(3-chlorophenyl)-1-hydroxy]- methylpyrrolidine

The title compound was prepared by the procedure described in Example 1 step G using the material prepared in step C.

¹H NMR (CD₃OD, 400 MHz) δ 7.47(1H, m), 7.42-7.30(3H, m),

5.07(1H, d, J=3.9Hz), 3.83(1H, m), 3.40-3.20(2H, m), 2.15-1.85(3H, m) and 1.70(1H, m) ppm.

Step F: 1-Trityl-4-(4-cyanobenzyl)-imidazole

To a suspension of activated zinc dust (3.57g, 54.98 mmol) in THF (50ml)was added dibromoethane (0.315ml, 3.60mmol) and the reaction stirred under argon at 20°C. The suspension was cooled to 0°C and α-bromo-p-tolunitrile (9.33g, 47.6 mmol) in THF (100ml) was added dropwise over a period of 10 min. The reaction was then allowed to stir at 20°C for 6hr. Bis(triphenylphosphine) Nickel II chloride (2.40g,

3.64mmol) and 5-iodotrityl imidazole (15.95g, 36.6mmol) was added in one portion.The resulting mixture was stirred 16hr at 20°C and then quenched by addition of saturated NH₄CI solution (100ml) and the mixture stirred for 2 hours. Saturated NaHCO₃ solution was added to give a pH of 8 and the solution was extracted with EtOAc ( 2x250ml), dried (MgSO₄) and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 0-20% EtOAc/CH₂Cl₂) to afford the title compound as a white solid.

¹H NMR CDCl₃ δ (7.54 (2H, d, J=7.9Hz), 7.38(1H, s), 7.36-7.29 (11H, m), 7.15-7.09(6H, m), 6.58(1H, s) and 3.93(2H, s)ppm.

Step G: 5-(4-Cyanobenzyl)-imidazol-1-yl-methylacetate

To a solution of methyl glycolate (0.545ml, 7.06 mmol), diisopropylethylamine (1.30ml, 7.46 mmol), in CH₂CI₂ at -78°C was added dropwise trifluoromethanesulfonyl anhydride (1.20ml, 7.13mmol) and the resulting mixture was stirred at -78°C for 1hr. A solution of 1- trityl-4-(4-cyanobenzyl)-imidazole (3.00 g, 7.05 mmol) in CH₂CI₂ (20ml) was cooled to -78°C and added dropwise to the above solution. The cooling bath was removed and the reaction was allowed to warm to room temperature and stirred for 3 hours, and then the solvent was evaporated in vacuo. The residue was dissolved in methanol (60ml), heated at refux for 30 min, cooled and the solvent evaporated in vacuo. The residue was partitioned between saturated NaHCO₃ solution and EtOAc. The organic extracts were dried (Na₂SO₄ and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 3 to 10% MeOH in CH₂CI₂ , gradient elution) and the title compound was obtained as a white solid.

¹H NMR δ CDCI₃ (7.61 (2H, d, J=7.9Hz), 7.53(1H, s), 7.27(2H, d, J=7.9Hz), 6.89(1H, s), 4.47(2H, s), 3.98(2H, s) and 3.66(3H, s)ppm. Step H: 5-(4-Cyanobenzyl)-imidazol-1-yl-acetic acid

The title compound was prepared using the procedure described in Example 1 step D using the methyl ester from step G.

1H NMR CDCl₃ δ 8.76(1H, s), 7.71 (2H, d, J=8.0Hz), 7.56(1H, s), 7.45(2H, d, J=8.0Hz), 7.15(1H, s), 4.72(2H, s) and 4.15(2H, s) ppm.

Step I: N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)- [1(R)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine- hydrochloride

To a solution of the acid from step H (135mg, 0.476mmol), the amine hydrochloride salt from step G (101mg, 0.477mmol), HOOBT (95mg, 0.58mmol), and triethylamine (0.16ml, 1.15mmol) in DMF

(10ml) was added EDC (109mg, 0,569 mmol). The reaction was stirred at room temperature for 48hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO₃, brine, dried (Na₂SO₄) and evaporated in vacuo. The residue was chromatographed (SiO₂, 7% MeOH in CH₂CI₂) to afford the desired amide which was converted to the corresponding hydrochloride salt by treatment with 1 equivalent of hydrochloric acid in aqueous acetonitrile and evaporation of the solvents in vacuo.

¹H NMR(CD₃OD, 400 MHz) δ 8.85-8.75(1H, m), 7.90-7.10(9H, m), 5.40-5.00(3H, m), 4.40-4.00(3H, m), 3.60-3.00(2H, m) and 2.30-1.20(4H, m)ppm.

FAB Mass spectmm, m/z = 435 (M+1).

Anal, calc'd for C₂₄H₂₃N₄O₂CI 1.00 HCl, 0.45 H₂O; C, 60.12; H, 5.23; N, 11.68; Found: C, 60.08; H, 5.09; N, 11.77.

EXAMPLE 43

Step A: 2(S)-[1(S)-1-(3-chlorophenyl)-1-hydroxy]

methylpyrrolidine hydrochloride

The title compound was prepared by the procedure described in Example 1 step G using the material prepared in Example 42 step D. ¹H NMR (CD₃OD, 400 MHz) δ 7.52(1H, m), 7.50-7.32(3H, m),4.75(1H, d, J=6.9Hz), 3.71(1H, q, J=8.0Hz), 3.40-3.20(2H, m) and 2.20-1.80(4H, m)ppm. Step B: N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)-[1(S)-

1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared by the procedure described in Example 42 step I using the amine hydrochloride from step A.

¹H NMR(CD₃OD, 400 MHz) δ 9.00-8.90(1H, m), 7.90-7.10(9H, m), 5.75(1H, d, J=17.0Hz), 5.30(1H, d, J=17.0Hz), 5.17(1H, q, J=18Hz),

4.46(1H, d, J=9.5Hz), 4.40-4.00(3H, m), 3.60-3.20(2H, m), 2.20-1.20(4H, m)ppm.

FAB Mass spectmm, m/z = 435 (M+1).

Anal, calc'd for C₂₄H₂₃N₄O₂CI 1.00 HCl, 0.55 H₂O; C, 59.89; H, 5.26; N, 11.64. Found: C, 59.86; H, 5.22; N, 12.00.

EXAMPLE 44

Step A: 1-Hydroxyethyl-5-(4-Cyanobenzyl)-imidazole

A solution of 5-(4-cyanobenzyl)-imidazol-1-yl- methylacetate (0.113 g, 0.472 mmol) in methanol (2ml) at 0°C was treated with sodium borohydride (80.7mg, 2.1mmol). After 1 hr the reaction was quenched by addition of saturated NH₄CI solution (2ml).

Saturated NaHCO₃ was added and the mixture extracted with ethyl acetate (3x25ml), dried (MgSO₄) and the solvent evaporated in vacuo.

The title compound was isolated by chromatography (SiO₂, 10%MeOH in CH₂CI₂) as a white solid.

¹H NMR CDCl₃ δ 7.61 (2H, d, J=7.9Hz), 7.55(1H, s), 7.27(2H, d,

J=7.9Hz), 6.83(1H, s), 4.05(2H, s), 3.87(2H, t, J=5.1Hz) and 3.74(2H, t,

J=5.1Hz)ppm. Step B: 5-(4-Cyanobenzyl)-imidazol-1-yl-ethyl methanesulfonate

A solution of 1-hydroxyethyl-5-(4-Cyanobenzyl)-imidazole (0.532 g, 2.34 mmol) in methylene chloride (70ml) at 0°C was treated with Hunigs base (0.489ml, 2.81 mmol) and methanesulfonyl chloride (0.219ml, 2.81 mmol). After 2 hrs the reaction was quenched by addition of saturated NaHCO₃ solution (50ml) and the mixture extracted with methylene chloride (50ml), dried (MgSO₄) and the solvent evaporated in vacuo. The title compound was used without furthur purification.

¹H NMR CDCl₃ δ 7.62 (2H, d, J=7.9Hz), 7.54(1H, s), 7.29(2H, d, J=7.9Hz), 6.87(1H, s), 4.25(2H, t), 4.10-4.00(4H, m), 3.74(2H, t,

J=5.1Hz) and 2.90(3H, s)ppm.

Step C: N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine To a solution of 5-(4-cyanobenzyl)-imidazol-1-yl)ethyl methanesulfonate (290 mg, 0.95 mmol) in DMF (10ml) was added the amine (200mg, 0.945 mmol) (prepared by treatment of the amine hydrochloride salt obtained in Example 42 step E with 1M sodium hydroxide extraction into EtOAc, drying (Na₂SO₄), and evaporation of solvent), sodium iodide (710mg, 4.74 mmol) and Hunig's base (0.330ml, 1.89 mmol). The mixture was stirred at 55°C for 12 hrs, and the solvent evaporated in vacuo. The residue was treated with water and 1M NaOH to a pH of 11 and extracted into EtOAc. The organic extracts were dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 1-2% saturated ammonia in acetonitrile, gradient elution. The residue was converted to the corresponding hydrochloride salt by treatment with 1 equivalent of hydrochloric acid in aqueous acetonitrile and evaporation of the solvents in vacuo..

FAB Mass spectmm, m/z = 421 (M+1).

Anal, calc'd for C₂₄H₂₅N₄OCI 2.00CH l , O.6OH₂O; C, 57.12 H, 5.63; N, 11.10. Found: C, 57.08; H, 5.71; N, 11.24. EXAMPLE 45

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[l(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared using the procedure described in Example 44 using the amine hydrochloride from Example 43 step A.

FAB Mass spectmm, m/z = 421 (M+1).

Anal, calc'd for C₂₄H₂₅N₄OCI 2.00 HCl, 0.20 H₂O; C, 57.95; H, 5.55; N, 11.26. Found: C, 57.95; H, 5.37; N, 11.30.

EXAMPLE 46

Step A: 1-Triphenylmethyl-4-(hydroxymethyl)-imidazole

To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35.0 g, 260 mmol) in dry DMF (250 ml) at room temperature was added triethylamine (90.6 ml, 650 mmol). A white solid precipitated from the solution. Chlorotriphenylmethane (76.1 g, 273 mmol) in of DMF (500 ml) was added dropwise. The reaction mixture was stirred for 20 hrs, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a white solid which was sufficiently pure for use in the next step.

Step B: 1-Triphenylmethyl-4-(acetoxymethyl)-imidazole

The alcohol from Step A (260 mmol, prepared above) was suspended in pyridine (500 ml). Acetic anhydride (74 ml, 780 mmol) was added dropwise, and the reaction was stirred for 48 hrs during which it became homogeneous. The solution was poured into EtOAc, washed sequentially with water, 5% aqueous HCl solution, saturated aqueous NaHCO₃, solution, and brine, the organic extracts were dried (Na₂SO₄), and concentrated in vacuo to provide the product as a white powder, which was sufficiently pure for use in the next reaction.

Step C: 1-(4-Cyanobenzyl)-5-(acetoxymethyl)-imidazole

hydrobromide

A solution of the product from Step B (85.8 g, 225 mmol) and 4-cyano benzyl bromide (50.1 g, 232 mmol) in EtOAc (500ml) was stirred at 60 °C for 20 hrs, during which a pale yellow precipitate formed. The reaction was cooled to room temperature and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume (200 ml), reheated at 60 °C for 2 hrs, cooled to room

temperature, and filtered again. The filtrate was concentrated in vacuo to a volume (100 m), reheated at 60 °C for another 2hrs, cooled to room temperature, and concentrated in vacuo to provide a pale yellow solid. All of the solid material was combined, dissolved in methanol (500ml), and warmed to 60 °C. After 2hrs, the solution was concentrated in vacuo to provide a white solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a white solid which was used in the next step without further purification.

Step D: 1-(4-Cyanobenzyl)-5-(hydroxymethyl)-imidazole

To a solution of the acetate from Step C (50.4 g, 150 mmol) in 3: 1 THF/water (1.5 1) at 0 °C was added lithium hydroxide

monohydrate (18.9 g, 450 mmol). After lhr, the reaction was

concentrated in vacuo, diluted with EtOAc (3 1), and washed with water, sat. aq. NaHCO₃ and brine. The solution was then dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde product as a pale yellow fluffy solid which was sufficiently pure for use in the next step without further purification. Step E: 1-(4-Cyanobenzyl)-5-(chloromethyl)-imidazole

A solution of 1-(4-Cyanobenzyl)-5-(hydroxymethyl)- imidazole (1.0g, 4.70mmol), in thionyl chloride (5ml), was stirred at 70°C for 16hrs. The solvent was evaporated in vacuo and the resulting solid suspended in CH₂CI₂, collected by filtration and dried in vacuo. The material was sufficiently pure to be used without furthur purification.

¹H NMR CD₃OD δ 9.06 (1H, s), 7.83(2H, d, J=8.0Hz), 7.77(1H, s), 7.55(2H, d, J=8.0Hz), 5.67(2H, s) and 4.78(2H, s) ppm. Step F : N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)- [1(R)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

A solution of the chloride from step E (127 mg, 0.474 mmol) in DMF (2 ml) was added 2(S)-[1(R)-1-(3-chlorophenyl)-1- hydroxy]methylpyrrolidine (prepared by treatment of the amine

hydrochloride salt obtained in Example 42 step E with 1M sodium hydroxide and extraction into EtOAc, drying (Na₂SO₄) and evaporation of solvent), ( 100mg, 0.472mmol) and Hunig's base (0.20ml, 1.15mmol). The mixture was stirred at room temperature for 12 hrs. The reaction was diluted with EtOAc and the pH adjusted to 11 by the addition of 1M NaOH. The organic extracts were dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, eluting with 3% saturated ammonia/acetonitrile). The residue was converted to the corresponding hydrochloride salt by treatment with 2 equivalents of hydrochloric acid in aqueous acetonitrile and evaporation of the solvents in vacuo.

FAB Mass spectmm, m/z = 407 (M+1).

Anal, calc'd for C₂₃H₂₃N₄OCI 2.00 HCl, 0.65 H₂O; C, 56.51; H, 5.36;

N, 11.46. Found: C, 56.57; H, 5.36; N, 11.35. EXAMPLE 47

The title compound was prepared using the procedure described in Example 46 using the amine hydrochloride from Example 43 step A.

FAB Mass spectmm, m/z = 407 (M+1).

Anal, calc'd for C₂₃H₂₃N₄OCI 2.00 HCl, 0.65 H₂O; C, 56.20; H, 5.39; N, 11.40. Found: C, 56.25; H, 5.33; N, 11.30.

EXAMPLE 48

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-4(R)-hydroxy-2(S)- [1(R)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine hydochloride

The title compound was prepared as in Example 42 steps A-I using 4(R)- t-butyldimethylsiloxy-prolinal.

¹H NMR CD₃OD δ 8.85 (1H, s), 7.74(2H, d, J=8.3Hz), 7.50(2H, d,

J=8.3Hz), 7.50-7.20(5H, m), 5.39(1H, m), 5.24(1H, d, J=17.1Hz), 5.05(1H, d, J=17.1Hz), 4.55(1H, m), 4.30(1H, m), 3.65(1H, dd, J=11.0 and 4.2Hz), 3.50(1H, d, J=11.0Hz), 3.40-3.00(2H, m), 2.14(1H, m) and

1.50(1H, m)ppm.

FAB Mass spectmm, m/z = 451 (M+1). EXAMPLE 49

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-4(R)-hydroxy-2(S)-

[1(S)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared as in Example 43 using 4(R)-hydroxy-2(S)-[1(S)-1-(3-chlorophenyl)-1- hydroxy]methylpyrrolidine.

Anal, calc'd for C₂₄H₂₃N₄O₃CI 1.00 HCl, 0.15 NH₄CI; C, 58.19; H, 5.01; N, 11.73. Found: C, 58.09; H, 5.33; N, 11.97. EXAMPLE 50

To a solution of 4(R)-hydroxy-2(S)-[1(R)-1-(3-chlorophenyl)-1- hydroxy]methylpyrrolidine (181mg, 0.79mmol), Hunigs base (0.138ml, 0.79mmol) and 1-(4-cyanobenzyl)-imidazol-5-yl) ethylmethanesulfonate (263mg, 0.79 mmol) in DMF (1.6ml) was added sodium iodide (594mg, 3.96 mmol) and the mixture heated at 55°C for 16hrs. The reaction was diluted withEtOAc and the pH adjusted to 12 with 1M NaOH. The organic extract was washed with brine, dried (MgSO₄), and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 2 to 5% NH₄OH in acetonitrile, gradient elution) to afford the title compound which was converted to an HCl salt.

Anal, calc'd for C₂₄H₂₅N₄O₂CI 2.00 HCl, 0.85 H₂O; C, 54.89; H, 5.51; N, 10.67. Found: C, 54.85; H, 5.43; N, 10.74.

FAB Mass spectmm, m/z = 437 (M+1).

EXAMPLE 51

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(S)-

1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared according to the procedure described in Example 50 using 4(R)-hydroxy-2(S)-[1(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine.

Anal, calc'd for C₂₄H₂₅N₄O₂CI 2.00 HCl, 0.60 H₂O, 0.35 EtOAc; C, 55.32; H, 5.67; N, 10.16. Found: C, 55.33; H, 5.75; N, 9.95.

FAB Mass spectmm, m/z = 437 (M+1). EXAMPLE 52

N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(R)-

1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared according to the procedure described in Example 44 step C using 4(R)-hydroxy-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxylmethylpyrrolidine.

Anal, calc'd for C₂₄H₂₅N₄O₂CI 2.00 HCl, 0.70 H₂O; C, 55.17; H, 5.48; N, 10.72. Found: C, 55.20; H, 5.43; N, 10.63.

FAB Mass spectmm, m/z = 437 (M+1).

EXAMPLE 53

N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(S)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared according to the procedure described in Example 52 using 4(R)-hydroxy-2(S)-[1(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

Anal, calc'd for C₂₄H₂₅N₄O₂CI 2.00 HCl, 0.95 H₂O; C, 54.70; H, 5.53; N, 10.63. Found: C, 54.75; H, 5.45; N, 10.55.

FAB Mass spectmm, m/z = 437 (M+1).

EXAMPLE 54

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl]-4(R)-hydroxy-2(S)-

[1(S)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared according to the procedure described in Example 46 step F using 4(R)-hydroxy-2(S)-[1(R)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine.

Anal, calc'd for C₂₃H₂₃N₄O₂CI 2.00 HCl, 0.80 H₂O; C, 54.14; H, 5.25;

N, 10.98. Found: C, 54.09; H, 5.30; N, 11.37.

FAB Mass spectmm, m/z = 423 (M+1). EXAMPLE 55

N-[1-(4-Cyanobenzyl)-1-imidazol-5-ylmethyl]-4(R)-hydroxy-2(S)-[1(R)-

1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

The title compound was prepared according to the procedure described in Example 46 step F using 4(R)-hydroxy-2(S)-[(3- chlorophenyl)-(R)-hydroxymethyl]-pyrollidine.

Anal, calc'd for C₂₃H₂₃N₄O₂Cl 2.00 HCl, 0.80 H₂O;, C, 54.14; H, 5.25; N, 10.98. Found: C, 54.13; H, 5.40; N, 11.09.

FAB Mass spectmm, m/z = 423 (M+1).

EXAMPLE 56

Step A: 4(R)-Hydroxyproline methyl ester

A suspension of 4(R)-hydroxyproline (35.12g, 267.8mmol) in methanol (500ml) was saturated with gasseous hydrochloric acid. The resulting solution was allowed to stand for 16hrs and the solvent evaporated in vacuo to afford the title compound as a white solid.

¹H NMR CD₃OD δ 4.60 (2H, m), 3.86(3H, s), 3.48(1H, dd, J=3.6 and 12.0Hz), 3.23(1H, d, J=12.0Hz), 2.43(1H, m) and 2.21(1H, m) ppm. Step B: N-t-Butoxycarbonyl-4(R)-hydroxyproline methyl ester

To a solution of 4(R)-hydroxyproline methyl ester (53.5g, 268mmol), and triethylamine (75ml, 540mmol), in CH₂CI₂ (500ml), at 0°C, was added a solution of di-t-butyl dicarbonate (58.48, 268mmol), in CH₂CI₂ (75ml). The resulting mixture was stirred for 48hrs at room temperature. The solution was washed with 10% aqueous citric acid solution, saturated NaHCO₃ solution, dried (Na₂SO₄) and the solvent evaporated in vacuo. The title compound was obtained as a yellow oil and used in the next step without furthur purification. ¹H NMR CD₃OD δ 4.40-4.30 (2H, m), 3.75(3H, m), 3.60-3.40(2H, m), 2.30(1H, m), 2.05(1H, m) and 1.55-1.40(9H, m) ppm.

Step C: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy proline methyl ester

To a solution of N-t-butoxycarbonyl-4(R)-hydroxy proline methyl ester (65.87g, 268mmol), and triethylamine (41ml, 294mmol), in CH₂CI₂ (536ml), at 0°C, was added a solution of t-butyldimethyl silylchloide (42.49g, 282mmol), in CH₂CI₂ (86ml). The resulting mixture was stirred for 16hrs at room temperature. The solution was washed with 10% aqueous citric acid solution, saturated NaHCO₃ solution, dried (Na₂SO₄) and the solvent evaporated in vacuo. The title compound was obtained as a yellow oil and used in the next step without furthur purification.

¹H NMR CD₃OD δ 4.60-4.40 (2H, m), 3.75(3H, m), 3.60-3.20(2H, m), 2.30-1.90(2H, m), 1.45-1.40(9H, m), 0.90-0.85(9H, m), 0.10-0.00(6H, m) ppm.

Step D: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy-2(S)- hydroxymethylpyrrolidine

A solution of N-t-butoxycarbonyl-4-(R)-t- butyldimethylsilyloxy proline methyl ester (86.65g, 241mmol), in THF (150ml), was added over 90 minutes to a solution of lithium aluminum hydride (247ml of a 1M solution in THF, 247mmol), under argon, so that the temperature did not exceed 12°C. Stirring was continued for 50 mins and then EtOAc (500ml) was added cautiously, followed by sodium sulphate decahydrate (34g), and the resulting mixture stirred for 16 hrs at room temperature. Anhydrous sodium sulphate (34g) was added and the mixture stirred an additional 30 min and then filtered. The solids were washed with EtOAc (800ml), the filtrates combined and the solvent evaporated in vacuo. The title compound was obtained as a colourless oil and used in the next step without further purification. Step E: N-t-Butoxycarbonyl-4(R)-t-butyldimethylsilyloxy-2(S)- methanesulfonyloxymethylpyrrolidine

The title compound was prepared according to the procedure described in Example 40 step B using N-t-butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-hydroxymethylpyrrolidine.

FAB Mass spectmm, m/z = 410(M+1).

¹H NMR CDCl₃ δ 4.60-4.00 (4H, m), 3.60-3.30(2H, m), 2.98(3H, s),

2.05-2.00(2H, m), 1.48-1.42(9H, m),0.90-0.80(9H, m), 0.10-0.00(6H, m) ppm.

Step F: Preparation of N-t-Butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-azidomethylpyrrolidine

In a flask protected by a safety screen, a solution of N-t- butoxycarbonyl-4(S)-t-butyldimethylsilyloxy-2(S)-methanesulfonyloxy methyl pyrroUdine(10.40g, 25.39mmol) and tetrabutylammonium azide (8.18g, 28.7mmol) in toluene (250ml) was stirred at 80°C for 5hr. The reaction was cooled to room temperature and diluted with EtOAc

(250ml), washed with water and brine and dried (Na₂SO₄). The solvent was evaporated in vacuo to afford the title compound as a yellow oil which was used in the next step without furthur purification.

¹H NMR CDCl₃ δ 4.60-3.20 (6H, m), 2.05-1.90(2H, m), 1.47(9H, s), 0.87(9H, s) and 0.10-0.00(6H, m) ppm.

Step G: Preparation of N-t-Butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-aminomethylpyrrolidine

A solution of N-t-butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-azidomethylpyrrolidine (9.06g, 25.39mmol) in EtOAc (120ml) was purged with argon and 10% palladium on carbon (1.05g) added. The flask was evacuated and stirred under an atmosphere of hydrogen (49 psi) for 16hrs. The hydrogen was replaced by argon, the catalyst removed by filtration and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 2.5 to 5% saturated NH₄OH in acetonitrile, gradient elution), to afford the title compound as an oil. ¹H NMR(CDCl₃, 400 MHz) δ 4.40-2.60 (6H, s), 2.05-1.80(2H, m), 1.46(9H, s), 1.36(2H, s), 0.87(9H, s), 0.10-0.00(6H, m)ppm. Step H: Preparation of N-t-Butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-{N'-3- chlorobenzyl}aminomethylpyrrolidine

To a slurry of 3-chlorobenzaldehyde (1.2ml, 10.6mmol), cmshed 3 A molecular sieves (9.5g) and the amine from step G (3.50g, 10.6mmol) in methanol (150 ml) was added sodium cyanoborohydride (11.0ml of a 1M solution in THF, 11.0mmol) at room temperature. The pH was adjusted to 7 by the addition of glacial acetic acid (0.68ml, 12mmol) and the reaction was stirred for 16 hrs. The reaction was filtered and the filtrate evaporated in vacuo. The residue was partitioned between EtOAc and saturated NaHCO₃ solution and the organic extract washed with brine, dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 2.5% MeOH in CH₂CI₂) to provide the title compound as an oil.

¹HNMR(CDCl₃, 400 MHz) δ 7.40-7.10(4H, m), 4.36(1H, s), 4.15- 3.90(2H, m), 3.90-3.30(2H, m), 2.85-2.60(2H, m), 2.05-1.90(2H, m), 1.44(9H, s), 0.87(9H, s) and 0.06(6H, m) ppm. Step I: Preparation of N-t-Butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-{N'-3-chlorobenzyl-N'-acetyl}- aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-4(R)-t- butyldimethylsilyloxy-2(S)-{N'-3-chlorobenzyl}-aminomethyl

pyrrolidine (3.80g, 8.35 mmol) in CH₂CI₂ (85ml) and triethylamine (2.40ml, 17.0 mmol) at 0°C was added acetyl chloride (0.60ml, 8.44 mmol). The reaction was stirred at room temperature for lhr, diluted with water and extracted with CH₂CI₂. The extracts were washed with brine, dried (Na₂SO₄) and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 10 to 25% EtOAc in CH₂CI₂, gradient elution).

¹HNMR (CDCl₃, 400 MHz) δ 7.40-7.00(4H, m), 5.10-3,00(8H, m), 2.20-1.70(5H, m), 1.50-1.30(9H, m), 0.87(9H, s) and 0.06(6H, m) ppm. Step J: Preparation of N-t-Butoxycarbonyl-4(R)-hydroxy-2(S)-{N'

-3-chlorobenzyl-N'-acetyl}-aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-4(R)-t- butyldimethylsilyloxy -2(S)-{N'-3-chlorobenzyl-N'-acetyl } - aminomethylpyrrolidine (4.02g, 8.09 mmol) in THF (80ml) at 0°C was added tetrabutylammonium fluoride (9.00ml of a 1M solution in THF.

9.00mmol). The reaction was stirred at 0°C for 1hr and then at room temperature for 30min. The reaction was quenched by the addition of a saturated NH₄CI solution (50ml), dilution with EtOAc. The organic extracts were washed with brine, dried (Na₂SO₄) and the solvent evaporated in vacuo. The residue purified by chromatography (SiO₂, 3 to

5% MeOH in CH₂CI₂, gradient elution) to afford the title compound as a foam.

¹HNMR (CDCl₃, 400 MHz) δ 7.40-7.00(4H, m), 5.00-4,00(4H, m), 4.00-3.10(4H, m), 2.30-1.60(5H, m) and 1.50-1.30(9H, m) ppm.

Step K: 4(R)-hydroxy-2(S)-{N'-3-chlorobenzyl-N'-acetyl}- aminomethylpyrrolidine hydrochloride

The title compound was prepared by the procedure described in Example 1 step G using N-t-butoxycarbonyl-4(R)-hydroxy-2(S)-{N'-3- chlorobenzyl-N'-acetyl}-aminomethylpyrrolidine.

¹H NMR(CD₃OD, 400 MHz) δ 7.50-7.15(4H, m), 4.75(2H, m), 4.52(1H, m), 4.00-3.90(2H, m), 3.45(2H, m), 3.18(1H, brd, J=7.3Hz), 2.20(3H,s),

2.05(1H, m) and 1.85(1H, m) ppm.

Step L: 1 -(4-Cyanobenzyl)-5-imidazole carboxaldehyde

To a solution of 1-(4-Cyanobenzyl)-5-(hydroxymethyl)- imidazole (21.5 g, 101 mmol) in DMSO (500ml) at room temperature was added triethylamine (56 ml, 402 mmol), then SO₃-pyridine complex (40.5 g, 254 mmol). After 45 min, the reaction was poured into EtOAc, washed with water and brine, dried (Na₂SO₄), and concentrated in vacuo to provide the aldehyde as a white powder which was sufficiently pure without further purification. Step M: N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)- hydroxy-2(S)-{N'-3-chlorobenzyl-N'-acetyl}- aminomethylpyrrolidine

To a slurry of 1-(4-Cyanobenzyl)-5-imidazole carboxaldehyde (165mg, 0.781 mmol), crashed 3A molecular sieves (0.78g), and the amine hydrochloride from step K (0.235mg, 0.66mmol) in methanol (10 ml) was added sodium cyanoborohydride (0.80ml of a 1M solution in THF, 0.80mmol) at room temperature. The reaction was stirred for 16 hrs, filtered and the filtrate evaporated in vacuo. The residue was partitioned between EtOAc and saturated NaHCO₃ solution and the organic extract washed with brine, dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 5% NH₄OH in acetonitrile) to provide the title compound as a foam. Anal, calc'd for C₂₆H₂₈N₅O₂CI 1.00H₂O: C, 62.96; H, 6.10; N, 14.12. Found: C, 62.96; H, 5.78; N, 14.02.

FAB HRMS exact mass calc'd for C₂₆H₂₉N₅O₂CI 478.200978(MH⁺), found 478.200698

EXAMPLE 57

The title compound was prepared using the procedure described in Example 1 stepH, and 4(R)-hydroxy-2(S)-{N'-acetyl-N'-3- chlorobenzyl}-aminomethypyrrolidine hydrochloride.

Anal, calc'd for C₂₇H₂₈N₅O₃CI 1.0-HCl, 1.15 H₂O: C, 61.57; H, 5.80;

N, 13.30. Found: C, 61.60; H, 5.47; N, 13.21.

FAB HRMS exact mass calc'd for C₂₆H₂₉N₅O₂CI 506.195893(MH⁺), found 506.197103. EXAMPLE 58

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

Step A: N-t-Butoxycarbonyl-4(R)-methoxy-2(S)-{N'-acetyl-N' -3- chlorobenzyl}aminomethylpyrrolidine

To a solution of N-t-Butoxycarbonyl-4(S)-hydroxy -2(S)- {N'-acetyl-N' 3-chlorobenzyl}aminomethylpyrrolidine (928mg, 2.42 mmol) in DMF (12ml) at 0°C was added sodium hydride (145mg of a 60% dispersion in mineral oil, 3.63mmol). Mter 15 min methyl iodide (0.30ml, 4,82mmol), was added and the reaction stirred at room

temperature for 16 hrs. The reaction was quenched with saturated

NaHCO₃ solution (2ml) and extracted with ethyl acetate. The orgainic extract was washed with brine and dried (Na₂SO₄, and the solvent evaporated in vacuo. The residue was purified by chromatography (SiO₂, 25 to 50% EtOAc in CH₂CI₂, gradient elution) to afford the title compound as a foam.

¹H NMR(CD₃OD, 400 MHz) δ 7.50-7.10(4H, m), 4.90-4.05(4H, m), 3.95(1H, m), 3.90-3.30(3H, m), 3.30(3H, s), 2.10-1.70(5H, s) and 1.60- 1.30(9H, m) ppm.

Step B: 4(S)-Methoxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl}- aminomethylpyrrolidine hydrochloride

The title compound was prepared by the procedure

described in Example 1 step G using N-t-butoxycarbonyl-4(S)-methoxy-

2(S)-{N'-acetyl-N'-3-chlorobenzyl-}aminomethylpyrrolidine.

¹H NMR(CD₃OD, 400 MHz) δ 7.40(1H, t, J=7.7Hz), 7.35(1H, d,

J=9.2Hz), 7.29(1H, s), 7.20(1H, d, J=7.7Hz), 4.73(1H, d, J=17.0Hz), 4.68(1H, d, J=17.0Hz), 4.10(1H, m), 3.96(1H, m), 3.81(1H, m), 3.50-

3.37(2H, m), 3.32-3.30(4H, m), 2.30-2.24(1H, m), 2.18(3H, s) and

1.75(1H, m)ppm. Step C: N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)- hydroxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl }

aminomethylpyrrolidine

The title compound was prepared by the procedure described in Example 56 step M using 1-(4-Cyanobenzyl)-5-imidazole

carboxaldehyde and the amine hydrochloride from step B.

Anal, calc'd for C₂₇H₃₀N₅O₂CI 2.25HC l , 1.6OH₂O: C, 53.79; H,

5.93N, 11.62. Found: C, 53.79; H, 5.92; N, 11.39.

FAB HRMS exact mass calc'd for C₂₇H₃₁N₅O₂CI

492.216628(MH⁺), found 492.216101.

EXAMPLE 59 N-{ 1-(4-Cyanophenethyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)- (N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

Step A: Preparation of 1-(4-Cyanophenyl)ethyl bromide

To a solution of 1-(4-Cyanophenyl)ethanol 1.01g,

6.84mmol), in diethyl ether (15ml) and triphenylphosphine (2.14g, 8.17 mmol), was added carbon tetrabromide (2.82g, 8.50mmol) in

dieathylether (20ml) at room temperature. After 30 min the reaction was filtered through celite and evaporated to dryness. The residue was purified by chromatography (SiO₂, 5% EtOAc in hexanes) to afford the title compound as an oil

¹H NMR(CDCl₃, 400 MHz) δ 7.64(2H, d, J=8.2Hz), 7.53(2H, d,

J=8.2Hz), 5.15(1H, q, J=7.0Hz) and 2.03(3H, d, J=7.0Hz) ppm.

Step B: 1-(4-Cyanophenethyl)-1H-imidazol-5-yl- carboxaldehyde

A mixture of 3-tritylimidazol-5yl-carboxaldehyde (805mg, 2.38mmol), and the bromide from step A (0.50g, 2,38mmol), was heated at 60°C for 16 hrs in the presense of tetrabutylammonium iodide (89mg, 0.24mmol) in acetonitrile (10ml). The cooled reaction was diluted with EtOAc and washed with saturated aqueous NaHCO₃, brine and dried (Na₂SO₄). The solvent was evaporated in vacuo and the residue chromatographed (SiO₂, 5%MeOH in CH₂CI₂) to afford the title compound. Step C: N-{ 1-(4-Cyanophenethyl)-1H-imidazol-5-yl-methyl-4(R)- hydroxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl}

aminomethylpyrrolidine

The title compound was prepared by the procedure

described in Example 56 step M using 1-(4-Cyanophenethyl)-1H- imidazol-5-yl- carboxaldehyde and 4(R)-methoxy-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine hydrochloride.

FAB HRMS exact mass calc'd for C₂₈H₃₃N₅O₂CI 506.232278(MH⁺), found 506.231473.

EXAMPLE 60

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-acetyl}-4(R)-methoxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared according to the procedure described in Example 1 step H using 4(R)-methoxy-2(S)-{N'-acetyl-N'-3- chlorobenzyl} aminomethylpyrrolidine hydrochloride.

Anal, calc'd for C₂₈H₃₀N₅O₂CI 2.00 TFA, 0.50 H₂O: C, 50.77; H,

4.39, N, 9.25. Found: C, 50.78; H, 4.38; N, 9.24.

FAB HRMS exact mass calc'd for C₂₈H₃₁N₅O₂CI

520.211543(MH⁺), found 520.211434.

EXAMPLE 61 AND 62

N-{ 1-(4-Cyanopheneth-1-yl)-1H-imidazol-5-yl-acetyl-4(R)-methoxy-

2(S)-(N'-acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine

Step A: Preparation of (R,S)[1-(4-cyanopheneth-1-yl)-1H-imidazol-

5-yl]acetic acid

The title compound was prepared according to the procedure in Example 1 steps C and D replacing 4 cyanobenzylbromide with 1-(4- cyanophenyl)ethyl bromide. ¹H NMR CD₃OD δ 8.44 (1H, d, J=0.8Hz) 7.73(2H,d, J=8.3Hz), 7.38(2H,d, J=8.3Hz),7.14(1H,s), 5.73(1H,q, J=7.0Hz), 3.55(1H,d, J=17.2Hz), 3.33(1H,d, J=17.2hz) and 1.92(3H,d, J=7.0Hz)ppm. Step B: N-{ 1-(4-Cyanophen-(R,S)-ethyl)-1H-imidazpl-5-yl-acetyl- 4(R)-methoxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl } aminomethylpyrrolidine

The title compounds was prepared according to the procedure described in Example 1 step H using 4(S)-Methoxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine hydrochloride and the acids from step A.

Anal, calc'd for C₂₉H₃₂N₅O₃CI 2.10 TFA, 0.35 H₂O: C, 51.14; H, 4.50, N, 8.98. Found: C, 51.15; H, 4.53; N, 8.99.

FAB HRMS exact mass calc'd for C₂₉H₃₃N₅O₃CI

534.227193(MH⁺), found 534.226630.

and

Anal, calc'd for C₂₉H₃₂N₅O₃CI 1.90 TFA, 0.25 H₂O: C, 52.17; H, 4.59, N, 9.27. Found: C, 52.15; H, 4.61; N, 9.19.

FAB HRMS exact mass calc'd for C₂₉H₃₃N₅O₃CI

534.227193(MH⁺), found 534.228764.

EXAMPLE 63

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

Step A: Preparation of (1-(4-Cyanobenzyl)-1H-imidazol-5-yl)- ethanol

To a stirred solution of the ester from Example 1, step C, (1.50g, 5.88mmol), in methanol (20ml) at 0°C, was added sodium borohydride (1.0g, 26.3mmol) portionwise over 5 minutes. The reaction was stirred at 0°C for 1 hr and then at room temperature for an additional 1 hr. The reaction was quenched by the addition of sat.NH₄Cl solution and the methanol was evaporated in vacuo.. The residue was partitioned between EtOAc and sat NaHCO₃ solution and the organic extracts dried (MgSO₄), and evaporated in vacuo.. The residue was purified by chromatography (SiO₂, 4 to 10% methanol in methylene chloride, gradient elution) to afford the title compound as a solid.

¹H NMR CDCl₃ δ 7.64(2H, d, J=8.2Hz), 7.57(1H, s), 7.11(2H, d,

J=8.2Hz), 6.97(1H, s), 5.23(2H, s), 3.79(2H, t, J=6.2Hz) and 2.66(2H, t, J=6.2Hz) ppm.

Step B: 1-(4-Cyanobenzyl)-imidazol-5-yl-ethylmethanesulfonate

A solution of (1-(4-Cyanobenzyl)-1H-imidazol-5-yl)-ethanol

(0.500 g, 2.20 mmol) in methylene chloride (6.0 ml) at 0°C was treated with Hunig's base (0.460ml, 2.64mmol) and methane sulfonyl chloride (0.204ml, 2.64mmol). After 2 hrs, the reaction was quenched by addition of saturated NaHCO₃ solution (50ml) and the mixture was extracted with methylene chloride (50ml), dried (MgSO₄) and the solvent evaporated in vacuo. The title compound was used without furthur purification.

¹H NMR CDCl₃ δ 7.69 (1H, s) 7.66(2H, d, J=8.2Hz), 7.15 (2H, d, J=8.2Hz), 7.04(1H, s), 5.24(2H, s), 4.31(2H, t, J=6.7Hz), 2.96(3H, s), and 2.88(2H, t, J=6.6Hz)ppm.

Step C: N{ 1-(4-Cyanobenzyl)-1H--imidazol-5-ylethyl}-4(R)- methoxy-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

A mixture of 4(R)-methoxy-2(S)-{N'-acetyl-N'-3- chlorobenzyl-aminomethyl} pyrrolidine (135mg, 0.405mmol), the mesylate from step B (114mg, 0.373mmol), potassium carbonate (140mg, 1.01mmol), and sodium iodide (243mg, 1.62mmol) in DMF (1.0ml), were heated at 55°C for 16 hrs. The cooled mixture was diluted with EtOAc, washed with NaHCO₃ solution and brine , dried (Na₂SO₄) and the solvent evaporated in vacuo. The residue was purified by preparative HPLC (C-18, 95:5 to 5:95 water in acetonitrile containing 0.1% TFA, gradient elution). The title compound was obtained as a white solid after lyophillisation. Anal. calc'd for C₂₈-H₃₂N₅O₂CI 3.15 TFA, 0.45 H₂O: C, 47.17; H, 4.16, N, 8.02. Found: C, 47.16; H, 4.19; N, 7.99.

FAB HRMS exact mass calc'd for C₂₈H₃₃N₅O₂CI

506.232278(MH⁺), found 506.231017.

EXAMPLE 64

The title compound was prepared by the procedure described in Example 63 using 2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

Anal, calc'd for C₂₇H₃₀N₅OCI 2.15 HCl, 3.05 H₂O: C, 53.22; H, 6.33,

N, 11.49. Found: C, 53.23; H, 6.33; N, 11.29.

EXAMPLE 65

N{ 1-(4-Cyanophenethyl)-1H-imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)-

(N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the procedure described in Example 63 using (R,S)-[1-(4-cyanopheneth-1-yl)-1H- imidazol-5-yl]acetic acid methyl ester in place of 1-(4-cyanobenzyl)-1H- imidazol-5-yl]acetic acid methyl ester.

Anal, calc'd for C₂₉H₃₄N₅O₂CI 3.15 TFA, 0.65 H₂O: C, 47.59; H, 4.35; N, 7.86. Found: C, 47.60; H, 4.35; N, 7.83.

FAB HRMS exact mass calc'd for C₂₉H₃₅N₅O₂CI

520.247928(MH⁺), found 520.247518.

EXAMPLE 66

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-benzyloxy-2(S)-

{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrolidine

The title compound was prepared as in Example 58 using benzyl bromide in place of methyl iodide. Anal. calc'd for C₃₃H₃₄N₅O₂CI 2.75 TFA, 0.95 H₂O: C, 51.45; H, 4.33; N, 7.79. Found: C, 51.45; H, 4.37; N, 7.70.

FAB HRMS exact mass calc'd for C₃₃H₃₅N₅O₂CI

568.247928(MH⁺), found 568.247609

EXAMPLE 67

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-benzyloxy-2(S)-

{N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

The title compound was prepared as in Example 63 using

4(R)-benzyloxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

Anal, calc'd for C₃₄H₃₆N₅O₂CI 3.00 TFA, 0.85 H₂O: C, 51.14; H,

4.37, N, 7.45. Found: C, 51.15; H, 4.42; N, 6.86.

FAB HRMS exact mass calc'd for C₃₄H₃₇N₅O₂CI

582.263579(MH⁺), found 582.263900.

EXAMPLE 68

N-{ 1-(4-Cyanobenzyl)-5-imidazolacetyl}-4(R)-benzyloxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine

The title compound was prepared as in Example 60 using

4(R)-benzyloxy-2(S)-{ N'-acetyl-N'-3-chlorobenzyl-aminomethyl } pyrrolidine

Anal, calc'd for C₃₄H₃₄N₅O₃CI 1.85 TFA, 0.60 H₂O: C, 55.37; H,

4.57; N, 8.56. Found: C, 55.35; H, 4.53; N, 8.57.

FAB HRMS exact mass calc'd for C₃₄H₃₅N₅O₃CI

596.242843(MH⁺), found 596.241293 EXAMPLE 69

N{ 1-(4-Cyanobenzyl)-5-imidazol-5-ylmethyl}-4(R)-(2-henylbenzyloxy)-

2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 58 using 2- phenylbenzyl bromide in place of methyl iodide. Anal. calc'd for C₃₉H₃₈N₅O₂CI 2.50 TFA, 0.10 H₂O: C, 56.76; H, 4.41; N, 7.52. Found: C, 56.78; H, 4.27; N, 7.16.

FAB HRMS exact mass calc'd for C₃₉H₃₉N₅O₂CI

644.279229(MH⁺), found 644.279744

EXAMPLE 70

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(4- chlorobenzyloxy)-2(S)-{N'-acetyl-N'-3 - chlorobenzyl)aminomethylpyrrolidine

The title compound was prepared as in Example 58 using 4- chlorobenzyl bromide in place of methyl iodide.

Anal, calc'd for C₃₃H₃₃N₅O₂CI₂ 3.15 TFA: C, 49.08; H, 3.79; N, 7.28.

Found: C, 49.10; H, 3.67; N, 7.31.

FAB HRMS exact mass calc'd for C₃₃H₃₄N₅O₂CI₂

602.208956(MH⁺), found 602.208118

EXAMPLE 71 N{ 1-(4-Cyanobenzyl)-5-imidazolemethyl}-4(R)-(4-cyanobenzyloxy)-

2(S)-(N'-acetyl-N'-3-chlorobenzyl)aminomethylpyrrolidine

The title compound was prepared as in Example 58 using 4- cyanobenzyl bromide in place of methyl iodide.

Anal, calc'd for C₃₄H₃₃N₆O₂CI 2.85 TFA: C, 51.94; H, 3.94; N, 9.15. Found: C, 51.93; H, 3.83; N, 9.16.

FAB HRMS exact mass calc'd for C₃₄H₃₄N₆O₂CI 593.243177 (MH⁺), found 593.243346

EXAMPLE 72

N{ 1-(4-Cyanobenzyl)-5-imidazol-5-ylmethyl}-4(R)-(3-pyridylmethoxy)-

2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 58 using 3- picolyl chloride in place of methyl iodide. Anal. calc'd for C₃₂H₃₃N₆O₂CI 4.45 TFA: C, 45.22; H, 3.58; N, 7.74. Found: C, 45.20; H, 3.56; N, 7.86.

FAB HRMS exact mass calc'd for C₃₂H₃₄N₆O₂CI 569.243177 (MH⁺), found 569.243177

EXAMPLE 73

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(phenoxy)-2(S)-

(N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 58 using diphenyliodonium chloride in place of methyl iodide.

Anal, calc'd for C₃₂H₃₂N₅O₂CI 2.75 TFA, 0.35 H₂O: C, 51.54; H,

4.09; N, 8.01. Found: C, 51.55; H, 4.12; N, 7.75.

FAB HRMS exact mass calc'd for C₃₂H₃₃N₅O₂CI 554.232278(MH⁺), found 554.232523.

EXAMPLE 74

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(2- methylacetyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 58 using 2- bromo methylacetate in place of methyl iodide.

FAB HRMS exact mass calc'd for C₂₉H₃₃N₅O₄CI 550.222108MH⁺), found 550.221829.

EXAMPLE 75

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(acetyloxy)-2(S)- (N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

To a solution of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- ylmethyl}-4(R)-(2-methylacetyloxy)-2(S)-{ N'-acetyl-N'-3-chlorobenzyl- aminomethyl} pyrrolidine (43mg, 0.055mmol) in THF (0.5ml) was added lithium hydroxide (0.221ml, 0.221mmol) and the solution stirred at room temperatore for 16hrs. The reaction was quenched by the addition of trifluoroacetic acid (0.013ml) and the solvents evaporated in vacuo. The residue was purified by preparative HPLC (C-18, 95 to 5% water in acetonitrile containing 0.1% TFA, gradient elution), to afford the title compound.

Anal, calc'd for C₂₈H₃₀N₅O₄CI 2.95 TFA, 1.15 H₂O: C, 45.59; H, 3.98; N, 7.84. Found: C, 45.59; H, 4.02; N, 7.83.

EXAMPLE 76 N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(2- methylacetyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl)aminomethylpyrrolidine

The title compound was prepared as in Example 60 using 2- bromo methylacetate in place of methyl iodide.

FAB HRMS exact mass calc'd for C₃₀H₃₃N₅O₅CI 578.217022(MH⁺), found 578.216687.

EXAMPLE 77 N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(acetyloxy)-2(S)-

{N'-3-chlorobenzyl-N'-acetyl} aminomethylpyrrolidine

To a solution of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- ylacetyl}-4(R)-(2-methylacetyloxy)-2(S)-{N'-acetyl-N'-3-chlorobenzyl}- aminomethylpyrrolidine (38mg, 0.055mmol) in THF (0.5ml) was added lithium hydroxide (0.164ml, 0.164mmol) and the solution stirred at room temperature for 16 hrs. The reaction was quenched by the addition of trifluoroacetic acid (0.013ml) and the solvents evaporated in vacuo. The residue was purified by preparative HPLC (C-18, 95 to 5% water in acetonitrile containing 0.1% TFA, gradient elution) to afford the title compound.

Anal, calc'd for C₂₉H₃₀N₅O₅CI 1.50 TFA, 1.15 H₂O: C, 50.85; H, 4.51; N, 9.27. Found: C, 50.84; H, 4.54; N, 9.18. EXAMPLE 78

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(S)-(phenoxy)-2(S)-

(N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

Step A: Preparation of N-t-Butoxycarbonyl-4(S)-phenoxy-2(S)-{N'- acetyl-N' 3-chlorobenzyl}aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-4(S)-hydroxy-2(S)- { N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine (200mg,

0.522mmol, prepared in step J Example 56), phenol (49.1mg,

0.522mmol) and triphenylphosphine (137.3mg, 0.524mmol), in THF (13.0ml), at room temperature was added diethylazodicarboxylate

(0.083ml, O.53mmol) and the mixtored stirred for 16hrs. The solvent was evaporated in vacuo and the residue purified by chromatography (SiO₂, 50% EtOAc in hexanes) to afford the title compound as an oil.

1H NMR CD₃OD d 7.50-6.70 (9H, m), 5.10-5.00 (1H, m), 4.80- 4.20(3H, m), 4.00-3.20(4H, m), 2.40-2.00(5H, m) and 1.46(9H,s) ppm.

Step B: 4(S)-Phenoxy-2(S)-{N'-acetyl-N'-3-chlorobenzyl}- aminomethylpyrrolidine

The title compound was prepared by the procedure described in Example 1 step G using N-t-butoxycarbonyl-4(S)-phenoxy-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

¹H NMR(CD₃OD, 400 MHz) δ 7.50-6.90 (9H, m), 5.18(1H, m),

4.70(2H, m), 4.10-4.00(1H, m), 3.94(1H, m), 3.63(1H, d, J=12.8Hz),

3.54(1H, dd, J=12.8 and 5.3Hz), 3.40(1H, dd, J=3.5 and 14.9Hz),

2.60(1H, m), 2.20(3H, s) and 2.00(1H, m) ppm.

Step C: 1-(4-Cyanobenzyl)-5-imidazolemethyl-4(R)-(phenoxy)-2(S)- {N'-3-chlorobenzyl-N'-acetyl}aminomethyl pyrrolidine

The title compound was prepared as in Example 73 using

4(S)-(phenoxy)-2(S)-{N' acetyl-N'-3-chlorobenzyl}- aminomethylpyrrolidine

Anal, calc'd for C₃₂H₃₂N₅O₂CI 2.70 TFA, 0.10 H₂O: C, 52.01; H, 4.07; N, 8.11. Found: C, 52.03; H, 4.10; N, 7.96. FAB HRMS exact mass calc'd for C₃₂H₃₃N₅O₂CI 554.232278(MH⁺), found 554.231721.

EXAMPLE 79

N{ 1-(4-Cyanobenzyl)-5-imidazolethyl}-4(S)-(phenoxy)-2(S)-{N'-acetyl-

N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 63 using 4(S)-(2-phenylbenzyloxy)-2(S)-{N'-acetyl-N'-3-chlorobenzyl}- aminomethylpyrrolidine

Anal, calc'd for C₃₃H₃₄N₅O₂CI 2.00 HCl, 0.55 H₂O: C, 60.89; H, 5.74; N, 10.76. Found: C, 60.90; H, 5.86; N, 11.06.

FAB MS 567 (M+1). EXAMPLE 80

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(S)-fluoro-2(S)-{N'- acetyl-N'-3-chlorobenzyl)aminomethylpyrrolidine Step A: N-t-Butoxycarbonyl-4(S)-fluoro -2(S)- { N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-4(S)-hydroxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine (2.11g, 5.5 lmmol, prepared in step J Example 56, and diethylaminosulfur trifluoride

(0.90ml, 6.8 lmmol), in CH₂CI₂ (120ml), at 0°C was stirred for lhr.

Methanol (20ml) was added and after 30min the reaction was diluted with CH₂CI₂ and washed with saturated aqueous NaHCO₃ solution, dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue purified by chromatography (SiO₂, 1.5 to 2.5% MeOH in CH₂CI₂ gradient elution) to afford the title compound as an oil. Step B: Preparation of 4(S)-fluoro-2(S)-{N'-acetyl-N'-3- chlorobenzyl} aminomethylpyrrolidine

The title compound was prepared by the procedure described in Example 1 step G using N-t-butoxycarbonyl-4(S)-fluoro-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

Step C: N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl-4(S)-(fluoro)- 2(S)-(N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine The title compound was prepared as in Example 63 using 4(S)-fluoro-2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine.

Anal, calc'd for C₂₇H₃₂₉N₅OCIF 2.90 TFA: C, 47.77; H, 3.90;N, 8.49.

Found: C, 47.80; H, 3.91; N, 8.46.

FAB MS 494 (M+1) EXAMPLE 81

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl-4(R)-(2-phenylbenzyloxy)-

2(S)-(N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 63 using 4(R)-(2-phenylbenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

Anal, calc'd for C₄₀H₄₀N₅O₂CI 3.15 TFA: C, 54.56; H, 4.29; N, 6.87.

Found: C, 54.56; H, 4.03; N, 6.93.

FAB HRMS exact mass calc'd for C₄₀H₄₁N₅O₂CI 658.294879(MH⁺), found 658.294834

EXAMPLE 82

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(4-chlorobenzyloxy)- 2(S)-{ N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 63 using

4(R)-(4-chlorobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

Anal, calc'd for C₃₄H₃₅N₅O₂CI₂ 3.20 TFA, 0.15 H₂O: C, 49.31; H, 3.94; N, 7.12. Found: C, 49.31; H, 3.72; N, 7.26. FAB HRMS exact mass calc'd for C₃₄H₃₆N₅O₂CI₂

616.224606(MH⁺), found 616.223491

EXAMPLE 83

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(4-cyanobenzyloxy)-

2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 63 using 4(R)-(4-cyanobenzyloxy)-2(S)-{N'-acetyl-N"-3- chlorobenzyl}aminomethylpyrrolidine

Anal, calc'd for C₃₅H₃₅N₆O₂CI 3.10 TFA, 0.10 H₂O: C, 51.42; H, 4.01; N, 8.73. Found: C, 51.44; H, 3.90; N, 8.51.

FAB HRMS exact mass calc'd for C₃₅H₃₆N₆O₂CI₂

607.258827(MH⁺), found 607.259832.

EXAMPLE 84

N{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(3-pyridylmethoxy)-

2(S)-(N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared as in Example 63 using

4(R)-(3-pyridylmethoxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethyl-pyrrolidine.

Anal, calc'd for C₃₃H₃₅N₆O₂CI 3.95 HCl , 1.10 EtOAc: C, 54.51; H,

5.84; N, 10.20. Found: C, 54.55; H, 6.07; N, 10.22.

FAB HRMS exact mass calc'd for C₃₃H₃₆N₆O₂CI 583.258827(MH⁺), found 583.259083. EXAMPLE 85

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-2(S)-{N'-acetyl-N'-3-cyanobenzyl}aminomethylpyrrolidine

Step A: Preparation of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- ylacetyl}- 2(S)-(N'-3-cvanobenzyl}aminomethylpyrrolidine To a slurry of 3-cyanobenzaldehyde (40.5mg, 0.309mmol), cmshed 3A molecular sieves (505mg), and N-{ 1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}-2(S)-aminomethyl}-pyrrolidine from Example 40 step E (100.9 mg, 0.312 mmol), and potassium acetate (51mg, o.54 mmol) in methanol (5 ml) was added sodium cyanoborohydride (0.31ml of a 1M solution in THF, 0.31 mmol) at room temperatore. The reaction was stirred for 24 hrs, diluted with EtOAc and filtered. The filtrate was washed with saturated aqueous NaHCO₃, dried (Na₂SO₄) and

evaporated in vacuo. The residue was purified by chromatography on a chromatatron (SiO₂, 5% NH₄OH in acetonitrile) to provide the title compound as an oil.

1HNMR(CDCl₃, 400 MHz) d 7.80-6.80(10H, m), 5.45-5.30(2H, m), 4.25-3.80(3H, m), 3.60-3.30(4H, m), 2.95-2.50(2H, m) and 2.20-1.80(4H, m) ppm.

Step B: N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-2(S)-{N'- acetyl-N'-3-cyanobenzyl}aminomethylpyrrolidine The title compound was prepared using the protocol described in Example 40 step G using acetyl chloride instead of methane sulfonyl chloride.

Anal, calc'd for C₂₈H₂₈N₆O₂ 0.25H₂O, 1.50TFA; C, 56.75; H, 4.61; N, 12.81. Found: C, 56.74; H, 4.62; N, 12.72.

FAB HRMS exact mass calc'd for C₂₈H₂₉N₆O₂481.235199(MH⁺), found 481.235799 EXAMPLE 86

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S)-{N'-acetyl-N'-3- methoxybenzyl}aminomethylpyrrolidine.

The title compound was prepared using the protocol described in Example 85 using 3-methoxybenzaldehyde.

Anal, calc'd for C₂₈H₃₁N₅O₃ 0.35 H₂O, 1.50 TFA; C, 56.17; H, 5.05; N, 10.56. Found: C, 56.18; H, 5.06; N, 10.90.

FAB HRMS exact mass calc'd for C₂₈H₃₂N₅O₃ 486.250515(MH⁺), found 486.250698.

EXAMPLE 87

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- trifluoromethylbenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using 3-trifluoromethylbenzaldehyde.

Anal, calc'd for C₂₈H₂₈N₅O₂F₃ 0.45 H₂O, 2.20 TFA; C, 49.73; H,

4.01; N, 8.95. Found: C, 49.75; H, 3.99; N, 9.17.

FAB HRMS exact mass calc'd for C₂₈H₂₉N₅O₂F₃ 524.227335(MH⁺), found 524.226844.

EXAMPLE 88

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-2- methoxybenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using 2-methoxybenzaldehyde.

Anal, calc'd for C₂₈H₃₁N₅O₃ 0.50H₂O, 2.15 TFA; C, 52.45; H, 4.65; N, 9.47. Found: C, 52.45; H, 4.67; N, 9.58.

FAB HRMS exact mass calc'd for C₂₈H₃₂N₅O₃ 486.250515 (MH⁺), found 486.249829. EXAMPLE 89

The title compound was prepared using the protocol described in Example 85 using 2-trifluoromethylbenzaldehyde.

Anal, calc'd for C₂₈H₂₈N₅O₂F₃ 0.40 H₂O, 2.05 TFA; C, 50.43; H, 4.07; N, 9.16. Found: C, 50.43; H, 4.07; N, 9.24.

FAB HRMS exact mass calc'd for C₂₈H₂₉N₅O₂F₃ 524.227335 (MH⁺), found 524.227352.

EXAMPLE 90

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-(2,2- diphenylethyl)}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using diphenylacetaldehyde.

Anal, calc'd for C₃₄H₃₅N₅O₂ 0.40 H₂O, 1.60 TFA; C, 60.76; H, 5.13;

N. 9.52. Found: C, 60.76; H, 5.11; N, 9.54.

EXAMPLE 91

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'- diphenylmethyl)aminomethylpyrrolidine

Step A: N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)

diphenylmethyl}aminomethylpyrrolidine

A solution of N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}- 2(S)-aminomethyl-pyrrolidine (0.175mg, 0.544 mmol), triethylamine (0.055ml, 0.544mmol) and benzhydrylbromide (0.134mg, 0.544mmol) in DMF (2.0 ml) were stirred at room temperatore for 24hrs.. The reaction was quenched with saturated NaHCO₃ solution and extracted with EtOAc. The organic extracts were washed with brine, dried (MgSO₄), and evaporated in vacuo. The residue was purified by chromatography (SiO₂, 5% NH₄OH in acetonitrile) to afford the title compound as an oil.

Step B: N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'- acetyl-N'-diphenylmethyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 41 using the material from step A.

Anal, calc'd for C₃₃H₃₃N₅O₂ 1.00 H₂O, 3.30 TFA; C, 51.37; H, 4.17; N, 7.56. Found: C, 51.36; H, 4.16; N, 7.85.

FAB HRMS exact mass calc'd for C₃₃H₃₄N₅O₂ 532.271251 (MH⁺), found 532.272495.

EXAMPLE 92

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N^,-2- chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using 2-chlorobenzaldehyde.

Anal, calc'd for C₂₇H₂₈N₅O₂CI 1.00 H₂O, 1.50 TFA; C, 53.06; H, 4.68; N, 10.31. Found: C, 53.04; H, 4.66; N, 10.32.

EXAMPLE 93 AND 94

N-{2(R)-Methyl-2-(1-(4-Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine and N-{2(S)- Methyl-2-(1-(4-Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)-{N'- acetyl-N'-3-chlorobenzyl)aminomethylpyrrolidine

Step A: 2(R,S)-Methyl-2-{ 1-(Triphenylmethyl)-1H-imidazol-4-yl}- acetic acid methyl ester

A solution of 1-(triphenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester (1.01g, 2.63mmol) in THF (25 ml) was cooled to -78°C.

Lithium hexamethyldisilazide (2.76ml of a 1M solution in THF, 2.76 mmol) was added dropwise and the reaction stirred 30min at -78°C.

Methyl iodide (0.164ml, 2.76mmol) was added and the reaction stirred a furthur 1 hr at -78°C and then at -20°C for 4 hrs. The reaction was quenched with water (10ml) and saturated NaHCO₃ solutoon (10ml) and extracted with EtOAc. The organic extracts were dried (MgSO₄) and the solvent evaporated in vacuo. Chromatography of the residue (SiO₂, 2 to 3% MeOH in CH₂CI₂, gradient elotion) afforded the product.

¹H NMR CDCl₃, δ 7.40-7.00(16H, m), 6.71(1H, s), 3.77(1H, q,

J=7.1Hz), 3.69(3H, s) and 1.47(3H, d, J=7.1Hz) ppm.

Step B: 2(R,S)-Methyl-2-(1-(4-cyanobenzyl)-1H-imidazol-5-yl)- acetic acid

The title compound was prepared according to the procedure described in Example 1 steps C and D using the material from step A.

¹H NMR CDCl₃, δ 8.15(1H, s), 7.75(2H, d, J=8.2Hz), 7.35(2H, d,

J=8.2Hz), 7.15(1H, s), 5.44(2H, m), 3.50(1H, q, J=7.1Hz) and 1.45(3H, d, J=7.1Hz) ppm.

Step C: N-{2(R)-Methyl-2-(l-(4-Cyanobenzyl)-1H-imidazol-5- yl))acetyl}- 2(S)-{N'-acetyl-N'-3-chlorobenzyl- aminomethyl}-pyrrolidine and N-{2(S)-Methyl-2-(1-(4- Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)-{N'-acetyl-

N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compounds were prepared as an inseparable mixture using the protocol described in Example 85 using 2(R,S)-methyl-

2-(l-(4-cyanobenzyl)-1H-imidazol-5-yl)-acetic acid.

Anal, calc'd for C₂₈H₃₀N₅O₂CI 0.55 H₂O, 0.30 EtOAc, 1.55 HCl; C,

59.86; H, 5.98; N, 11.95. Found: C, 59.82; H, 5.99; N, 11.95.

Anal, calc'd for C₂₈H₃₀N₅O₂CI 0.35 H₂O, 0.25 EtOAc, 1.45 HCl; C,

59.52; H, 5.88; N, 11.97. Found: C, 59.52; H, 5.88; N, 11.90. EXAMPLE 95

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using 3-chlorobenzaldehyde.

Anal, calc'd for C₂₇H₂₈N₅O₂Cl 0.95 H₂O, 1.50 TFA; C, 53.13; H, 4.67; N, 10.33. Found: C, 53.09; H, 4.65; N, 10.36. EXAMPLE 96

The title compound was prepared using the protocol described in Example 85 using 4-chlorobenzaldehyde.

Anal, calc'd for C₂₇H₂₈N₅O₂Cl 1.05 H₂O, 1.55 TFA; C, 52.73; H, 4.65; N, 10.47. Found: C, 52.71; H, 4.65; N, 10.47.

EXAMPLE 97

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-2,3- dichlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 85 using 2,3-dichlorobenzaldehyde.

Anal, calc'd for C₂₇H₂₇N₅O₂CI₂ 0.20 H₂O, 1.65 TFA; C, 50.82 H, 4.09; N, 9.78. Found: C, 50.82; H, 4.12; N, 9.80.

EXAMPLE 98

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl-4(R)-benzyloxy-2(S)- (N'-acetyl-N'-naphth-1-ylmethyl)aminomethylpyrrolidine

Step A: N-t-Butoxycarbonyl-4(R)-benzyloxyproline naphth-1- ylmethylamide The title compound was prepared using the procedure in Example 1 step H using N-t-butoxycarbonyl-4(R)- benzyloxyproline and naphth-1-ylmethylamine. StepB: N-t-Butoxycarbonyl-4(R)-benzyloxy-2(S)-{N'-naphth-1- ylmethyl}aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-4(R)-benzyloxy proline naphth-1-y-methylamide (1.20g, 2.606 mmol), in THF (34ml) at -35°C was added borane (5.20ml of a 1M solution in THF, 5.2mmol). The reaction was allowed to warm to room temperatore and stirred for 16 hrs. The reaction was quenched with methanol (30ml) and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 50% EtOAc in hexanes), to afford the title compound as an oil.

FAB MS 446 (M+1).

Step C: N-t-Butoxycarbonyl-4(R-benzyloxy-2(S)-{N'-acetyl-N'- naphth-1-ylmethyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 40 step G using acetyl chloride.

1HNMR (CDCl₃, 400 MHz) d 8.10-7.00(1 2H, m), 5.70-2.90(13H, m), 2.40-2.00(2H, m) and 1.45(9H, s)ppm.

FAB MS 489(M+1).

Step D: 4(R)-Benzyloxy-2(S)-{N'-acetyl-N'-naphth-1-ylmethyl}- aminomethylpyrrolidine hydrochloride

The title compound was prepared using the protocol described in Example 1 step G and the compound prepared in step C.

¹HNMR(CD₃OD, 400 MHz) δ 8.00(1H, d, J=8.6Hz), 7.94(1H, d,

J=7.1Hz), 7.87(1H, d, J=8.2Hz), 7.70- 7.40(3H, m), 7.40-7.20(6H, m), 5.24(1H, d, J=17.6Hz), 5.16(1H, d, J=17.6Hz), 4.50(1H, d, J=11.7Hz),

4.47(1H , d, J=11.7Hz), 4.31(1H, t, J=4.5Hz), 4.05(1H, m), 3.90(1H, m),

3.60-3.30(3H, m), 2.12(1H, m), 2.20(3H, s) and1.89(1H, m) ppm.

FAB MS 389 (M+1). Step E: Preparation of N-[1-(4-cyanobenzyl)-1H-imidazol-5- yl]acetyl-4(R)-benzyloxy-2(S)-{N'-acetyl-N'-naphth-1- ylmethyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 1 step H and the compound prepared in step D.

Anal, calc'd for C₃₈H₃₇N₅O₃ 0.15H₂O, 1.95 TFA; C, 60.14; H, 4.73;

N, 8.37. Found: C, 60.16; H, 4.76; N, 8.31.

FAB HRMS exact mass calc'd for C₃₈H₃₈N₅O₃ 612.297465 (MH⁺), found 612.298079.

EXAMPLE 99

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl-4(R)-benzyloxy-proline naphth-1-ylmethylamide

The title compound was prepared using the protocol described in Example 1 step H and 4(R)-benzyloxy proline naphth-1- ylmethylamide.

Anal, calc'd for C₃₆H₃₃N₅O₃ 0.60 H₂O, 1.50T FA; C, 61.19; H, 4.70;

N, 9.15. Found: C, 61.21; H, 4.67; N, 9.21.

FAB HRMS exact mass calc'd for C₃₆H₃₄N₅O₃ 584.266165 (MH⁺), found 584.267734.

EXAMPLE 100 N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylproline naphth-1- ylmethylamide

The title compound was prepared using the protocol described in Example 99 and proline naphth- 1 -ylmethylamide

Anal, calc'd for C₂₉H₂₇N₅O₂ 0.65 H₂O, 1.00 TFA; C, 61.72; H, 4.90; N, 11.61. Found: C, 61.70; H, 5.05; N, 11.58.

FAB HRMS exact mass calc'd for C₂₉H₂₈N₅O₂478.224300 (MH⁺), found 478.224053. EXAMPLE 101

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)-methoxy-2(S)-{N'- acetyl-N'-5.6.7.8-tetrahvdronaphth-1-ylmethyllaminomethylpyrrolidine

Step A: N-t-Butoxycarbonyl-4(R)-hydroxy-2(S)-{N'-acetyl-N'- 5,6,7,8-tetrahydronaphth-1-ylmethyl}aminomethyl- pyrrolidine

The title compound was prepared using the protocol described in Example 56 step G and N-t-butoxycarbonyl-4(R)-benzyloxy-

2(S)-{N'-acetyl-N'-naphth-1-ylmethyl}aminomethylpyrrolidinefrom

Example 98, Step C.

FAB MS 403 (M+1). Step B: N-t-Butoxycarbonyl-4(R)-methoxy-2(S)-{N'-acetyl-N'- 5,6,7,8-tetrahydronaphth-1- ylmethyl)aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 58 step A using N-t-butoxycarbonyl-4(S)-hydroxy- 2(S)-{N'-acetyl-N'-5,6,7,8-tetrahydronaphthylmethyl}- aminomethylpyrrolidine from Step A.

Step C: 4(S)-Methoxy-2(S)-{N'-acetyl-N'-tetrahydronaphth-1- ylmethyl}aminomethylpyrrolidine hydrochloride The title compound was prepared using the protocol described in Example 1 step G.

St p D: N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)- methoxy-2(S)-{N'-acetyl-N'-5,6,7,8-tetrahydronaphth-1- ylmethyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in

Example 1 step H.

Anal, calc'd for C₃₂H₃₇N₅O₃ 0.40 H₂O, 2.25 TFA; C, 54.57; H, 5.02; N, 8.72. Found: C, 54.57; H, 5.02; N, 8.82. FAB HRMS exact mass calc'd for C₃₂H₃₈N₅O₃ 540.297465(MH⁺), found 540.296505.

EXAMPLE 102

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-5,56,7,8-tetrahydronaphth-1-ylmethyl}aminomethyl- pyrrolidine

The title compound was prepared using the protocol described in Example 101 using benzyl bromide in place of methyl iodide.

Anal, calc'd for C₃₈H₄₁N₅O₃ 0.40H₂O, 2.05 TFA; C, 59.02; H, 5.16; N, 8.17. Found: C, 59.01; H, 5.15; N, 8.22.

FAB HRMS exact mass calc'd for C₃₈H₄₂N₅O₃ 616.328766 (MH⁺), found 616.327514.

EXAMPLE 103

1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl-2(S)-{N'-acetyl-N'-3- chlorobenzyl)aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 56 step M and 2(S)-{N'-acetyl-N'-3^:

chlorobenzyl}amino-methylpyrrolidine.

Anal, calc'd for C₂₆H₂₈N₅OCI 0.50 H₂O, 2.65 TFA; C, 48.96; H, 4.22; N, 8.98. Found: C, 48.96; H, 4.20; N, 8.81.

FAB HRMS exact mass calc'd for C₂₆H₂₉N₅OCI 462.206064 (MH⁺), found 462.206270. EXAMPLE 104

N-Allyloxycarbonyl-2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

Step A: 2(S)-N-t-Butoxycarbonylamino-3(S)-methyl-pentanamine

The title compound was prepared using the procedure described in Example 40 steps B, C and E using 2(S)-N-t- butoxycarbonylamino-3(S)-methyl-pentanol in place of 2(S)-N-t- butoxycarbonylhydroxymethyl pyrrolidine.

¹H NMR(CDCl₃, 400 MHz) δ 4.55(1H, s), 3.60-3.40(3H, m), 2.83(1H, m), 2.62(1H, m), 1.60(1H, m), 1.45(9H, s) and 1.30-0.80(8H, m)ppm.

Step B: N-Allyloxycarbonyl-2(S)-N-t-butoxycarbonylamino-3(S)- methyl-pentanamine

A solution of 2(S)-N-t-butoxycarbonylamino-3(S)-methyl- pentanamine (1.921g, 8.88mmol), triethylamine (2.50ml, 18.0 mmol) in CH₂CI₂ (90ml) was treated with allylchloroformate (1.45 ml, 8.88 mmol) at 0°C and the reaction allowed to warm to room temperatore and stirred for 16 hrs. The solvent was evaporated in vacuo and the residue chromatographed (SiO₂, 15-20% EtOAc in hexanes to afford the title compound as an oil.

¹HNMR(CDCl₃, 400 MHz) δ 5.92(1H, m), 5.30(1H, d, J=17.5Hz), 5.22(1H, d, J=10.0Hz), 5.10(1H, s), 4.60-4.50(3H, m), 3.58(1H, s), 3.40- 3.20(2H, m), 1.60(1H, m), 1.45(9H, s) and 1.25-0.90(8H, m)ppm.

Step C: N-Allyloxycarbonyl-2(S)-amino-3(S)-methyl-pentanamine hydrochloride

The title compound was prepared by the procedure described in Example 1 step G.

¹HNMR(CD₃OD, 400 MHz) δ 5.95(1H,m), 5.35(1H, d, J=17.5Hz), 5.22(1H, d, J=10.0Hz), 4.60(2H, s), 3.60-3.10(3H, m), 1.78(1H, m), 1.60(1H, m) and 1.25(1H,m) and1.10-0.90(6H, m) ppm. Step D: N-Allyloxycarbonyl-2(S)-{(1-(4-Cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine

The title compound was prepared by the procedure described in Example 1 step G using N-Allyloxycarbonyl-2(S)-amino-

3(S)-methyl-pentanamine hydrochloride.

Anal, calc'd for C₂₃H₂₉N₅O 0.25 H₂O; C, 64.54; H, 6.95; N, 16.36.

Found: C, 64.56; H, 6.86; N, 16.04.

FAB HRMS exact mass calc'd for C₂₃H₃₀N₅O 424.234865 (MH⁺), found 424234627.

EXAMPLE 105

Step A: 2(S)- { ( 1 -(4-cyanobenzyl)- 1 H-imidazol-5-yl)acetyl } amino-

3(S)-methyl-pentanamine

To a solution of N-allyloxycarbonyl-2(S)-{(l-(4- cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine (2.372g, 5.60mmol) and 5,5- dimethyl-1,3-cyclohexanedione (6.21g, 44.3mmol) in THF (70ml) was added (tetrakistriphenylphosphine) palladium (0) (1.12g, 0.969mmol) and the reaction was stirred in the dark for 2 hrs. The solvent was evaporated in vacuo and the residue

partitioned between Et₂O and IM aqueous HCl. The aqueous layer was treated with Na₂CO₃ solution until pH 10 and extracted with EtOAc. The organic extracts were washed with brine, dried (Na₂SO₄), and the solvent evaporated in vacuo. The residue was chromatographed (SiO₂, 3% NH₄OH in acetonitrile) to afford an enamine. The title compound was obtained by treating the enamine with bromine water following the procedure of Halpem Aust. J. Chem .17 1964, 1282.

FAB HRMS exact mass calc'd for C₁₉H₂₆N₅O 340.213736 (MH⁺), found 340.213895. Step B: 2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetylamino}-

3(S)-methyl-N-(naphth-2-ylsulfonyl)-ρentanamine

The title compound was prepared using the protocol described in Example 40 step G using naphth-2-ylsulfonyl chloride instead of methane sulfonyl chloride.

Anal, calc'd for C₂₉H₃₁N₅O₃S 0.30 H₂O, 1.65 TFA; C, 53.64; H, 4.63;

N, 9.68. Found: C, 53.62; H, 4.67; N, 9.69.

FAB HRMS exact mass calc'd for C₂₉H₃₂N₅O₃S 530.222587

(MH⁺), found 530.224351.

EXAMPLE 106

2(S)-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl}acetyl}amino-3(S)-methyl-N-

(naphth-1-ylsulfonyl)-pentanamine

The title compound was prepared using the protocol described in Example Example 105 using naphth-1-ylsulfonyl chloride.

Anal, calc'd for C₂₉H₃₁N₅O₃S 0.40 H₂O, 1.40 TFA; C, 54.84; H, 4.80;

N, 10.06. Found: C, 54.87; H, 4.81; N, 10.08.

FAB HRMS exact mass calc'd for C₂₉H₃₂N₅O₃S 530.222587 (MH⁺), found 530.221441.

EXAMPLE 107

N-Acetyl-N-2-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl)amino-3(S)-methyl-pentanamine

Step A: N-2-chlorobenzyl-2(S)-{ 1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl)amino-3(S)-methyl-pentanamine

The title compound was prepared using the protocol described in Example 10 step G using 2-chlorobenzaldehyde and the amine from Example 105 step A.

FAB MS 464 (M+1).

Step B: N-Acetyl-N-2-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl)amino-3(S)-methyl-pentanamine The title compound was prepared using the protocol described in Example 41 using the amine from step A.

FAB HRMS exact mass calc'd for C₂₈H₃₃N₅O₂CI 506.232278 (MH⁺), found 506.233741.

EXAMPLE 108

Step A: N-3-Chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

The title compound was prepared using the protocol described in Example 10 step G using 3-chlorobenzaldehyde and the amine from Example 105 step A.

FAB MS 464 (M+1)

Step B: N-Acetyl-N-3-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine

The title compound was prepared using the protocol described in Example 41 using the amine from step A.

FAB HRMS exact mass calc'd for C₂₈H₃₃N₅O₂CI 506.232278 (MH⁺), found 506.231892. EXAMPLE 109

N-Acetyl-N-4-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine Step A: N-4-Chlorobenzyl-2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-

5-yl)acetyl)amino-3(S)-methyl-pentanamine

The title compound was prepared using the protocol described in Example 10 step G using 4-chlorobenzaldehyde and the amine from Example 105 step A.

FAB MS 464 (M+1) Step B: N-Acetyl-N-4-chlorobenzyl-2(S)-{(1-(4-Cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine

Anal, calc'd for C₂₈H₃₂N₅O₂CI 1.00 H₂O, 1.95 TFA; C, 51.33; H, 4.85;

N. 9.38. Found: C, 51.34; H, 4.84; N, 9.28.

FAB HRMS exact mass calc'd for C₂₈H₃₃N₅O₂CI 506.232278

(MH⁺), found 506.232238.

EXAMPLE 110

N-Acetyl-N-2,3-dichlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)-methyl-pentanamine

Step A: N-2,3-Dichlorobenzyl-2(S)-{(1-(4-Cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methyl-pentanamine

The title compound was prepared using the protocol described in Example 10 step G using 2,3-dichlorobenzaldehyde and the amine from Example 105 step A.

FAB MS 498 (M+1).

Anal, calc'd for C₂₈H₃₁N₅O₂CI₂ 0.30 H₂O, 1.85 TFA; C, 50.31; H,

4.45; N, 9.25. Found: C, 50.32; H, 4.47; N, 9.43.

FAB HRMS exact mass calc'd for C₂₈H₃₂N₅O₂CI₂ 540.193327 (MH⁺), found 540.193425. EX AMPLE 111

N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{2(R,S)-methyl-2-(1-(4- cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine

The title compound was prepared according to the

procedures described in Example 1 using 2(R,S)-methyl-2-{(1-(4- cyanobenzyl)-1H-imidazol-5-yl}acetic acid.

Anal, calc'd for C₃₅H₃₉N₅O₃ 0.05 H₂O, 1.45 TFA; C, 61.19; H, 5.49; N, 9.41. Found: C, 61.15; H, 5.50; N, 9.58.

EXAMPLE 112

N-t-Butoxycarbonylaminoacetyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4- cyanobenzyl)-1H-imidazol-5-ylacetyl}amino-3(S)-methylpentanamine

The title compound was prepared using the protocol described in Example 1 step H using N-t-butoxycarbonyl glycine and N- naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- ylacetyl}amino-3(S)-methyl pentanamine from Example 2.

FAB HRMS exact mass calc'd for C₃₇H₄₅N₆O₄ 630.350229(MH⁺), found 637.350834.

EXAMPLE 113

N-Aminoacetyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H- imidazol-5-ylacetyl}amino-3(S)-methylρentanamine

The title compound was prepared using the protocol described in Example 1 step G using N-t-butoxycarbonylaminoacetyl-N- naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H-imidazol-5- ylacetyl}amino-3(S)-methylpentanamine.

Anal, calc'd for C₃₂H₃₆N₆O₂ 3.10 HCl; C, 59.16; H, 6.07; N, 12.94.

Found: C, 59.09; H, 6.27; N, 12.85.

FAB HRMS exact mass calc'd for C₃₂H₃₇N₆O₂ 537.297800(MH⁺), found 537.297766. EXAMPLE 114

The title compound was prepared using the protocol described in Example 44 using 2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethyl-pyrrolidine.

Anal, calc'd for C₂₇H₃₀N₅OCI 2.00 HCl, 0.70 H₂O; C, 57.75; H, 6.00; N, 12.47. Found: C, 57.75; H, 6.04; N, 12.20.

EXAMPLE 115

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethoxycarbonyl}-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the protocol described in Example 44 using 2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethyl-pyrrolidine Anal, calc'd for C₂₈H₃₀N₅O₃CI 2.10 HCl, 0.60 EtOAc; C, 56.22; H, 5.73; N, 10.78. Found: C, 56.20; H, 5.48; N, 10.75.

EXAMPLE 116 N-{5-(4-Cyanobenzyl)-1H-imidazol-1-ylacetyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

The title compound was prepared using the procedure described in Example 42 using 2(S)-{N'-acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine

Anal, calc'd for C₂7H₂₈N₅O₂CI 1,00 HCl, 1.50 H₂O, 0.16 EtOAc; C, 60.22; H, 6.06; N, 12.77. Found: C, 60.21; H, 5.82; N, 12.48. EXAMPLE 117

Step A: N-t-Butoxycarbonyl-2(S)-{N'-acetylaminomethyl}- pyrrolidine

The title compound was prepared using the procedure described in Example 41 using N-t-butoxycarbonyl-2(S)-aminomethyl- pyrrolidine.

Step B: N-t-Butoxycarbonyl-2(S)-{N'-acetyl-N'-3-chlorophenyl } - aminomethylpyrrolidine

To a solution of N-t-butoxycarbonyl-2(S)-{N'- acetyl}aminomethylpyrrolidine (1.55g, 6.40 mmol) and triethylamine (1.34ml, 9.60 mmol) in CH₂CI₂ (50 ml) was added tri-(3- chlorophenyl)bismuth (6.86g, 12.62 mmol) and copper II acetate (1.74g, 9.60 mmol). The reaction was stirred at room temperatore for 16hrs, silica gel (75g) was added and the mixture filtered. The solid was washed with 5% MeOH in CH₂CI₂. The filtrate was evaporated in vacuo and the residue purified by chromatography (SiO₂, 10-100% EtOAc in hexanes, gradient elution) to afford the title compound as an oil.

¹H NMR (CDCl₃, 400 MHz) δ 7.60-7.20(4H, m), 4.25(1H, m), 3.90(1H, m), 3.80(1H, m), 3.50-3.20(2H, m), 2.20-1.80(7H, m) and 1.50-1.10(9H, m)ppm.

Step C: 2(S)-{N'-Acetyl-N'-3-chlorophenyl}aminomethyl- pyrrolidine hydrochloride

The title compound was prepared using the procedure described in Example 1 step G and the material prepared in step B.

¹H NMR (CDCl₃, 400 MHz) δ 7.54-7.46(3H, m), 7.35-7.30(1H, m),

4.30(1H, m), 3.75-3.65(2H,m), 3.48-3.38(2H, m), 2.20-2.02(3H,m),

1.92(3H, s), 1.78-1.66(1H, m) ppm. Step D: N-{ 1-(4-Cyanobenzyl)-1H-inιidazol-5-yl)ethyl}-2(S)-{N'- acetyl-N'-3-chlorophenyl}aminomethylpyrrolidine

The title compound was prepared using the procedure described in Example 63 using 2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine.

FAB HRMS exact mass calc'd for C₂₆H₂₉N₅OCI 462.206064(MH⁺), found 462.207329.

EXAMPLE 118

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine hydrochloride

The title compound was prepared using the procedure described in Example 56 using 2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethyl-pyrrolidine.

Anal, calc'd for C₂₅H₂₆N₅OCI 2.40HC l , 1.40H₂O; C, 53.56; H, 5.61; N, 12.49. Found: C, 53.60; H, 5.60; N, 12.36.

EXAMPLE 119

The title compound was prepared using the procedure described in Example 1 step H using 2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine.

Anal, calc'd for C₂₆H₂₆N₅OCI 1.30 HCl, 0.50 H₂O; C, 58.66; H, 5.36; N, 13.15. Found: C, 58.66; H, 5.37; N, 13.06.

EXAMPLE 120

N-[1-(3-[1H-Imidazol-4-yl]ρropionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)glycine N'-(3-chlorophenyl)amide

Step A: 2-Methylbenzylglycine methyl ester hydrochloride To a solution of 2-methylbenzyl alcohol (100 g, 0.82 mol) and diisopropylethylamine (171 mL, 0.98 mol) in CH₂CI₂ (400 mL) at -5°C was added dropwise methanesulfonyl chloride (74 mL, 0.95 mmol) with stirring under argon. After 1 hr at -5° and 3 hr at 20°C, this solution was added dropwise simultaneously with diisopropylethylamine (428 mL, 2.46 mol) to a slurry of glycine methyl ester hydrochloride (308.8 g, 2.45 mol) in DMF (400 mL) at 0°C. The reaction mixture was allowed to warm to ambient temperatore for overnight, then treated slowly with satd NaHCO₃ solution (1 L) and EtOAc (1 L). The layers were separated, the aqueous washed with EtOAc, and the organics combined, washed with satd NaHCO₃ solution, brine, and dried (MgSO₄). This solution was filtered, cooled to 0°C, and HCl was bubbled into the solution to precipitate the title compound. ¹H NMR (CDCl₃) δ 7.61 (d, 1H, J = 7 Hz), 7.7 -7.8 (m, 3H), 4.31 (s, 2H), 3.77 (s, 3H), 3.65 (s, 2H), 2.46 (s, 3H).

Step B: N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine methyl ester

2-Methylbenzylglycine methyl ester hydrochloride(36.7 g, 0.16 mol) and N-[(tert-Butyloxy)carbonyl-prolinal (Pettit et al., J. Org. Chem. (1994) 59, [21] 6287-95) (31.6 g, 0.159 mol) were dissolved in CH₂CI₂ (500 mL), treated with 3A molecular sieves (2 Og) and stirred for 18 hrs at room temperatore under argon. The reaction mixture was filtered, quenched with aq satd NaHCO₃ (5 mL) and concentrated and the residue was extracted with EtOAc 3 x 200 mL). The extracts were combined, washed with aq satd NaHCO₃ solution, brine, and dried

(MgSO₄). Filtration and concentration the title compound as a yellow oil which was used without further purification. Step C: N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine

N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine methyl ester (41.85 g, 0.111 mol) was dissolved in CH₃OH (300 mL) at 0°C. and treated with 2 N NaOH solution (111 mL, 0.222 mol) and allowed to stir at ambient temperatore for 3 hr. 1 N HCl (235 mL, 0.235 mol) was added, the CH₃OH was removed on a rotary evaporator, and the residue was extracted with EtOAc (2 x 1.5 L), washed with brine, and dried (MgSO₄). Filtration and concentration to dryness gave the title compound as a white solid. ¹H NMR (CD₃OD) δ 7.56 (d, 1H, J = 7.5 Hz), 7.15 -7.36 (m, 3H), 4.70 (d, 1H, J = 13 Hz), 4.27 (d, 1H, J = 13 Hz), 4.1 - 4.2 (m, 1H), 3.73 (d, 1H, J = 16 Hz), 3.59 (d, 1H, J = 16 Hz), 3.15 - 3.5 (m, 4H), 2.49 (s, 3H), 2.1 - 2.2 (m, 1H), 1.7 - 1.9 (m, 2H), 1.6 - 1.7 (m, 1H), 1.46 (s, 9h).

Step D: N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)- glycine N'-3-chlorophenyl)amide

N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine (5.4 g, 0.115 mol), 3-chloroaniline (2.4 mL, 0.227 mol), HOOBT ( 3.65 g, 0.224 mol), and EDC (4.28 g, 0.223 mol) were dissolved in DMF (20 mL) at ambient temperatore and the pH was adjusted with Et₃N (3.10 mL, 0.222 mol). After stirring overnight, the mixture was concentrated to remove the DMF, and the residue partitioned between EtOAc and H₂O. The aqueous layer was extracted with EtOAc, the organics combined, washed with H₂O, brine, and dried (MgSO₄), then filtered and concentrated to give the title compound as a yellow oil.

Step E: Pyrrolidin-2(S)-ylmethyl-(N-2-methylbenzyl)- glycine N'-(3- chlorophenyl) amide hydrochloride

N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)- glycine N'-(3-chlorophenyl) amide (2.56 g, 5.42 mmol) was dissolved in EtOAc (125 mL), cooled to 0°C, and HCl gas was bubbled into the solution for 10 min followed by stirring under argon for 3 hr. Argon was bubbled into the solution and the solvent was removed in vacuo to give the title compound as a white amorphous solid. Step F: N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)glycine N'-(3-chlorophenyl) amide hydrochloride

Pyrrolidin-2(S)-ylmethyl]-(N-2-methylbenzyl)- glycine N'- (3-chlorophenyl) amide hydrochloride (0.26 g, 0.58 mmol), 1H-imidazol- 4-yl]propionic acid hydrochloride (0.26 g, 1.5 mmol), EDC (0.22 g, 1.1 mmol), HOOBT (0.19 g, 1.2 mmol) were dissolved in DMF (19 mL) at 25°C, the pH of the mixture adjusted to 8 with Et₃N (0.485 mL, 3.48 mmol). After stirring for 18 h, the reaction mixture was partitioned between EtOAc and satd NaHCO₃ solution, the organic layer separated, washed with brine, dried (MgSO₄), filtered, and concentrated to dryness to give the title compound after preparative RP HPLC (Vydac column, 0.1% TFA/CH₃CN: 0.1% TFA/H₂O, 95:5 to 5:95 gradient),

lyophilization, and conversion to its HCl salt.

Anal, calcd for C₂₇H₃₂N₅O₂CI•2 HCl• 1.6 H₂O:

C, 54.43; H, 6.29; N, 11.76; found: C, 54.44; H, 6.48; N, 11.56. FAB MS 494 (M+1). EXAMPLE 121

1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)-glycine N'-(3-chlorophenylmethyl) amide hydrochloride

1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetic acid (0.14g,

0.494 mmol), pyrrolidin-2(S)-ylmethyl]-(N-2-methylbenzyl)-glycine N'- (3-chlorophenyl) amide hydrochloride (Example 120, Step E) (0.109 g, 0.245 mmol), EDC (0.09 g, 0.469 mmol), HOOBT (0.08 g, 0.49 mmol) were dissolved in DMF (5 mL) at 25°C, the pH of the mixture adjusted to 8 with Et₃N (0.205 mL, 1.47 mmol). After stirring for 18 h, the reaction mixture was partitioned between EtOAc and satd NaHCO₃ solution, the organic layer separated, washed with brine, dried (MgSO₄), filtered, and concentrated to dryness to give the title compound after preparative RP HPLC (Vydac column, 0.1% TFA/CH₃CN: 0.1% TFA/H₂O, 95:5 to 5:95 gradient), lyophilization, and conversion to its HCl salt.

Anal, calcd for C₃₄H₃₅N₆O₂CI• 2.1 HCl• 0.95 H₂O:

C, 59.30; H, 5.71; N, 12.20;

Found: C, 59.34; H, 5.71; N, 11.85.

FAB MS 595 (M+1).

EXAMPLE 122

N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)- glycine N'-methyl-N'-(3-chlorophenyl) amide

Step A: N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine N'-methyl-N'-3-chlorophenyl) amide N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)- glycine-N-3-chlorophenyl) amide (Example 120, Step D) (3.97 g, 8.41 mmol) was dissolved in dry THF (40 mL) with stirring at 0°C under Ar, treated with NaH (60% dispersion in mineral oil, 0.68 g, 17 mmol), and after 15 min treated with iodomethane (2.10 mL, 33.7 mmol). The reaction mixture was stirred at 25 °C. for 4 h, then

evaporated to dryness and partitioned between EtOAc and aq satd

NaHCO₃ solution. The organic layer was separated, washed with brine, dried (MgSO₄), filtered, and concentrated to dryness to give the title compound as a white solid. FAB MS 486 (M+1).

Step B: Pyrrolidin-2(S)-ylmethyl]-(N-2-methylbenzyl)-glycine N'- methyl-N'-(3-chlorophenyl) amide hydrochloride N-[(t-Butyloxycarbonyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)- glycine N'-methyl-N'-(3-chlorophenyl) amide (3.75 g, 7.17 mmol) was dissolved in EtOAc (125 mL), cooled to 0°C, and HCl gas was bubbled into the solution for 10 min followed by stirring under argon for 3 hr. Argon was bubbled into the solution and the solvent was removedd in vacuo to give the title compound as a white amorphous solid which was used without further purification. Step C: N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)-y lmemyl]-(N-2-metoylbenzyl)glycine N'-methyl-N'-(3- chlorophenyl) amide hydrochloride

Pyrrolidin-2(S)-ylmethyl]-(N-2-methylbenzyl)- glycine-N- methyl-N-(3-chlorophenyl) amide hydrochloride (0.43 g, 0.94 mmol), 1H-imidazol-4-yl]propionic acid hydrochloride (0.33 g, 1.9 mmol), EDC (0.36 g, 1.9 mmol), HOOBT (0.31 g, 1.9 mmol) were dissolved in DMF (20 mL) at 25°C, the pH of the mixture adjusted to 8 with Et₃N

(0.917mL, 6.58 mmol). After stirring for 72 h, the reaction mixture was partitioned between EtOAc and satd NaHCO₃ solution, the organic layer separated, washed with brine, dried (MgSO₄), filtered, and concentrated to dryness to give the title compound after preparative RP HPLC (Vydac column, 0.1% TFA/CH₃CN: 0.1% TFA/H₂O, 95:5 to 5:95 gradient), lyophilization, and conversion to its HCl salt.

Anal, calcd for C₂₈H₃₄N₅O₂CI• 2 HCl• 0.5 H₂O:

C, 57.00; H, 6.32; N, 11.87;

Found: C, 56.98; H, 6.57; N, 11.51.

FAB MS 508 (M+1). EXAMPLE 123

1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)-glycine N'-methyl-N'-(3- chlorophenylmethyl) amide hydrochloride

1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetic acid (0.14 g,

0.494 mmol), pyrrolidin-2(S)-ylmethyl]-(N-2-methylbenzyl)- glycine N'- methyl-N'-3-chlorophenyl) amide hydrochloride (Example 122, Step B) (0.107 g, 0.232 mmol), EDC (0.09 g, 0.469 mmol), HOOBT (0.08 g, 0.49 mmol) were dissolved in DMF (5 mL) at 25°C, the pH of the mixture adjusted to 8 with Et₃N (0.194 mL, 1.39mmol). After stirring for 18 h, the reaction mixture was partitioned between EtOAc and satd NaHCO₃ solution, the organic layer separated, washed with brine, dried (MgSO₄), filtered, and concentrated to dryness to give the title compound after preparative RP HPLC (Vydac column, 0.1% TFA/CH₃CN: 0.1% TFA/H₂O, 95:5 to 5:95 gradient), lyophilization, and conversion to its HCl salt.

Anal, calcd for C₃₅H₃₇N₆O₂CI• 2.15 HCl• 1.25 H₂O:

C, 59.22; H, 5.91; N, 11.84;

Found: C, 59.22; H, 5.92; N, 11.67.

FAB MS 609 (M+1).

EXAMPLE 124 (S)-2-[(1-(4-cyanobenzyl)-5-imidazolylmethyl)amino]-1-[N-(2,3- dimethylphenyl)acetamidolhexane hydrochloride

Step A: 1-Triphenylmethyl-4-(hydroxymethyl)imidazole

To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35 g) in 250 mL of dry DMF at room temperatore was added

triethylamine (90.6 mL). A white solid precipitated from the solution.

Chlorotriphenylmethane (76.1 g) in 500 mL of DMF was added

dropwise. The reaction mixtore was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a white solid which was sufficiently pure for use in the next step.

Step B: 1-Triphenylmethyl-4-(acetoxymethyl)imidazole

Alcohol from Step A was suspended in 500 mL of pyridine.

Acetic anhydride (74 mL) was added dropwise, and the reaction was stirred for 48 hours during which it became homogeneous. The solution was poured into 2 L of EtOAc, washed with water (3 x 1 L), 5% aq. HCl soln. (2 x 1 L), sat. aq. NaHCO₃, and brine, then dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde product. The acetate was isolated as a white powder which was sufficiently pure for use in the next step. Step C: 1-(4-Cyanobenzyl)-5-(acetoxymethyl)imidazole

hydrobromide

A solution of the product from Step B and α -bromo-p - tolunitrile (50.1 g) in 500 mL of EtOAc was stirred at 60 °C for 20 hours, during which a pale yellow precipitate formed. The reaction was cooled to room temperatore and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume 200 mL, reheated at 60 °C for two hours, cooled to room temperatore, and filtered again. The filtrate was concentrated in vacuo to a volume 100 mL, reheated at 60 °C for another two hours, cooled to room temperatore, and concentrated in vacuo to provide a pale yellow solid. All of the solid material was combined, dissolved in 500 mL of methanol, and warmed to 60 °C. After two hours, the solution was reconcentrated in vacuo to provide a white solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a white solid which was used in the next step without further purification.

Step D: 1-(4-Cyanobenzyl)-5-(hydroxymethyl)imidazole

To a solution of the acetate from Step C (50.4 g) in 1.5 L of

3:1 THF/water at 0 °C was added lithium hydroxide monohydrate (18.9 g). After one hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 L), and washed with water, sat. aq. NaHCO₃ and brine. The solution was then dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde product as a pale yellow fluffy solid which was sufficiently pure for use in the next step without further purification.

Step E: 1-(4-Cyanobenzyl)-5-imidazolecarboxaldehyde

To a solution of the alcohol from Step D (21.5 g) in 500 mL of DMSO at room temperatore was added triethylamine (56 mL), then SO₃-pyridine complex (40.5 g). After 45 minutes, the reaction was poured into 2.5 L of EtOAc, washed with water (4 x 1 L) and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the titled aldehyde as a white powder which was sufficiently pure for use in the next step without further purification.

Step F: N-Methoxy-N-methyl-2(S)-(t-butoxycarbonylamino)- hexanamide

3(S)-Butoxycarbonylaminohexanoic acid (24.6 g, 0.106 mol), N,O-dimethylhydroxylamine hydrochloride (15.5 g, 0.15 mol), EDC hydrochloride ( 22.3 g, 0.117 mol) and HOBT (14.3 g, 0.106 mol) were stirred in dry, degassed DMF (300 mL) at 20°C under nitrogen. N- Methylmorpholine was added to obtain pH 7. The reaction was stirred overnight, the DMF distilled under high vacuum, and the residue partitioned between ethyl acetate and 2% potassium hydrogen suifate. The organic phase was washed with satorated sodium bicarbonate, water, and satorated brine, and dried with magnesium suifate. The solvent was removed in vacuo to give the title compound.

Step G: 2(S)-(tert- Butoxycarbonylamino)hexanal

A mechanically stirred suspension of lithium aluminum hydride (5.00 g, 0.131 mol) in ether (250 mL) was cooled to -45°C under nitrogen. A solution of the product from Step A (28.3 g, 0.103 mol) in ether (125 mL) was added, maintaining the temperatore below -35°C. When the addition was complete, the reaction was warmed to 5°C, then recooled to -45°C. A solution of potassium hydrogen suifate (27.3 g, 0.200 mol) in water was slowly added, maintaining the temperatore below -5°C. After quenching, the reaction was stirred at room

temperature for lh. The mixtore was filtered through Celite, the ether evaporated, and the remainder partitioned between ethyl acetate and 2% potassium hydrogen suifate. After washing with satorated brine, drying over magnesium suifate and solvent removal, the title compound was obtained. Step H: N-(2,3-Dimethylphenyl)-2(S)-(tert

butoxycarbonylamino)hexanamine

2,3-Dimethylaniline (8.32 mL, 68.3 mmol) was dissolved in dichloroethane under nitrogen. Acetic acid was added to obtain pH 5, and sodium triacetoxyborohydride (17.2 g, 80.8 mmol) and cmshed molecular sieves (4 g) were added. A solution of the product from Step B (13.3 g, 62.1 mmol) in dichloroethane (80 mL) was added slowly dropwise at 20°C. The reaction was stirred overnight, then quenched with satorated sodium bicarbonate solution. The aqueous layer was removed, the organic phase washed with satorated brine and dried over magnesium suifate. Crystallization from hexane gave the title compound.

Step I: 2(S)-(tert- Butoxycarbonylamino)-1-[N-(2,3- dimethylphenyl)acetamidolhexane

To a solution of the product of Step H (500 mg, 1.56 mmol) and triethylamine (0.240 mL, 1.72 mmol) in 10 mL of dichloromethane at 0 °C was added acetyl chloride (0.122 mL, 1.72 mmol). After 20 min, the solution was warmed to room temperature, then stirred another 2 hours. The reaction was poured into CH₂CI₂, washed with 10% citric acid and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the titled product.

Step J: (S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)amino]-1- [(2,3-dimethylphenyl)amino]hexane

Through a solution of the product from Step I (533 mg, 1.47 mmol) in 20 mL of EtOAc at 0 °C was bubbled HCl gas. The satorated solution was warmed to room temperature and stirred for 40 minutes, then concentrated in vacuo. To a solution of this amine salt in 6 mL of 1:1 MeOH/THF at 0 °C was added the aldehyde from Step E (325 mg, 1.54 mmol) and 0.05 mL of acetic acid. After one hour, sodium

cyanoborohydride was added (97 mg, 1.54 mmol), and the solution was allowed to warm to room temperatore overnight. After ~16 hours, the reaction was poured into EtOAc, washed with sat. aq. NaHCO₃ and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting product was purified by silica gel chromatography (1-2% MeOH/CHCl₃). A portion of this was taken up in EtOAc/Et₂O and treated with excess HCl gas, then stripped to provide the titled compound.

FAB mass spectmm m/e 458 (M+1).

Analysis calculated for C₂₈H₃₅N₅O• 2.0 HCl:

C, 63.39; H, 7.03; N, 13.20; Found: C, 63.03; H, 6.97; N, 12.92.

EXAMPLE 125

(S)-2-[N-(1-(4-cyanobenzyl)-5-imidazolylmethyl)-N-(methyl)amino]-1-

[N-(2,3-dimethylphenyl)acetamidolhexane hydrochloride

To a solution of the product from Step J of Example 124 (186 mg, 0.41 mmol) and formaldehyde (0.158 mL, 37% in H₂O, 2.1 mmol) in 2 mL of acetonitrile was added sodium cyanoborohydride (41 mg, 0.66 mmol). The pH of the solution was adjusted to 5-7 by dropwise addition of AcOH. After 4 hours, another portion of sodium

cyanoborohydride was added (30 mg), and the reaction was stirred overnight. The reaction was poured into EtOAc, washed with sat. aq. NaHCO₃ and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting product was purified by silica gel chromatography (EtOAc, then 10% MeOH/CHCl₃). A portion of this was taken up in EtOAc/Et₂O and treated with excess HCl gas, then stripped to provide the titled compound.

FAB mass spectmm m/e 472 (M+1).

Analysis calculated for C₂₉H₃₇N₅O• 2.0 HCl:

C, 58.50; H, 6.88; N, 11.62; Found: C, 58.53; H, 7.52; N, 11.53. EXAMPLE 126

N-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-N'-(3- chlorophenyl)ethylenediamine hydrochloride

Step A: N-(2-aminoethyl)-3-chloroaniline hydrochloride

To a solution of 3-chloroaniline (30 mL) in 500 mL of dichloromethane at 0 °C was added dropwise a solution of 4 N HCl in 1,4-dioxane (80 mL). The solution was warmed to room temperatore, then concentrated to dryness in vacuo to provide a white powder. A mixtore of this powder with 2-oxazolidinone (24.6 g) was heated under nitrogen atmosphere at 160 °C for 10 hours, during which the solids melted, and gas evolution was observed. The reaction was allowed to cool, forming the titled compound as a pale brown solid.

Step B: N-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-N'-(3- chlorophenyl)ethylenediamine

The amine hydrochloride from Step A (978 mg) was partitioned between dilute aqueous NaHCO₃ solution and methylene chloride. The aqueous layer was washed with three portions of CH₂CI₂, and the combined organics were dried (Na₂SO₄), filtered, and

concentrated in vacuo to provide the free amine. To a solution of the amine in 11 mL of 1,2-dichloroethane at 0 °C was added 4 A powdered molecular sieves (2 g), followed by sodium triacetoxyborohydride (3.04 g). The aldehyde from Step E of Example 1 (1.21 g) was added, and the reaction was stirred at 0 °C. After 15 hours, , the reaction was poured into EtOAc, washed with sat. aq. NaHCO₃ , and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting product was taken up in 60 mL of 5: 1 benzene:CH₂Cl ₂, and propylamine (10 mL) was added. The reaction was stirred for 12 hours, then concentrated in vacuo, and purified by silica gel chromatography (5% MeOH/CHCl₃) to provide the titled compound as a white foam. A portion of this was taken up in CH₂CI₂ and treated with excess

HCl/Et₂O, then stripped to provide the titled compound.

FAB mass spectmm m/e 366 (M+1).

Analysis calculated for C₂₀H₂₀N₅CI• 2.70 HCl:

C, 51.77; H, 4.93; N, 15.09;

Found: C, 51.81; H, 4.96; N, 13.43.

EXAMPLE 127 1-(4-Cyanobenzyl)-5-[N-(3-phenylpropyl)aminomethyl] imidazole hydrochloride

The titled compound was prepared from from the aldehyde product from Step E of Example 124 and 3-phenylpropylamine using the procedure described in Step B of Example 126.

FAB mass spectrum m/e 331 (M+1).

Analysis calculated for C₂₁H₂₂N₄• 2.10 HCl• 0.80 H₂O:

C, 59.86; H, 6.15; N, 13.30; Found: C, 59.97; H, 6.18; N, 13.09. EXAMPLE 128

(S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)amino]-N- (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4-(methanesulfonyl)butanamine hydrochloride

Step A: (S)-2-(tert-Butoxycarbonylamino)-N-methoxy-N-methyl- 4-

(methylthio)butanamide

L-N- Boc-methionine (30.0 g, 0.120 mol), N,O- dimethylhydroxylamine hydrochloride (14.1 g, 0.144 mol), EDC hydrochloride (27.7 g, 0.144 mol) and HOBT (19.5 g, 0.144 mol) were stirred in dry DMF (300 mL) at 20°C under nitrogen. More N,O- dimethylhydroxylamine hydrochloride (2.3 g, 23 mmol) was added to obtain pH 7-8. The reaction was stirred overnight, the DMF distilled to half the original volume under high vacuum, and the residue partitioned between ethyl acetate and sat. NaHCO₃ soln. The organic phase was washed with satorated sodium bicarbonate, water, 10% citric acid, and brine, and dried with sodium suifate. The solvent was removed in vacuo to give the titled compound.

Step B: (S)-2-(tert-Butoxycarbonylamino)-N-metooxy-N-methyl-4-

(methanesulfonyl)butanamide

To solution of the product from Step A (23.1 g, 79.2 mmol) in methanol (300 mL) at 0 °C was added a suspension of magnesium monoperoxyphthalate (117 g, 238 mmol) in 500 mL MeOH. The reaction was allowed to warm to room temperatore. After 16 hours, the reaction was quenched at 0 °C by the addition of 2N Na₂S₂O₃ soln. The solution was poured into EtOAc and sat NaHCO₃ solution, and the organic layer was washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde titled compound.

Step C: (S)-2-(tert-Butoxycarbonylamino)-4-

(methanesulfonyl)butanal

A suspension of lithium aluminum hydride (5.15 g, 0.136 mol) in ether (290 mL) was stirred at room temperature for one hour. The solution was cooled to -75 °C under nitrogen, and a solution of the product from Step B (23.9 g, 73.6 mol) in THF (60 mL) was added over ca. 30 min, maintaining the temperatore below -40 °C. When the addition was complete, the reaction was warmed to -15 °C, then recooled to -35 °C. A solution of potassium hydrogen suifate (19.4 g) in 77 mL water was slowly added. The mixture was warmed to room temperatore, and stirred for one hour. The solution was filtered through a pad of celite, washed with 10% HCl solution, sat. NaHCO₃ solution and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the titled aldehyde. Step D: (S)-2-(tert-butoxycarbonylamino)-N-(3-chlorobenzyl)-4-

(methanesulfonyl)butanamine

To a solution of 3-chlorobenzylamine (0.628 mL, 5.14 mmol) and cmshed molecular sieves (1.5 g) in dichloroethane (10 mL) under nitrogen at 0 °C was added sodium triacetoxyborohydride (2.73 g,

12.9 mmol), followed the product from Step C (2.73 g, 5.14 mmol). The reaction was stirred overnight, allowing it to warm to room temperatore.

The solution was poured into EtOAc and sat NaHCO₃ solution, and the organic layer was washed with brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde product which was purified by silica gel chromatography (2.5-5% MeOH/CHCl₃) to obtain the titled compound as a white foam.

Step E: (S)-2-(tert-Butoxycarbonylamino)-N- (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4-

(methanesulfonyl)butanamine

To a solution of the amine from Step D (754 mg, 1.93 mmol) and triethylamine (0.403 mL, 2.89 mmol) in 5 mL of

dichloromethane at 0 °C was added benzylchloroformate (0.303 mL, 2.12 mmol). Mter 2 hours, the solution was poured into EtOAc and sat NH₄CI solution, and the organic layer was washed with sat. NaHCO₃ soln. and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo to provide the cmde product which was purified by silica gel

chromatography (30-40% EtOAc/hexane) to obtain the titled

compound as a white foam.

Step F: (S)-2-[(1-(4-cyanobenzyl)-5-imidazolylmethyl)amino]-N-

(benzyloxycarbonyl)-N-(3-chlorobenzyl)-4-

(methanesulfonyl)butanamine

To a solution of the product from Step E (360 mg, 0.686 mmol) in 6 mL of dichloromethane was added at room temperatore dropwise 3 mL of trifluoroacetic acid. After 30 minutes, the solution was concentrated in vacuo. The resulting product was reconcentrated from benzene three times to remove excess trifluoroacetic acid. To a solution of the amine salt in 4.2 mL of 1,2-dichloroethane at 0 °C was added 4A powdered molecular sieves, followed by sodium triacetoxyborohydride (363 mg, 1.71 mmol). The aldehyde from Step E of Example 1 (159 mg, 0.754 mmol) was added at 0 °C, followed by N-methylmorpholine (0.076 mL, 0.69 mmol). The reaction was stirred overnight, allowing it to warm to room temperatore. The reaction was poured into EtOAc, washed with sat. aq. NaHCO₃ and brine, dried (Na₂SO₄), filtered, and concentrated in vacuo. The resulting product was purified by silica gel chromatography (50-75% acetone/hexane) to provide the desired product . A portion of this was taken up in CH₂CI₂ and treated with excess HCl/Et₂O, then stripped to provide the titled compound.

FAB mass spectmm m/e 620 (M+1).

Analysis calculated for C₃₂H₃₄N₅O₄SCI• 2.0 HCl• 0.30 H₂O

C, 55.03; H, 5.28; N, 10.03;

Found: C, 55.00; H, 5.42; N, 9.99.

EXAMPLE 129

In vitro inhibition of ras famesyl transferase

Assays of famesyl-protein transferase. Partially purified bovine FPTase and Ras peptides (Ras-CVLS, Ras-CVIM and RAS-CAIL) were prepared as described by Schaber et al, J. Biol Chem. 265:14701-14704 (1990), Pompliano, et al, Biochemistry 31:3800 (1992) and Gibbs et al, PNAS U.S.A. 86:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 μl containing 100 mM N-(2-hydroxy ethyl)

piρerazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM [3H]-farnesyl diphosphate ([3H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 μg/ml FPTase at 31°C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB β-plate counter. The assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [3H]-FPP was utilized during the reaction period. Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incoφoration of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.

Human FPTase was prepared as described by Omer et al., Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1% (w/v) polyethylene glycol 20,000, 10 μM ZnCl₂ and 100 nM Ras-CVIM were added to the reaction mixtore. Reactions were performed for 30 min., stopped with 100 μl of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.

The compounds of the instant invention described in

Examples 1-128 were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC₅₀ of < 50 μM.

EXAMPLE 130

In vivo ras famesylation assay

The cell line used in this assay is a v-ras line derived from either Rat1 or NlH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. et al, Cancer Research 51:112-111, (1991). Cells in 10 cm dishes at 50-75%

confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37°C, the cells are labelled in 3 ml methionine-free DMEM supple-meted with 10% regular DMEM, 2% fetal bovine semm and 400

mCi[³⁵S]methionine (1000 Ci/mmol). Mter an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are bought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al, J. Virol 43:294-304, (1982)).

Following a 2 hour antibody incubation at 4°C, 200 ml of a 25%

suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and

autoradiographed. The intensities of the bands corresponding to farnesylated and nonfamesylated ras proteins are compared to determine the percent inhibition of famesyl transfer to protein.

EXAMPLE 131 In vivo growth inhibition assay

To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Rat 1 cells transformed with either a v- ras, v-raf, or v-mos oncogene is tested. Cells transformed by v-Raf and v-Mos maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.

Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x 10⁴ cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine semm) over a bottom agarose layer (0.6%). Both layers contain 0.1% methanol or an

appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay). The cells are fed twice weekly with 0.5 ml of medium A containing 0.1% methanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

Claims

WHAT IS CLAIMED IS:

1. A compound which inhibits Ras farnesyl-transferase having the Formula I:

wherein:

R^1a is independently selected from:

a) hydrogen,

b) aryl, heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂- C₂₀ alkynyl, R¹⁰O-, RHs(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-,

c) C₁-C₆ alkyl unsubstitoted or substitoted by aryl,

a) hydrogen,

b) substitoted or unsubstituted aryl, substitoted or unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, R¹⁰O-, R^{1 1}S(O)_m-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃ or -N(R¹⁰)₂,

c) C₁-C₆ alkyl unsubstitoted or substitoted by substitoted or unsubstitoted aryl, substitoted or unsubstitoted heterocyclic,

C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, R¹⁰o-, R^{1 1}S(O)_m-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃ or -N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a natorally occurring amino acid,

b) an oxidized form of a side chain of a natorally occurring

amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substitoted or unsubstitoted C₁-C₂₀ alkyl, substitoted or unsubstitoted C₂-C₂₀ alkenyl, substitoted or unsubstitoted

C₃-C₁₀ cycloalkyl, substitoted or unsubstitoted aryl or substitoted or unsubstitoted heterocyclic group, wherein the substituent is selected from F, Cl, Br, N(R¹⁰)₂, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-,

CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, R¹¹O C(O)NR¹⁰- and C₁-C₂₀ alkyl, and d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl; or

R² and R³ are combined to form - (CH₂)_s - ; or

R² or R³ are combined with R⁷ to form a ring such that

R⁴ and R⁵ are independently selected from:

a) hydrogen, b) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₂₀ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) unsubstitoted or substitoted aryl, unsubstituted or

substitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₂0 alkenyl, halogen, R¹⁰O-, R^{1 1}S(O)_m-,

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₂₀ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) unsubstitoted or substituted aryl, unsubstituted or

substitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₂0 alkenyl, halogen, R¹⁴O-, R^{1 1}S(O)_m-,

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R⁶ is selected from:

a) hydrogen,

b) substitoted or unsubstituted aryl, substitoted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₁-C₂O perfluoroalkyl, allyloxy, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, R¹⁰ ₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstitoted or substitoted by substitoted or unsubstituted aryl, substitoted or unsubstituted heterocycle,

C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂- C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-,

R¹⁰C(O)NH-, CN, H₂N-C(NH)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R¹⁰OC(O)NH-; R⁷ is independently selected from

a) hydrogen,

b) unsubstitoted or substitoted aryl,

c) unsubstitoted or substituted heterocycle_,

d) unsubstitoted or substituted C₃-C₁₀ cycloalkyl, and e) C₁-C₆ alkyl substitoted with hydrogen or an unsubstitoted or substitoted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl;

R⁸ is selected from:

a) hydrogen,

b) substitoted or unsubstitoted aryl, substitoted or unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₁-C₂₀ perfluoroalkyl, allyloxy, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, -S(O)₂NR¹⁰ ₂, CN, NO₂, R¹⁰ ₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstitoted or substitoted by substituted or unsubstitoted aryl, substitoted or unsubstitoted heterocycle,

C₃-C₁₀ cycloalkyl, C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂- C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O, R^{1 1}S(O)_m-,

R⁹ is selected from: a) hydrogen,

b) C₂-C₂₀ alkenyl, C₂-C₂₀ alkynyl, C₂-C₂₀ perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C-(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃,

-N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₂₀

perfluoroalkyl, F, Cl, Br, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl and aryl; R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substitoted with CO₂R¹⁰, C₁-C₆ alkyl substitoted with aryl, C₁- C₆ alkyl substitoted with substitoted aryl, C₁-C₆ alkyl substitoted with heterocycle, C₁-C₆ alkyl substitoted with substitoted heterocycle, aryl and substitoted aryl; A¹, A² and A³ are independently selected from: a bond, -CH=CH-,

A⁴ is selected from: a bond, O, -N(R⁷)- or S,

V is selected from:

a) hydrogen,

b) heterocycle,

c) aryl, d) C₁-C₂₀ alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from O, S, and N, and e) C₂-C₂₀ alkenyl,

W is a heterocycle;

Z is independently R^1a ₂ or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

r is 0 to 5, provided that r is 0 when V is hydrogen;

s is 4 or 5; and

t is 3, 4 or 5; or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 of the formula I:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from:

a) hydrogen, b) substitoted or unsubstituted aryl, substituted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O-, -N(R¹⁰)₂ or C₂-C₆ alkenyl, and

c) C₁-C₆ alkyl unsubstitoted or substituted by substitoted or unsubstitoted aryl, substitoted or unsubstituted heterocycle,

C₃-C₁₀ cycloalkyl, C₂-C₆ alkenyl, R¹⁰O-, or -N(R¹⁰)₂;

R² and R³ are independently selected from:

a) a side chain of a natorally occurring amino acid,

b) an oxidized form of a side chain of a natorally occurring amino acid which is:

i) methionine sulfoxide, or

ii) methionine sulfone,

c) substitoted or unsubstitoted C₁-C₁₀ alkyl, substitoted or unsubstitoted C₂-C₁₀ alkenyl, substitoted or unsubstitoted

C₃-C₁₀ cycloalkyl, substitoted or unsubstituted aryl or substitoted or unsubstitoted heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃,

-N(R¹⁰)₂, R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl, and d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl;

wherein said substitoted group is substitoted with 1 or 2 substitotents selected from: F, Cl, Br, CF₃, NH₂, N(C₁-C₆ alkyl)₂, NO₂, CN, (C₁-C₆ alkyl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, (C₁-C₆ alkyl)C(O)NH-, H₂N-C(NH)-, (C₁- C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)-, N₃,( C₁-C₆ alkyl)OC(O)NH- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstituted or substitoted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N-

C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstituted aryl, substitoted or

unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, halogen, R¹⁰O-, R^{1 1}S(O)_m-,

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl;

R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstitoted or substituted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N-

C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstitoted aryl, substitoted or

unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, halogen, R¹⁴O-, R^{1 1}S(O)_m-,

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from aryl, heterocyclic and

C₃-C₁₀ cycloalkyl; R⁶ is independently selected from:

a) hydrogen,

b) substitoted or unsubstituted aryl, substitoted or unsubstituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁ -C₆ alkyl substitoted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstitoted or substitoted aryl,

c) unsubstituted or substitoted heterocycle,

d) unsubstituted or substitoted C₃-C₁₀ cycloalkyl, and e) C₁-C₆ alkyl substitoted with hydrogen or an unsubstitoted or substitoted group selected from aryl, heterocycle and C₃- C₁₀ cycloalkyl;

a) hydrogen,

b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

c) C₁-C₆ alkyl substitoted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R¹¹OC(O)NR¹⁰-; R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}s(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substitoted by C₁-C₆

perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R¹⁰ is independently selected from hydrogen, C₁-C₆ alkyl, benzyl and aryl; R¹¹ is independently selected from C₁-C₆ alkyl and aryl;

R¹² is independently selected from hydrogen, C₁-C₆ alkyl and aryl, or (R¹²)₂ forms - (CH₂)_s - ; R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substitoted with CO₂R¹⁰, C₁-C₆ alkyl substitoted with aryl, C₁- C₆ alkyl substitoted with substitoted aryl, C₁-C₆ alkyl substitoted with heterocycle, C₁-C₆ alkyl substitoted with substitoted heterocycle, aryl and substitoted aryl;

A¹, A² and A³ are independently selected from: a bond, -CH=CH-,

-C≡C-, -C(O)-, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-, -NR⁷S(O)₂-, O, -N(R⁷)-, or S(O)_m; A⁴ is selected from: a bond, O, -N(R⁷)- or S;

V is selected from:

a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl,

c) aryl,

W is a heterocycle selected from pyrrolidinyl, imidazolyl, imidazolinyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, oxazolyl, isoxazolyl, indolyl, quinolinyl, or isoquinolinyl; Z is independently R^{1 a2} or O ; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is 0, 1, 2, 3 or 4;

r is 0 to 5, provided that r is 0 when V is hydrogen; and

t is 3, 4 or 5; or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 of the formula I:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from:

a) hydrogen,

b) substitoted or unsubstituted aryl, substitoted or unsubstituted heterocycle, C₃-C₁₀ cycloalkyl, R¹⁰O- or C₂-C₆ alkenyl, c) C₁-C₆ alkyl unsubstitoted or substitoted by aryl,

R² and R³ are independently selected from:

a) a side chain of a natorally occurring amino acid,

i) methionine sulfoxide, or

ii) methionine sulfone, and

c) substitoted or unsubstituted C₁-C₁₀ alkyl, substitoted or unsubstitoted C₂-C₁₀ alkenyl, substitoted or unsubstituted

C₃-C₁₀ cycloalkyl, substituted or unsubstituted aryl or substitoted or unsubstituted heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂,

R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen, b) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstituted aryl, substitoted or

unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, fluoro, chloro, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from substitoted or unsubstitoted aryl, substitoted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl; R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstitoted aryl, substituted or

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from substitoted or unsubstitoted aryl, substitoted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl;

R⁶ is independently selected from:

a) hydrogen,

b) substitoted or unsubstituted aryl, substitoted or unsubstitoted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy,

R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁-C₆ alkyl substitoted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstitoted or substitoted aryl,

c) unsubstituted or substitoted heterocycle,

d) unsubstitoted or substitoted cycloalkyl, and

e) C₁-C₆ alkyl substitoted with hydrogen or an unsubstitoted or substituted group selected from aryl, heterocycle and cycloalkyl;

a) hydrogen,

b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C1 -C₆

c) C₁-C₆ alkyl substitoted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or

R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substitoted by C₁-C₆

R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substitoted with CO₂R¹⁰, C₁-C₆ alkyl substitoted with aryl, C₁- C₆ alkyl substitoted with substitoted aryl, C₁-C₆ alkyl substituted with heterocycle, C₁-C₆ alkyl substituted with substitoted heterocycle, aryl and substitoted aryl;

A¹ and A² are independently selected from: a bond, -CH=CH-,

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

A³ is selected from: a bond, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-,

-NR⁷S(O)₂- or -N(R⁷)-;

V is selected from:

c) aryl,

W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or

isoquinolinyl; Z is independently R^1a ₂ or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is O or 1;

r is 0 to 5, provided that r is 0 when V is hydrogen; and

t is 3, 4 or 5; or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 1 of the formula I:

wherein:

R^1a is independently selected from: hydrogen or C₁-C₆ alkyl;

R^1b is independently selected from:

a) hydrogen,

R² and R³ are independently selected from:

a) a side chain of a natorally occurring amino acid,

i) methionine sulfoxide, or

ii) methionine sulfone, and

C₃-C₁₀ cycloalkyl, substitoted or unsubstituted aryl or substitoted or unsubstituted heterocyclic group, wherein the substituent is selected from F, Cl, Br, NO₂, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, N₃, -N(R¹⁰)₂,

R^{1 1}OC(O)NR¹⁰- and C₁-C₂₀ alkyl; or

R² or R³ are combined with R⁷ to form a ring such that:

R⁴ and R⁵ are independently selected from:

a) hydrogen, b) C₁-C₆ alkyl unsubstitoted or substituted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstitoted aryl, substituted or

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substituted group selected from substitoted or unsubstitoted aryl, substitoted or unsubstitoted heterocyclic and C₃-C₁₀ cycloalkyl; R^13a and R^13b are independently selected from:

a) hydrogen,

b) C₁-C₆ alkyl unsubstitoted or substitoted by C₂-C₆ alkenyl, R¹⁰O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, N₃, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, c) substitoted or unsubstitoted aryl, substitoted or

unsubstitoted heterocycle, C₃-C₁₀ cycloalkyl, C₂- C₆ alkenyl, fluoro, chloro, R¹⁴O-, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, N₃, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-, and

d) C₁-C₆ alkyl substitoted with an unsubstitoted or

substitoted group selected from substitoted or unsubstitoted aryl, substituted or unsubstituted heterocyclic and C₃-C₁₀ cycloalkyl;

R⁶ is independently selected from:

a) hydrogen,

b) substituted or unsubstituted aryl, substitoted or unsubstituted heterocycle, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆ perfluoroalkyl, F, Cl, R¹⁰O-, allyloxy,

R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, (R¹²)₂NC(O)- or R^{1 1}OC(O)NR¹⁰-, and c) C₁ -C₆ alkyl substitoted by C₁-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁷ is independently selected from

a) hydrogen,

b) unsubstitoted or substitoted aryl,

c) unsubstitoted or substitoted heterocycle,

d) unsubstituted or substitoted cycloalkyl, and

e) C₁-C₆ alkyl substitoted with hydrogen or an unsubstitoted or substitoted group selected from aryl, heterocycle and cycloalkyl;

a) hydrogen,

b) C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₁-C₆

c) C₁-C₆ alkyl substitoted by Cχ-C₆ perfluoroalkyl, R¹⁰O-, R¹⁰C(O)NR¹⁰-, (R¹⁰)₂N-C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or R^{1 1}OC(O)NR¹⁰-; R⁹ is selected from:

a) hydrogen,

b) C₂-C₆ alkenyl, C₂-C₆ alkynyl, C 1-C₆ perfluoroalkyl, F, Cl, R¹⁰O, R^{1 1}S(O)_m-, R¹⁰C(O)NR¹⁰-, CN, NO₂, (R¹⁰)₂N- C(NR¹⁰)-, R¹⁰C(O)-, R¹⁰OC(O)-, -N(R¹⁰)₂, or

R^{1 1}OC(O)NR¹⁰-, and

c) C₁-C₆ alkyl unsubstituted or substituted by C₁-C₆

R^{1 1} is independently selected from C₁-C₆ alkyl and aryl;

R¹⁴ is independently selected from hydrogen, C₁-C₆ alkyl, C₁-C₆ alkyl substitoted with CO₂R¹⁰, C₁-C₆ alkyl substitoted with aryl, C₁- C₆ alkyl substitoted with substitoted aryl, C₁-C₆ alkyl substituted with heterocycle, C₁-C₆ alkyl substitoted with substitoted heterocycle, aryl and substituted aryl;

A¹ and A² are independently selected from: a bond, -CH=CH-,

A⁴ is selected from: a bond, O, -N(R⁷)- or S;

A³ is selected from: a bond, -C(O)NR⁷-, -NR⁷C(O)-, -S(O)₂NR⁷-,

-NR⁷S(O)₂- or -N(R⁷)-;

V is selected from:

c) aryl,

Z is independently R^1a ₂ or O; m is 0, 1 or 2;

n is 0, 1, 2, 3 or 4;

p is 0, 1, 2, 3 or 4;

q is O or 1;

r is 0 to 5, provided that r is 0 when V is hydrogen; and

t is 3, 4 or 5; or a pharmaceutically acceptable salt thereof.

5. A compound which inhibits famesyl-protein transferase which is: N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{ 1-(4-cyanobenzyl)- 1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Acetyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)-methylpentanamine N-Propionyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine N-Methylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Ethylsulfonyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

N-Propyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)- methylpentanamine

N-3-Chlorobenzyl-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine N-(2-Imidazolylmethyl )-N-naphth-1-ylmethyl-2(S)-{(1-(4-cyanobenzyl)- 1H-imidazol-5-yl)acetyl}amino-3(S)- methylpentanamine

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(naphth-1-ylmethyl)propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(2-methylbenzyl) propionamide

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] acetyl}amino-3-(t- butoxycarbonyl)amino- N-(3-methylbenzyl) propionamide 2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- amino-N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- amino-N-methyl-N-benzyl propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- amino-N-(2-methylbenzyl)propionamide 2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- amino-N-(3-methylbenzyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- acetylamino-N-(3-methylbenzyl)propionamide

2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- (phenylacetyl)amino-N-(naphth-1-ylmethyl)propionamide 2(RS)-{[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]acetyl}amino-3- (phenylacetyl)amino-N-methyl-N-benzyl)propionamide

[1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)]-N-butylacetamide [1-(Naphth-2-ylmethyl)-1H-imi-azol-5-yl)]-N-methyl-N-(3,3- diphenylρropyl)acetamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-methyl-N-benzyl propionamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(t- butoxycarbonyl)amino-N-(3-methylbenzyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-methyl-N-benzyl-propionamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-(3-methylbenzyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-amino N-(naphth-1-ylmethyl)propionamide

2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(2- methylpropionyl)amino-N-(naphth-1-ylmethyl)propionamide 2(RS)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl}amino-3-(2- methylpropionyl)amino-N-(naphth-1-ylmethyl)propionamide

N-[2(S)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylρentyl]-N-(1-naphthylmethyl)glycineisopropylamide

N-[2(S)-{[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylamino)-3(S)- methylρentyl]-N-(1-naphthylmethyl)glycine piperidinylamide 2(RS)-{ [1-(4-Cyanobenzyl)-1H-imidazol-5-yl] acetyl} amino -3-(t- butoxycarbonyl)amino - N- methyl-N-(naphth-1-ylmethyl) propionamide N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S){N - methanesulfonyl-N'-(naphth-1-ylmethyl)aminomethyl}-pyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethyl}-2(S)-[1(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)_methyl}-2(S)-[1(R)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)methyl}-2(S)-[l(S)-1-(3- chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)acetyl}-4(R)-hydroxy-2(S)- [1(S)-1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chl orophenyl)-1-hydroxy]methylpyrrolidine

N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine N-[5-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl]-4(R)-hydroxy-2(S)-[1(S)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-[1-(4-Cyanobenzyl)-1-imidazol-5-ylmethyl]-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy]methylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-hydroxy-2(S)-{N- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)-{N' acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanophenethyl)-1H-imidazol-5-yl-methyl-4(R)-hydroxy-2(S)- { N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl-acetyl}-4(R)-methoxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanopheneth-1-yl)-1H-imidazol-5-yl-acetyl-4(R)-methoxy- 2(S)-{N'-acetyl-N'-3-chlorobenzyl} aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-- imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-2(S)-{N^,-acetyl-N'-3- chlorobenzyl-aminomethyl}pyrrolidine

N-{ 1-(4-Cyanophenethyl)-1H-- imidazol-5-yl-ethyl}-4(R)-methoxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethyl pyrrolidine

aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl}-4(R)-(acetyloxy)-2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(2- methylacetyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-4(R)-(acetyloxy)-2(S)- { N'-S-chlorobenzyl-N'-acetyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-5-imidazolethyl}-4(S)-(phenoxy)-2(S)-{N'-acetyl- N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(S)-fluoro-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(4- chlorobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(4- cyanobenzyloxy)-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylethyl}-4(R)-(3-pyridylmethoxy)- 2(S)-{N'-acetyl-N'-3-chlorobenzyl}aminomethyl-pyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl}-2(S)-{N'-acetyl-N^,-3- cyanobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-2- chlorobenzyl}aminomethylpyrrolidine

N-{2(R)-Methyl-2-(l-(4-Cyanobenzyl)-1H-imidazol-5-yl))acetyl}- 2(S)- {N'-acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-4- chlorobenzyl}aminomethylpyrrolidine

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetyl-4(R)-benzyloxy-2(S)- {N'-acetyl-N'-naphth-1-ylmethyl}aminomethylpyrrolidine

N-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]acetylproline naphth-1- ylmethylamide

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl-4(R)-methoxy-2(S)-{N'- acetyl-N'-5,6,7,8-tetrahydronaphm-1-ylmethyl}aminomethylpyrrolidine

1-(4-Cyanobenzyl)-1H-imidazol-5-ylmethyl-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-Allyloxycarbonyl-2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine 2(S)-{(1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)-methyl- N-(naphth-2-ylsulfonyl)-ρentanamine

N-Acetyl-N-2-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine N-Acetyl-N-3-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

N-Acetyl-N-4-chlorobenzyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl-pentanamine

N-Acetyl-N-2,3-dichlorobenzyl-2(S)-{(l-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)-methyl-pentanamine N-Allyloxycarbonyl-N-naphth-1-ylmethyl-2(S)-{2(R,S)-methyl-2-(l-(4- cyanobenzyl)-1H-imidazol-5-yl)acetyl}amino-3(S)-methyl-pentanamine

N-{5-(4-Cyanobenzyl)-1H-imidazol-1-yl)ethoxycarbonyl}-2(S)-{N'- acetyl-N'-3-chlorobenzyl}aminomethylpyrrolidine N-{5-(4-Cyanobenzyl)-1H-imidazol-1-ylacetyl}-2(S)-{N'-acetyl-N'-3- chlorobenzyl}aminomethylpyrrolidine

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-5-yl)acetyl}-2(S)-{N'-acetyl-N'-3- chlorophenyl}aminomethylpyrrolidine N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)glycine N'-(3-chlorophenyl)amide 1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl]-(N-2-methylbenzyl)-glycine N'-(3-chlorophenylmethyl) amide

N-[1-(3-[1H-Imidazol-4-yl]propionyl)-pyrrolidin-2(S)-ylmethyl]-(N-2- methylbenzyl)-glycine N'-methyl-N'-(3-chlorophenyl) amide

1-[1-(4-Cyanobenzyl)-1H-imidazol-5-ylacetyl] pyrrolidin-2(S)- ylmethyl}-(N-2-methylbenzyl)-glycine N'-methyl-N'-(3- chlorophenylmethyl) amide (S)-2-[(1-(4-cyanobenzyl)-5-imidazolylmethyl)aminol-1-[N-(2,3- dimethylphenyl)acetamidolhexane

(S)-2-[N-(1-(4-cyanobenzyl)-5-imidazolylmethyl)-N-(methyl)aminol-1- [N-(2,3-dimethylphenyl)acetamido]hexane

N-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-N'-(3- chlorophenyl)ethylenediamine

1-(4-Cyanobenzyl)-5-[N-(3-phenylpropyl)aminomethyl] imidazole or

(S)-2-[(1-(4-Cyanobenzyl)-5-imidazolylmethyl)amino]-N- (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4-(methanesulfonyl)butanamine or a pharmaceutically acceptable salt or optical isomer thereof.

6. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-Allyloxycarbonyl-N-naphthylmethyl-2(S)-{ 1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methyl pentanamine

or a pharmaceutically acceptable salt or optical isomer thereof.

7. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-Acetyl-N-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol-5- yl)acetyl}amino-3(S)-methyl pentanamine

or a pharmaceutically acceptable salt or optical isomer thereof.

8. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-Propionyl-N-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H-imidazol- 5-yl)acetyl}amino-3(S)- methyl pentanamine

or a pharmaceutically acceptable salt or optical isomer thereof.

9. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-Methylsulfonyl-N-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methyl pentanamine

or a pharmaceutically acceptable salt or optical isomer thereof.

10. The compound according to Claim 5 which inhibits famesyl-protein transferase which is: N-Ethylsulfonyl-N-naphthylmethyl-2(S)-{(1-(4-cyanobenzyl)-1H- imidazol-5-yl)acetyl}amino-3(S)- methyl pentanamine

or a pharmaceutically acceptable salt or optical isomer thereof.

11. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

2(RS)-{ [1-(Naphth-2-ylmethyl)-1H-imidazol-5-yl)] aaetyl}amino-3- (phenylacetyl)amino- N-methyl-N-benzyl) propionamide

or a pharmaceutically acceptable salt or optical isomer thereof.

12. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

13. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-{ 1-(4-cyanobenzyl)-1H-imidazol-5-yl)acetyl}- 2(S)-{N'-acetyl-N'- naphthylmethyl-aminomethyl}-pyrrolidine

or a pharmaceutically acceptable salt thereof.

14. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

15. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

16. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

N-{ 1-(4-Cyanobenzyl)-1H-imidazol-1-ylethyl}-4(R)-hydroxy-2(S)-[1(R)- 1-(3-chlorophenyl)-1-hydroxy}methylpyrrolidine

or a pharmaceutically acceptable salt or optical isomer thereof.

17. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

18. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

19. The compound according to Claim 5 which inhibits famesyl-protein transferase which is:

or a pharmaceutically acceptable salt or optical isomer thereof.

20. The compound according to Claim 5 which inhibits famesyl-protein transferase which is :

or a pharmaceutically acceptable salt or optical isomer thereof.

21. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1.

22. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 2.

23. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 5.

24. A method for inhibiting farnesylation of Ras protein which comprises administering to a mammal in need thereof a therapeutically effective amount of the composition of Claim 21.

25. A method for inhibiting farnesylation of Ras protein which comprises administering to a mammal in need thereof a therapeutically effective amount of the composition of Claim 22.

26. A method for inhibiting farnesylation of Ras protein which comprises administering to a mammal in need thereof a therapeutically effective amount of the composition of Claim 23.

27. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 21.

28. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 22.

29. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 23.

30. A method for treating or preventing a disease or condition in a mammal, the disease or condition which is selected from: a) a benign proliferative disorder component of NF-1;

b) infection of hepatitis delta and related vimses;

c) restenosis;

d) polycystic kidney disease; and

e) fungal infections; which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 21.